

XX Example 13; Page 64-65; 115pp; English.

PS The invention relates to a novel nucleic acid molecule expressed in liver

CC or stomach tissue, useful for diagnosing or treating obesity, anorexia

CC etc. The nucleic acid molecule is useful as a diagnostic and therapeutic

CC agent or as a target for agents which act as modulators and/or monitors

CC of physiological processes associated with obesity, anorexia, weight

CC maintenance, impaired muscle development, diabetes and/or metabolic

CC energy levels and/or other physiological conditions. Alkylguanine

CC alkyltransferase (AGT)-117, AGT-110, AGT-199, AGT-107, AGT-114, AGT-116,

CC AGT-115 and/or AGT-108 genes of the invention and the agent that modulate

CC their expression or activity are useful in manufacturing a medicament for

CC treating a condition characterised by obesity, anorexia, diabetes and/or

CC energy imbalance. The invention is useful in gene therapy. The present

CC sequence is human AGT-114 protein

XX SQ Sequence 395 AA;

Query Match 30.0%; Score 6; DB 6; Length 395;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
|||||

Db 365 QMLETK 370

RESULT 8

ADJ70703

ID ADJ70703 standard; protein; 395 AA.

XX AC ADJ70703;

XX DT 06-MAY-2004 (first entry)

XX DE Human heat mitochondrial protein as a therapeutic target SeqID2509.

XX KW mitochondrial; human; screening assay; diabetes mellitus;

KW Huntington's disease; osteoarthritis;

KW Leber's hereditary optic neuropathy; LHON;

KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;

KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;

KW neuroprotective; nontropic; antidiabetic; anticonvulsant; antiarthritic;

KW osteopathic; ophthalmological; cytostatic.

XX OS Homo sapiens.

XX PF WO2003087769-A2.

XX PD 23-OCT-2003.

XX PF 04-APR-2003; 2003WO-US010870.

XX PR 12-APR-2002; 2002US-0372843P.

PR 17-JUN-2002; 2002US-0389987P.

PR 20-SEP-2002; 2002US-0412418P.

XX PA (MITO-) MITOKOR.

PA (BUCK-) BUCK INST AGE RES.

XX Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;

PI Warnock DE;

XX WPI; 2003-845369/78.

XX Identifying a mitochondrial target for drug screening assays and for

PT treating diseases associated with altered mitochondrial function.

PT comprises detecting a modified polypeptide in a sample and correlating

PT with the disease.

XX Claim 1; SEQ ID NO 2509; 180pp; English.

CC This invention relates to novel mitochondrial targets that can be used

CC for therapeutic intervention in treating a disease associated with

CC altered mitochondrial function. Specifically, it refers to a method for

CC identifying proteins of the human heart mitochondrial proteome that are

CC useful for drug screening assays, as well as therapeutic targets. The

CC present invention describes a method for identifying such proteins that

CC can be used in the treatment of various diseases associated with altered

CC mitochondrial function including diabetes mellitus, Huntington's disease,

CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial

CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy

CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these

CC compositions have neuroprotective, nontropic, antidiabetic,

CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and

CC cytostatic activities. This polypeptide sequence is a human heart

CC mitochondrial protein of the invention.

XX SQ Sequence 395 AA;

Query Match 30.0%; Score 6; DB 7; Length 395;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
|||||

Db 365 QMLETK 370

RESULT 9

ABU49025

ID ABU49025 standard; protein; 434 AA.

XX AC ABU49025;

XX DT 19-JUN-2003 (first entry)

XX DE Protein encoded by Prokaryotic essential gene #34552.

XX KW Antisense; prokaryotic essential gene; cell proliferation; drug design.

XX OS Vibrio cholerae.

XX PN WO200277183-A2.

XX PD 03-OCT-2002.

XX PF 21-MAR-2002; 2002WO-US009107.

XX PR 21-MAR-2001; 2001US-00815242.

PR 06-SEP-2001; 2001US-00948993.

PR 25-OCT-2001; 2001US-0342923P.

PR 08-FEB-2002; 2002US-00072851.

PR 06-MAR-2002; 2002US-0362699P.

XX PA (ELIT-) ELITRA PHARM INC.

XX Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;

PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;

XX WPI; 2003-029926/02.

DR N-PSDB; ACA52895.

XX New antisense nucleic acids, useful for identifying proteins or screening

PT for homologous nucleic acids required for cellular proliferation to

PT isolate candidate molecules for rational drug discovery programs.

XX Claim 25; SEQ ID NO 76949; 1766pp; English.

XX The invention relates to an isolated nucleic acid comprising any one of

CC the 6213 antisense sequences given in the specification where expression

CC of the nucleic acid inhibits proliferation of a cell. Also included are:

CC (1) a vector comprising a promoter operably linked to the nucleic acid

CC encoding a polypeptide whose expression is inhibited by the antisense

CC nucleic acid; (2) a host cell containing the vector; (3) an isolated

CC polypeptide or its fragment whose expression is inhibited by the
 CC antisense nucleic acid; (4) an antibody capable of specifically binding
 CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular
 CC proliferation or the activity of a gene in an operon required for
 CC proliferation; (7) identifying a compound that influences the activity of
 CC the gene product or that has an activity against a biological pathway
 CC required for proliferation, or that inhibits cellular proliferation; (8)
 CC identifying a gene required for cellular proliferation or the biological
 CC pathway in which a proliferation-required gene or its gene product lies
 CC or a gene on which the test compound that inhibits proliferation of an
 CC organism acts; (9) manufacturing an antibiotic; (10) profiling a
 CC compound's activity; (11) a culture comprising strains in which the gene
 CC product is overexpressed or underexpressed; (12) determining the extent
 CC to which each of the strains is present in a culture or collection of
 CC strains; or (13) identifying the target of a compound that inhibits the
 CC proliferation of an organism. The antisense nucleic acids are useful for
 CC identifying proteins or screening for homologous nucleic acids required
 CC for cellular proliferation to isolate candidate molecules for rational
 CC drug discovery programs, or for screening homologous nucleic acids
 CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,
 CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of
 CC the target prokaryotic essential genes. Note: The sequence data for this
 CC patent did not form part of the printed specification, but was obtained
 CC in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 434 AA;

Query Match 30.0%; Score 6; DB 6; Length 434;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 APMWLR 9
 |||||
 DB 177 APMWLR 182

RESULT 10
 ABB66870
 ID ABB66870 standard; protein; 444 AA.
 XX
 AC ABB66870;
 DT 26-MAR-2002 (first entry)
 XX
 DE Drosophila melanogaster polypeptide SEQ ID NO 27402.
 XX
 KW Drosophila; developmental biology; cell signalling; insecticide;
 XX pharmaceutical.
 XX Drosophila melanogaster.
 XX WO200171042-A2.
 XX 27-SEP-2001.
 XX 23-MAR-2001; 2001WO-US009231.
 XX 23-MAR-2000; 2000US-0191637P.
 XX 11-JUL-2000; 2000US-00614150.
 XX (PEXE) PE CORP NY.
 XX Venter JC, Adams M, Li PWD, Myers EW;
 XX WPI; 2001-656860/75.
 XX N-PSDB; ABL10973.
 XX New isolated nucleic acid detection reagent for detecting 1000 or more
 XX genes from *Drosophila* and for elucidating cell signalling and cell-cell
 XX interactions.
 XX Disclosure; SEQ ID NO 27402; 21pp + Sequence Listing; English.

XX The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from *Drosophila*. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
 CC ABB72072). The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 444 AA;

Query Match 30.0%; Score 6; DB 4; Length 444;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKFL 20
 |||||
 DB 334 LETKFL 339

RESULT 11
 ABB61409
 ID ABB61409 standard; protein; 444 AA.

XX ABB61409;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Drosophila melanogaster polypeptide SEQ ID NO 11019.
 XX
 KW Drosophila; developmental biology; cell signalling; insecticide;
 XX pharmaceutical.
 XX Drosophila melanogaster.
 XX WO200171042-A2.
 XX 27-SEP-2001.
 XX 23-MAR-2001; 2001WO-US009231.
 XX 23-MAR-2000; 2000US-0191637P.
 XX 11-JUL-2000; 2000US-00614150.
 XX (PEXE) PE CORP NY.
 XX Venter JC, Adams M, Li PWD, Myers EW;
 XX WPI; 2001-656860/75.
 XX N-PSDB; ABL05512.
 XX New isolated nucleic acid detection reagent for detecting 1000 or more
 XX genes from *Drosophila* and for elucidating cell signalling and cell-cell
 XX interactions.

Disclosure; SEQ ID NO 11019; 21pp + Sequence Listing; English.

XX The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from *Drosophila*. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
 CC ABB72072). The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 444 AA;

Query Match 30.0%; Score 6; DB 4; Length 444;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKFL 20
 DB 334 LETKFL 339
 |||||

RESULT 12
 AAG65822
 ID AAG65822 standard; protein; 501 AA.
 XX
 AC AAG65822;
 XX
 DT 30-JAN-2002 (first entry)
 XX
 DE Human GPR38 variant GPR38V polypeptide.
 XX
 KW GPR38V; variant; antibacterial; cytostatic; analgesic; antiasthmatic;
 KW anti-Parkinsonian; hypertensive; hypotensive; antidiabetic; osteopathic;
 KW antiallergic; antimigraine; neuroleptic; nootropic; anticonvulsant;
 KW antiulcer; antiemetic; cardiant; vaccine; human.
 XX

OS Homo sapiens.
 XX
 PN WO200164836-A2.
 XX
 PD 07-SEP-2001.
 XX
 PF 28-FEB-2001; 2001WO-US006277.
 XX
 XX 01-MAR-2000; 2000US-00516315.
 XX (SMIX) SMITHKLINE BEECHAM CORP.
 XX
 PI Elshourbagy N, Shabon U;
 XX
 DR WPI; 2001-638956/73.
 DR N-PSDB; AA166989.
 XX
 PT New human GPR38V polypeptide and polynucleotide, useful for treating e.g.
 PT bacterial, fungal, protozoal and viral infections, cancers or allergies,
 PT as vaccines, and for identifying agonists and antagonists potentially
 useful in therapy.
 XX
 PS Claim 1; Page 26; 32pp; English.
 XX

CC This represents a human GPR38 variant (GPR38V) polypeptide. GPR38V can be
 CC expressed by standard recombinant methodology. The polynucleotides and
 CC polypeptides are used in the treatment of bacterial, fungal, protozoal
 CC and viral infections, infections caused by HIV-1 or HIV-2, pain, cancers,
 CC diabetes, obesity, anorexia, asthma, Parkinson's disease, acute heart
 CC failure, hypertension, urinary retentions, osteoporosis, allergies,
 CC ulcers, migraine, psychotic and neurological disorders, or dyskinesias.
 CC They are also useful for identifying agonists and antagonists that are
 CC potentially useful in therapy, as vaccines to induce immunological
 CC response in a mammal. The polypeptides may also be used as immunogens to
 CC produce antibodies immunospecific for the polypeptides, and to identify
 CC membrane bound or soluble receptors
 XX
 SQ Sequence 501 AA;

Query Match 30.0%; Score 6; DB 4; Length 501;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPM 6
 DB 85 PRGAPM 90
 |||||

RESULT 13

ABR58452
 ID ABR58452 standard; protein; 571 AA.
 XX
 AC ABR58452;
 XX
 DT 07-JUL-2003 (first entry)
 XX
 DE Human NOV47c.
 XX
 KW Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
 KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO2003029423-A2.
 XX
 PD 10-APR-2003.
 XX
 PF 02-OCT-2002; 2002WO-US031358.
 XX
 PR 02-OCT-2001; 2001US-0326483P.
 PR 05-OCT-2001; 2001US-0327342P.
 PR 09-OCT-2001; 2001US-0327917P.
 PR 09-OCT-2001; 2001US-0328029P.
 PR 09-OCT-2001; 2001US-0328044P.
 PR 09-OCT-2001; 2001US-0328056P.
 PR 12-OCT-2001; 2001US-0328849P.
 PR 15-OCT-2001; 2001US-0329414P.
 PR 17-OCT-2001; 2001US-0330142P.
 PR 22-OCT-2001; 2001US-0341058P.
 PR 24-OCT-2001; 2001US-0332666P.
 PR 24-OCT-2001; 2001US-0343629P.
 PR 29-OCT-2001; 2001US-0349575P.
 PR 01-NOV-2001; 2001US-0346357P.
 PR 12-APR-2002; 2002US-0371972P.
 PR 12-APR-2002; 2002US-0371980P.
 PR 17-APR-2002; 2002US-0373261P.
 PR 19-APR-2002; 2002US-0373805P.
 PR 23-APR-2002; 2002US-0374738P.
 PR 16-MAY-2002; 2002US-0381101P.
 PR 17-MAY-2002; 2002US-0381635P.
 PR 29-MAY-2002; 2002US-0383830P.
 PR 01-OCT-2002; 2002US-00262839.
 XX
 (CURA-) CURAGEN CORP.
 XX
 PI Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
 PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
 PI Rekuda R, Leach MD, Li L, Miller CB, Patturajan M, Rieger DK;
 PI Rothenberg ME, Shinkets RA, Smithson G, Spyttek KA, Taupier RJ;
 PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
 XX
 WPI: 2003-381625/36.
 DR N-PSDB; ACC72164.
 XX
 PT NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 PS Claim 1; Page 256; 487pp; English.
 XX
 CC The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome
 CC associated with a human disease. the NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune

CC disorders, haematopoietic disorders and various dyslipidaemias
 XX
 SQ Sequence 571 AA;

Query Match 30.0%; Score 6; DB 6; Length 571;
 Best Local Similarity 100.0%; Pred. No. 2.8e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
 |||||

DB 546 QMLETK 550

RESULT 14
 ABR58460
 ID ABR58460 standard; protein; 577 AA.

XX ABR58460;

DT 07-JUL-2003 (first entry)

XX Human NOV47k.

XX Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
 KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.

XX Homo sapiens.

OS WO2003029423-A2.

PN 10-APR-2003.

PD 02-OCT-2002; 2002WO-US031358.

PR 02-OCT-2001; 2001US-0326483P.

PR 05-OCT-2001; 2001US-0327342P.

PR 09-OCT-2001; 2001US-0327917P.

PR 09-OCT-2001; 2001US-0328029P.

PR 09-OCT-2001; 2001US-0328044P.

PR 12-OCT-2001; 2001US-0328056P.

PR 12-OCT-2001; 2001US-0328849P.

PR 15-OCT-2001; 2001US-0329414P.

PR 17-OCT-2001; 2001US-0330142P.

PR 22-OCT-2001; 2001US-0341058P.

PR 24-OCT-2001; 2001US-0339266P.

PR 24-OCT-2001; 2001US-0343629P.

PR 29-OCT-2001; 2001US-0349575P.

PR 01-NOV-2001; 2001US-0346357P.

PR 12-APR-2002; 2002US-0371972P.

PR 12-APR-2002; 2002US-0371980P.

PR 17-APR-2002; 2002US-0373261P.

PR 19-APR-2002; 2002US-0373805P.

PR 23-APR-2002; 2002US-0374738P.

PR 16-MAY-2002; 2002US-0381101P.

PR 17-MAY-2002; 2002US-0381635P.

PR 29-MAY-2002; 2002US-0383830P.

PR 01-OCT-2002; 2002US-00262839.

XX (CURA-) CURAGEN CORP.

XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
 PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
 PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
 PI Rothenberg ME, Shinkets RA, Smithson G, Spytek KA, Taupier RJ;
 PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;

XX WPI; 2003-381625/36.

DR N-PSDB; ACC72172.

XX

PT NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.

XX Claim 1; Page 265; 487pp; English.

XX The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome
 CC associated with a human disease. The NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune
 CC disorders, haematopoietic disorders and various dyslipidaemias

XX SQ Sequence 577 AA;

Query Match 30.0%; Score 6; DB 6; Length 577;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18

|||||

DB 546 QMLETK 551

RESULT 15

ADJ71063

ID ADJ71063 standard; protein; 731 AA.

XX AC

ADJ71063;

XX DT 06-MAY-2004 (first entry)

XX DE

XX Human heat mitochondrial protein as a therapeutic target SeqID2869.

KW mitochondrial; human; screening assay; diabetes mellitus;

KW Huntington's disease; osteoarthritis;

KW Leber's hereditary optic neuropathy; LHON;

KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;

KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;

KW neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;

KW osteopathic; ophthalmological; cytostatic.

XX OS Homo sapiens.

XX WO2003087768-A2.

XX 23-OCT-2003.

XX 04-APR-2003; 2003WO-US010870.

XX 12-APR-2002; 2002US-0372843P.

XX 17-JUN-2002; 2002US-0389987P.

XX 20-SEP-2002; 2002US-0412418P.

XX (MITO-) MITOKOR.

XX (BUCK-) BUCK INST AGE RES.

XX Ghosh SS, Faby ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;

XX Warnock DE;

XX WPI; 2003-845369/78.

XX Identifying a mitochondrial target for drug screening assays and for
 PT treating diseases associated with altered mitochondrial function,
 PT comprises detecting a modified polypeptide in a sample and correlating
 PT with the disease.

PS Claim 1; SEQ ID NO 2869; 180pp; English.

XX This invention relates to novel mitochondrial targets that can be used

CC for therapeutic intervention in treating a disease associated with
 CC altered mitochondrial function. Specifically, it refers to a method for
 CC identifying proteins of the human heart mitochondrial proteome that are
 CC useful for drug screening assays, as well as therapeutic targets. The
 CC present invention describes a method for identifying such proteins that
 CC can be used in the treatment of various diseases associated with altered
 CC mitochondrial function including diabetes mellitus, Huntington's disease,
 CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
 CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
 CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
 CC compositions have neuroprotective, nootropic, antidiabetic,
 CC anticonvulsant, antiarthritic, osteoprotic, ophthalmological and
 CC cytotactic activities. This polypeptide sequence is a human heart
 CC mitochondrial protein of the invention.

XX Sequence 731 AA;

Query Match 30.0%; Score 6; DB 7; Length 731;
 Best Local Similarity 100.0%; Pred. No. 3.4e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPM 6
 |||||
 Db 542 PRGAPM 547

RESULT 16

ADN99559
 ID ADN99559 standard; protein; 847 AA.

XX AC

ADN99559;

XX 29-JUL-2004 (first entry)

XX Novel human protein sequence #375.

XX anti-inflammatory; dermatological; neuroprotective; immunomodulator;
 KW antibacterial; virucide; antipsoriatic; cytostatic; gene therapy;
 KW vaccine; inflammatory; CNS; immune disorder; cancer; psoriasis; diabetes;
 KW early aging; hormonal imbalance; ischemic heart disease;
 KW ulcerative colitis.

XX Homo sapiens.

XX WC0204038003-A2.

XX 06-MAY-2004.

XX 24-OCT-2003; 2003WO-US033947.

XX 25-OCT-2002; 2002US-0421061P.

PR 25-OCT-2002; 2002US-0421080P.

PR 25-OCT-2002; 2002US-0421552P.

PR 25-OCT-2002; 2002US-0421614P.

PR 30-OCT-2002; 2002US-0422177P.

PR 30-OCT-2002; 2002US-0422178P.

PR 15-NOV-2002; 2002US-0426355P.

PR 15-NOV-2002; 2002US-0426384P.

PR 15-NOV-2002; 2002US-0426394P.

PR 15-NOV-2002; 2002US-0426430P.

PR 15-NOV-2002; 2002US-0426916P.

PR 27-NOV-2002; 2002US-0429224P.

PR 27-NOV-2002; 2002US-0429275P.

PR 27-NOV-2002; 2002US-0429302P.

PR 27-NOV-2002; 2002US-0429326P.

PR 27-NOV-2002; 2002US-0429651P.

PR 04-DEC-2002; 2002US-0430645P.

PR 04-DEC-2002; 2002US-0430651P.

PR 04-DEC-2002; 2002US-0430657P.

PR 04-DEC-2002; 2002US-0430663P.

PR 04-DEC-2002; 2002US-0430668P.

PR 05-DEC-2002; 2002US-0430937P.

PR 05-DEC-2002; 2002US-0430965P.
 PR 05-DEC-2002; 2002US-0431458P.
 PR 12-DEC-2002; 2002US-0433251P.
 PR 12-DEC-2002; 2002US-0433500P.
 PR 13-DEC-2002; 2002US-0433316P.
 PR 13-DEC-2002; 2002US-0433318P.
 PR 23-DEC-2002; 2002US-0436236P.
 PR 03-JAN-2003; 2003US-0437914P.
 PR 17-JAN-2003; 2003US-0440820P.
 PR 17-JAN-2003; 2003US-0440821P.
 PR 18-APR-2003; 2003US-0463700P.
 PR 18-APR-2003; 2003US-0463708P.
 PR 18-APR-2003; 2003US-0463716P.
 PR 18-APR-2003; 2003US-0463732P.
 PR 02-MAY-2003; 2003US-0467199P.
 PR 02-MAY-2003; 2003US-0467201P.
 PR 02-MAY-2003; 2003US-0467203P.
 PR 02-MAY-2003; 2003US-0467230P.
 PR 19-MAY-2003; 2003US-0471306P.
 PR 19-MAY-2003; 2003US-0471336P.
 PR 22-MAY-2003; 2003US-0472420P.
 PR 22-MAY-2003; 2003US-0472430P.
 PR 09-JUN-2003; 2003US-0476609P.
 PR 09-JUN-2003; 2003US-0476621P.
 PR 09-JUN-2003; 2003US-0476632P.
 PR 09-JUN-2003; 2003US-0476641P.
 PR 08-JUL-2003; 2003US-0485217P.
 PR 08-JUL-2003; 2003US-0485218P.
 PR 08-JUL-2003; 2003US-0485223P.
 PR 08-JUL-2003; 2003US-0485224P.
 PR 08-JUL-2003; 2003US-0485325P.
 PR 08-JUL-2003; 2003US-0485359P.
 PR 14-JUL-2003; 2003US-0486446P.
 PR 14-JUL-2003; 2003US-0486480P.
 PR 15-JUL-2003; 2003US-0486891P.
 PR 15-JUL-2003; 2003US-0486960P.
 PR 08-AUG-2003; 2003US-0493341P.
 PR 08-AUG-2003; 2003US-0493370P.
 PR 08-AUG-2003; 2003US-0493573P.
 PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Kothakota S, Lin H, Linnemann T, Pierce X, Wang Y;

Wong JGP, Wu G, Zhang H, Zeng C;

WPI; 2004-365511/34.

N-PSDB; ADN98775.

New nucleic acid molecules, useful in preparing a composition for
 treating or preventing e.g. inflammatory, CNS, bacterial or viral
 disorders, cancer, psoriasis, diabetes, ischemic heart disease or
 ulcerative colitis.

Claim 14; SEQ ID NO 1159; 532pp; English.

The invention relates to a nucleic acid molecule comprising a

polynucleotide sequence or its complement that encodes a polypeptide. The
 nucleic acid is useful in preparing a composition for treating or
 preventing inflammatory, CNS, immune, bacterial or viral disorder,
 cancer, psoriasis, diabetes, early aging, hormonal imbalance, ischemic
 heart disease or ulcerative colitis. This sequence corresponds to a
 protein of the invention.

XX Sequence 847 AA;

Query Match

Best Local Similarity 30.0%; Score 6; DB 8; Length 847;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKFL 20

|||||

Db 385 LETKFL 390

RESULT 17

ID ADL15079 standard; protein; 1290 AA.

XX AC ADL15079;

XX DT 06-MAY-2004 (first entry)

XX DE Human adult male brain KIAA0960 protein for cancer treatment.

XX KW cytostatic; gene therapy; binding moiety; medicine; imaging; diagnosis;

XX KW prognosis; mantle cell lymphoma; cancer.

XX OS Homo sapiens.

XX PN WO2003068268-A2.

XX PD 21-AUG-2003.

XX PF 13-FEB-2003; 2003WO-EP001461.

XX PR 14-FEB-2002; 2002GB-00003480.

XX PR 29-JUN-2002; 2002GB-00015095.

XX PA (BIOL-) BIOINVENT INT AB.

XX PI Ek S, Borrebaeck CAK, Ehinger M;

XX DR WPI; 2003-697496/66.

XX DR N-PSDB; ADL15080.

XX PT New compound for treating, imaging, diagnosing or prognosing mantle cell

PT lymphoma, comprises a binding moiety (e.g. antibody) that binds to a

PT protein (e.g. human autotoxin polypeptide), and a further moiety (e.g.

PT nucleic acid).

XX PS Disclosure; SEQ ID NO 91; 342pp; English.

XX CC The invention relates to a compound comprising a binding moiety which

CC selectively binds to a protein or polypeptide listed in the specification

CC (e.g. human autotoxin polypeptide or human CD24 signal transducer

CC polypeptide), and a further moiety. The compound is useful in medicine or

CC in the treatment, imaging, diagnosis or prognosis of mantle cell

CC lymphomas (MCL). It is used in preparing a medicament for treating MCL, a

CC diagnostic or prognostic agent for MCL, or an agent for imaging MCL cells

CC in the body of an individual. This sequence corresponds to one of the

CC polypeptides of the invention.

SQ Sequence 1290 AA;

Query Match 30.0%; Score 6; DB 7; Length 1290;

Best Local Similarity 100.0%; Pred. No. 5.2e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18

Db 1095 QMLETK 1100

RESULT 18

ID ABR58454

XX AC ABR58454 standard; protein; 1490 AA.

XX AC ABR58454;

XX DT 07-JUL-2003 (first entry)

XX DE Human NOV47e.

XX KW Human; NOV; antidiabetic; anorectic; antibacterial; virucide;

immunomodulator; cytostatic; neurotropic; neuroprotective; dyslipidaemia;

antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;

diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;

neurodegenerative disorder; Alzheimer's disease; immune disorder;

haematopoietic disorder.

OS Homo sapiens.

PN WO2003029423-A2.

XX PD 10-APR-2003.

XX PF 02-OCT-2002; 2002WO-US031358.

XX PR 02-OCT-2001; 2001US-0326483P.

PR 05-OCT-2001; 2001US-0327342P.

PR 09-OCT-2001; 2001US-0327917P.

PR 09-OCT-2001; 2001US-0328029P.

PR 09-OCT-2001; 2001US-0328044P.

PR 12-OCT-2001; 2001US-0328056P.

PR 15-OCT-2001; 2001US-0328849P.

PR 17-OCT-2001; 2001US-0329414P.

PR 17-OCT-2001; 2001US-0330142P.

PR 22-OCT-2001; 2001US-0341058P.

PR 24-OCT-2001; 2001US-0339266P.

PR 24-OCT-2001; 2001US-0343629P.

PR 29-OCT-2001; 2001US-0349575P.

PR 01-NOV-2001; 2001US-0346357P.

PR 12-APR-2002; 2002US-0371972P.

PR 12-APR-2002; 2002US-0371980P.

PR 17-APR-2002; 2002US-0373261P.

PR 19-APR-2002; 2002US-0373805P.

PR 23-APR-2002; 2002US-0374738P.

PR 16-MAY-2002; 2002US-0381101P.

PR 17-MAY-2002; 2002US-0381635P.

PR 29-MAY-2002; 2002US-0383830P.

PR 01-OCT-2002; 2002US-00262839.

XX PA (CURA-) CURAGEN CORP.

XX PI Alsbrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;

PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;

PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;

PI Rothenberg ME, Shinkets RA, Smithson G, Spytek KA, Taupier RJ;

PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;

XX WPI; 2003-381625/36.

XX N-PSDB; ACC72166.

XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or

PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or

PT dyslipidemia, and in chromosome mapping, tissue typing or

PT pharmacogenomics.

XX Claim 1; Page 258-259; 487pp; English.

XX The present invention relates to novel human NOV proteins and their

CC coding sequences (ACC72075-ACC72181 and ABR58469). The NOV

CC proteins are useful in manufacturing a medicament for treating a syndrome

CC associated with a human disease. The NOV proteins and coding sequences

CC may be used to diagnose, treat or prevent metabolic disorders such as

CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative

CC disorders such as Alzheimer's disease or Parkinson's disease, immune

CC disorders, haematopoietic disorders and various dyslipidaemias

XX SQ Sequence 1490 AA;

Query Match 30.0%; Score 6; DB 6; Length 1490;

Best Local Similarity 100.0%; Pred. No. 5.8e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18

|||||

Db 1393 QMLETK 1398
 RESULT 19
 ABR58453
 ID ABR58453 standard; protein; 1545 AA.
 AC ABR58453;
 XX
 XX Query Match 30.0%; Score 6; DB 6; Length 1545;
 DT Best Local Similarity 100.0%; Fred. No. 5.9e+02;
 XX Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DE Human NOV47d.
 XX
 XX Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
 KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.
 XX
 OS Homo sapiens.
 OS
 PN WO2003029423-A2.
 XX
 XX 10-APR-2003.
 XX
 XX 02-OCT-2002; 2002WO-US031358.
 XX
 PR 02-OCT-2001; 2001US-0326483P.
 PR 05-OCT-2001; 2001US-0327342P.
 PR 09-OCT-2001; 2001US-0327917P.
 PR 09-OCT-2001; 2001US-0328029P.
 PR 09-OCT-2001; 2001US-0328044P.
 PR 09-OCT-2001; 2001US-0328056P.
 PR 12-OCT-2001; 2001US-0328949P.
 PR 15-OCT-2001; 2001US-0329414P.
 PR 17-OCT-2001; 2001US-0330142P.
 PR 22-OCT-2001; 2001US-0330158P.
 PR 22-OCT-2001; 2001US-0330158P.
 PR 24-OCT-2001; 2001US-0330158P.
 PR 24-OCT-2001; 2001US-0330158P.
 PR 29-OCT-2001; 2001US-0330158P.
 PR 01-NOV-2001; 2001US-0346357P.
 PR 12-APR-2002; 2002US-0371972P.
 PR 12-APR-2002; 2002US-0371980P.
 PR 17-APR-2002; 2002US-0373261P.
 PR 19-APR-2002; 2002US-0373805P.
 PR 23-APR-2002; 2002US-0374738P.
 PR 16-MAY-2002; 2002US-0381101P.
 PR 17-MAY-2002; 2002US-0381635P.
 PR 29-MAY-2002; 2002US-0383830P.
 PR 01-OCT-2002; 2002US-00262839.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
 PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
 PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
 PI Rothenberg ME, Shinkets RA, Smithson G, Spytek KA, Taupier RJ;
 PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
 XX
 XX WPI; 2003-381625/36.
 DR N-PSDB; ACC72165.
 XX
 XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 XX Claim 1; Page 257; 487pp; English.
 PS
 PS The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58453). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome

CC associated with a human disease. The NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune
 CC disorders, haematopoietic disorders and various dyslipidaemias
 XX
 SQ Sequence 1545 AA;
 Query Match 30.0%; Score 6; DB 6; Length 1545;
 Best Local Similarity 100.0%; Fred. No. 5.9e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 QMLETK 18
 Db 1393 QMLETK 1398
 RESULT 20
 ABR58455
 ID ABR58455 standard; protein; 1549 AA.
 AC ABR58455;
 XX
 XX 07-JUL-2003 (first entry)
 DT
 XX Human NOV47E.
 DE
 XX Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
 KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.
 XX
 OS Homo sapiens.
 OS
 PN WO2003029423-A2.
 XX
 XX 10-APR-2003.
 XX
 XX 02-OCT-2002; 2002WO-US031358.
 XX
 PR 02-OCT-2001; 2001US-0326483P.
 PR 05-OCT-2001; 2001US-0327342P.
 PR 09-OCT-2001; 2001US-0327917P.
 PR 09-OCT-2001; 2001US-0328029P.
 PR 09-OCT-2001; 2001US-0328044P.
 PR 09-OCT-2001; 2001US-0328056P.
 PR 12-OCT-2001; 2001US-0328949P.
 PR 15-OCT-2001; 2001US-0329414P.
 PR 17-OCT-2001; 2001US-0330142P.
 PR 22-OCT-2001; 2001US-0330158P.
 PR 22-OCT-2001; 2001US-0330158P.
 PR 24-OCT-2001; 2001US-0330158P.
 PR 24-OCT-2001; 2001US-0330158P.
 PR 29-OCT-2001; 2001US-0330158P.
 PR 01-NOV-2001; 2001US-0346357P.
 PR 12-APR-2002; 2002US-0371972P.
 PR 12-APR-2002; 2002US-0371980P.
 PR 17-APR-2002; 2002US-0373261P.
 PR 19-APR-2002; 2002US-0373805P.
 PR 23-APR-2002; 2002US-0374738P.
 PR 16-MAY-2002; 2002US-0381101P.
 PR 17-MAY-2002; 2002US-0381635P.
 PR 29-MAY-2002; 2002US-0383830P.
 PR 01-OCT-2002; 2002US-00262839.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
 PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
 PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
 PI Rothenberg ME, Shinkets RA, Smithson G, Spytek KA, Taupier RJ;
 PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
 XX
 XX WPI; 2003-381625/36.
 DR N-PSDB; ACC72165.
 XX
 XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 XX Claim 1; Page 257; 487pp; English.
 PS
 PS The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58453). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome

XX WPI; 2003-381625/36.
 DR N-PSDB; ACC72167.
 XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX Claim 1; Page 260; 487pp; English.
 XX The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR59469). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome
 CC associated with a human disease. The NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune
 CC disorders, haematopoietic disorders and various dyslipidaemias
 XX Sequence 1549 AA;
 SQ Query Match 30.0%; Score 6; DB 6; Length 1549;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 QMLETK 18
 Db 1395 QMLETK 1400
 |||||
 RESULT 21
 AAM41081
 ID AAM41081 standard; protein; 1551 AA.
 XX AAM41081;
 AC 22-OCT-2001 (first entry)
 XX Human polypeptide SEQ ID NO 6012.
 DE Human; nontropic; immunosuppressant; cytostatic; gene therapy; cancer;
 XX peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX Homo sapiens.
 OS WO200153312-A1.
 XX 26-JUL-2001.
 PN 26-DEC-2000; 2000WO-US034263.
 PD 23-DEC-1999; 99US-00471275.
 PF 21-JAN-2000; 2000US-00488725.
 XX 25-APR-2000; 2000US-00552317.
 PR 20-JUN-2000; 2000US-00598042.
 XX 19-JUL-2000; 2000US-00620312.
 PR 03-AUG-2000; 2000US-00653450.
 XX 14-SEP-2000; 2000US-00662191.
 PR 19-OCT-2000; 2000US-00693036.
 XX 29-NOV-2000; 2000US-00727344.
 XX (HYSE-) HYSEQ INC.
 PA Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 XX Wang JT, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
 PI Zhou P, Goodrich R, Drmanac RT;
 XX WPI; 2001-442253/47.

DR N-ESDB; AAI60237.
 XX Novel nucleic acids and polypeptides, useful for treating disorders such
 PT as central nervous system injuries.
 XX Example 2; SEQ ID NO 6012; 10078pp; English.
 XX The invention relates to human nucleic acids (AAI57798-AAI61369) and the
 CC encoded polypeptides (AAM38642-AAM42213) with nontropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening, and
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders. Note: The sequence data for this patent did not form
 CC part of the printed specification
 XX Sequence 1551 AA;
 SQ Query Match 30.0%; Score 6; DB 4; Length 1551;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 QMLETK 18
 Db 1356 QMLETK 1361
 |||||
 RESULT 22
 ADO00979
 ID ADO00979 standard; protein; 1568 AA.
 XX ADO00979;
 AC 01-JUL-2004 (first entry)
 XX Mouse homologue of Fruit fly AD-related protein CGI5671.
 DE Mouse; Alzheimer's disease; Gamma secretase; Psn gene; P-element; EP;
 XX APPL-SV; Amyloid precursor-like protein; APP;
 KW suppressor of hairless transcription factor; Su(H);
 KW VP16 activation domain; dementia; memory loss; language deterioration;
 KW impaired visuospatial skill.
 XX Mus sp.
 OS US2004067535-A1.
 XX 08-APR-2004.
 PD 03-OCT-2002; 2002US-00263929.
 XX 03-OCT-2002; 2002US-00263929.
 PR (LIFE-) LIFE SCI DEV CORP.
 XX Kim J, Galant R;
 PI WPI; 2004-355296/33.
 XX N-PSDB; ADO00877.
 DR Identifying compound by exposing cell that expresses gene having
 PT enhancing or suppression effect on APPL-SV phenotype to agent,
 PT identifying modulation of Alzheimer's disease (AD), regulation of gene or
 PT protein expression with AD.
 XX Claim 18; SEQ ID NO 117; 185pp; English.

XX The invention relates to identifying a compound comprising exposing cell
 CC expressing gene 1 having enhancing or suppression effect on an APP-SV
 CC phenotype (a transgenic fruit fly expressing the Amyloid precursor-like
 CC protein, APP, as a fusion protein with the suppressor of hairless
 CC transcription factor, Su(H) and Vp16 activation domain. The fusion
 CC protein is cleaved by gamma secretase (encoded by the Psn gene) to
 CC release the Su(H-Vp16, which affects wing vein development. Genes
 CC affecting Psn expression/activity were screened by crossing the APP-SV
 CC line with an EP P-element insertion library, and the DNA recovered from
 CC the appropriate EP strain and sequenced) chosen from AD000863-AD000964,
 CC being the identified fruit fly genes affecting APP processing and their
 CC mammalian homologues, identifying modulation of Alzheimer's disease (AD)
 CC symptom, regulation of biological pathway, gene expression or protein
 CC function associated with AD relative to cell in absence of agent. Also
 CC included are regulating AD (involves providing a subject with AD or
 CC symptoms of AD and an agent that changes the expression of a gene
 CC detailed above or changes the activity of a polypeptide having a sequence
 CC chosen from AD000965-AD001066, and treating the subject with the agent)
 CC and a composition (comprising a nucleic acid encoding a polypeptide
 CC detailed above or an expression vector comprising the nucleic acid or a
 CC host cell comprising the expression vector or an antisense
 CC oligonucleotide that hybridises under stringent conditions to the nucleic
 CC acid or polypeptide or an antibody that specifically binds to the
 CC polypeptide). The method is useful for identifying compounds modulating
 CC symptom of Alzheimer's disease (AD), regulation of biological pathway
 CC associated with AD, or regulation of gene expression or protein function
 CC of gene or protein associated with AD. The nucleic acids and proteins are
 CC useful in drug screening and useful in screening and treating the subject
 CC having increased susceptibility to AD or symptoms of AD such as dementia,
 CC memory loss, language deterioration and impaired visuospatial skills. The
 CC present sequence is a mouse homologue of a fruit fly protein from a gene
 CC identified as having an effect on the APP-SV phenotype.

SQ Sequence 1568 AA;

Query Match 30.0%; Score 6; DB 8; Length 1568;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVCQ 13
 |||||
 Db 394 LRCVCQ 399

RESULT 23
 AAB20155
 ID AAB20155 standard; protein; 1588 AA.
 XX
 AC AAB20155;
 XX
 DT 30-APR-2001 (first entry)
 DE Secreted protein SECP1.
 XX
 KW SECP1; secreted protein; human; diagnosis; therapy; lung cancer.
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..23 /label= Signal_peptide
 FT Protein 24..1588 /label= Mature protein
 FT /note= "Mature SECP1 is also specifically claimed in
 FT Claim 1"
 XX
 PN WO200105971-A2.
 XX
 XX 25-JAN-2001.
 XX
 XX 20-JUL-2000; 2000WO-US019890.

PR 20-JUL-1999; 99US-0144722P.
 PR 29-NOV-1999; 99US-0167785P.
 PR 19-JUL-2000; 2000US-00619252.

XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Fernandes E;

XX WPI: 2001-091973/10.

DR N-PSDB; AAF30188.

XX New polypeptide designated SECP, its encoding nucleic acid and its
 PT immunospecific antibody, useful for diagnosing, preventing and treating
 SECP-associated disorders such as cancer.

XX Claim 1; Fig 1; 124pp; English.

XX The present sequence is that of novel secreted protein SECP1, which is
 CC predicted to localise in the plasma membrane. The protein shows homology
 CC to human KIAA0960 protein. RNA species with homology to the SECP1 cDNA
 CC were detected in endothelial cells, pancreas, adipose, adrenal gland,
 CC thyroid, mammary gland, myometrium, uterus, placenta, prostate, testis,
 CC and in neoplastic cells derived from ovarian carcinoma, breast carcinoma,
 CC prostate carcinoma (bone metastases) and melanoma. SECP1 was also highly
 CC expressed in a small cell lung cancer, a large cell lung cancer, and a
 CC non-small cell lung cancer, and may be useful as a target for the
 CC treatment of such cancers. The predicted SECP1 protein showed homology to
 CC human KIAA0960. The invention provides 9 novel SECP secreted proteins
 CC (see AAB20155-63), nucleic acids encoding them (see AAF30188-96),
 CC antibodies, mutants or fragments. These can be used to detect, treat or
 CC prevent an SECP-associated disorder, to screen for predisposition to such
 CC a disorder, and to identify agents that modulate the expression or
 CC activity of SECP

XX Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 4; Length 1588;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
 |||||
 Db 1393 QMLETK 1398

RESULT 24
 AAM39295
 ID AAM39295 standard; protein; 1588 AA.
 XX
 AC AAM39295;
 XX
 DT 22-OCT-2001 (first entry)
 DE Human polypeptide SEQ ID NO 2440.
 XX
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX
 OS Homo sapiens.
 XX
 XX WO200153312-A1.
 PN
 XX 26-JUL-2001.
 XX
 XX 26-DEC-2000; 2000WO-US034263.
 PF
 XX 23-DEC-1999; 99US-00471275.
 PR 21-JAN-2000; 2000US-00488725.
 PR 25-APR-2000; 2000US-00552317.

```

PR 20-JUN-2000; 2000US-00598042.
PR 19-JUL-2000; 2000US-00620312.
PR 03-AUG-2000; 2000US-00653450.
PR 14-SEP-2000; 2000US-00662191.
PR 19-OCT-2000; 2000US-00693036.
PR 29-NOV-2000; 2000US-00727344.
XX (HYSE-) HYSEQ INC.
XX
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
PI Zhou P, Goodrich R, Drmanac RT;
XX
XX WPI; 2001-442253/47.
DR N-PSDB; AAI58451.
XX
XX Novel nucleic acids and polypeptides, useful for treating disorders such
PT as central nervous system injuries.
XX
XX Example 4; SEQ ID NO 2440; 10078pp; English.
XX
XX The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC encoded polypeptides (AAI38642-AAI42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders. Note: The sequence data for this patent did not form
CC part of the printed specification
XX
XX Sequence 1588 AA;
XX
XX Query Match 30.0%; Score 6; DB 4; Length 1588;
XX Best Local Similarity 100.0%; Pred. No. 6e+02; Mismatches 0; Gaps 0;
XX Matches 6; Conservative 0; Indels 0;
XX
XX QY 13 QMLETK 18
XX 1393 QMLETK 1398
XX
XX RESULT 25
XX ABR58450
XX ID ABR58450 standard; protein; 1588 AA.
XX AC ABR58450;
XX XX
XX XX 07-JUL-2003 (first entry)
XX XX Human NOV47a.
XX XX
XX KW Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW antiparkinsonian; antilepaemic; gene therapy; metabolic disorder;
KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW haematopoietic disorder.
XX
XX OS Homo sapiens.
XX XX
XX XX WO2003029423-A2.
XX PD
XX PD 10-APR-2003.
XX XX
XX XX 02-OCT-2002; 2002WO-US031359.
XX XX

```

```

PR 02-OCT-2001; 2001US-0326483P.
PR 05-OCT-2001; 2001US-0327342P.
PR 09-OCT-2001; 2001US-0327917P.
PR 09-OCT-2001; 2001US-0328029P.
PR 09-OCT-2001; 2001US-0328044P.
PR 09-OCT-2001; 2001US-0328056P.
PR 12-OCT-2001; 2001US-0328849P.
PR 15-OCT-2001; 2001US-0329414P.
PR 17-OCT-2001; 2001US-0330142P.
PR 22-OCT-2001; 2001US-0341058P.
PR 24-OCT-2001; 2001US-0339286P.
PR 24-OCT-2001; 2001US-0343629P.
PR 29-OCT-2001; 2001US-0349575P.
PR 01-NOV-2001; 2001US-0346357P.
PR 12-APR-2002; 2002US-0371972P.
PR 12-APR-2002; 2002US-0371980P.
PR 17-APR-2002; 2002US-0373261P.
PR 19-APR-2002; 2002US-0373805P.
PR 23-APR-2002; 2002US-0374738P.
PR 16-MAY-2002; 2002US-0381101P.
PR 17-MAY-2002; 2002US-0381635P.
PR 29-MAY-2002; 2002US-0383830P.
PR 01-OCT-2002; 2002US-00262839.
XX (CURA-) CURAGEN CORP.
XX
XX Alsbrook JP, Anderson DW, Boldog PL, Burgess CE, Catterton E;
PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
PI Ketuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
PI Rothenberg ME, Shinkets RA, Smithson G, Spytek KA, Taupier RJ;
PI Vernet CAM, Voss EZ, Zernhusen BD, Zhong M;
XX
XX WPI; 2003-381625/36.
DR N-PSDB; ACC72162.
XX
XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
XX dyslipidemia, and in chromosome mapping, tissue typing or
XX pharmacogenomics.
XX
XX Claim 1; Page 254-255; 487pp; English.
XX
XX The present invention relates to novel human NOV proteins and their
CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC proteins are useful in manufacturing a medicament for treating a syndrome
CC associated with a human disease. The NOV proteins and coding sequences
CC may be used to diagnose, treat or prevent metabolic disorders such as
CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC disorders such as Alzheimer's disease or Parkinson's disease, immune
CC disorders, haematopoietic disorders and various dyslipidaemias
XX
XX Sequence 1588 AA;
XX
XX Query Match 30.0%; Score 6; DB 6; Length 1588;
XX Best Local Similarity 100.0%; Pred. No. 6e+02; Mismatches 0; Gaps 0;
XX Matches 6; Conservative 0; Indels 0;
XX
XX QY 13 QMLETK 18
XX 1393 QMLETK 1398
XX
XX RESULT 26
XX ABR58456
XX ID ABR58456 standard; protein; 1588 AA.
XX XX
XX AC ABR58456;
XX XX
XX XX 07-JUL-2003 (first entry)
XX XX Human NOV47g.
XX XX
XX KW Human; NOV; antidiabetic; anorectic; antibacterial; virucide;

```

KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.

XX Homo sapiens.

OS WO2003029423-A2.

XX 10-APR-2003.

XX 02-OCT-2002; 2002WO-US031358.

XX 02-OCT-2001; 2001US-0326483P.

PR 05-OCT-2001; 2001US-0327342P.

PR 08-OCT-2001; 2001US-0327917P.

PR 08-OCT-2001; 2001US-0328029P.

PR 09-OCT-2001; 2001US-0328044P.

PR 09-OCT-2001; 2001US-0328056P.

PR 12-OCT-2001; 2001US-0328849P.

PR 15-OCT-2001; 2001US-0329414P.

PR 17-OCT-2001; 2001US-0330142P.

PR 22-OCT-2001; 2001US-0341058P.

PR 24-OCT-2001; 2001US-0339266P.

PR 24-OCT-2001; 2001US-0339266P.

PR 24-OCT-2001; 2001US-0339266P.

PR 29-OCT-2001; 2001US-0343629P.

PR 29-OCT-2001; 2001US-0343629P.

PR 01-NOV-2001; 2001US-034357P.

PR 12-APR-2002; 2002US-0371972P.

PR 12-APR-2002; 2002US-0371980P.

PR 17-APR-2002; 2002US-0373261P.

PR 19-APR-2002; 2002US-0373805P.

PR 17-APR-2002; 2002US-0373805P.

PR 23-APR-2002; 2002US-0374738P.

PR 16-MAY-2002; 2002US-0381101P.

PR 17-MAY-2002; 2002US-0381635P.

PR 29-MAY-2002; 2002US-0383830P.

PR 01-OCT-2002; 2002US-00262839.

XX (CURA-) CURAGEN CORP.

XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;

PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;

PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;

PI Rothenberg ME, Shimkets RA, Smithson G, Spytek KA, Taupier RJ;

PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;

XX WPI; 2003-381625/36.

DR N-PSDB; ACC72168.

XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or

PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or

PT dyslipidemia, and in chromosome mapping, tissue typing or

PT pharmacogenomics.

XX Claim 1; Page 262; 487pp; English.

XX The present invention relates to novel human NOV proteins and their

CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV

CC proteins are useful in manufacturing a medicament for treating a syndrome

CC associated with a human disease. The NOV proteins and coding sequences

CC may be used to diagnose, treat or prevent metabolic disorders such as

CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative

CC disorders such as Alzheimer's disease or Parkinson's disease, immune

CC disorders, haematopoietic disorders and various dyslipidaemias

XX Sequence 1588 AA;

SQ

Query Match 30.0%; Score 6; DB 6; Length 1588;

Best Local Similarity 100.0%; Pred. No. 6e+02; 0; Indels 0; Gaps 0;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18

|||||

Db 1393 QMLETK 1398

RESULT 27

ABR58459

ID ABR58459 standard; protein; 1588 AA.

XX ABR58459,

AC ABR58459,

XX 07-JUL-2003 (first entry)

DT Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

XX Human NOV47j.

CC associated with a human disease. The NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune
 CC disorders, haematopoietic disorders and various dyslipidaemias
 XX
 SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 6; Length 1588;
 Best Local Similarity 100.0%; Pred. No. 6e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 6; Conservative 0;

Qy 13 QMLETK 18
 |||||
 Db 1393 QMLETK 1398

RESULT 28
 ABR58462
 ID ABR58462 standard; protein; 1588 AA.

XX ABR58462;

XX 07-JUL-2003 (first entry)

XX Human NOV47m.

XX Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
 KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
 KW antiparkinsonian; antilipaeamic; gene therapy; metabolic disorder;
 KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
 KW haematopoietic disorder.

XX Homo sapiens.

XX WO2003029423-A2.

XX 10-APR-2003.

XX 02-OCT-2002; 2002WO-US031358.

XX 02-OCT-2001; 2001US-0326483P.

XX 05-OCT-2001; 2001US-0327342P.

XX 09-OCT-2001; 2001US-0327917P.

XX 09-OCT-2001; 2001US-0328029P.

XX 09-OCT-2001; 2001US-0328044P.

XX 09-OCT-2001; 2001US-0328056P.

XX 12-OCT-2001; 2001US-0328849P.

XX 15-OCT-2001; 2001US-0329414P.

XX 17-OCT-2001; 2001US-0330142P.

XX 22-OCT-2001; 2001US-0341058P.

XX 24-OCT-2001; 2001US-0339266P.

XX 24-OCT-2001; 2001US-0343629P.

XX 29-OCT-2001; 2001US-0349575P.

XX 01-NOV-2001; 2001US-0346357P.

XX 12-APR-2002; 2002US-0371972P.

XX 12-APR-2002; 2002US-0371980P.

XX 17-APR-2002; 2002US-0373261P.

XX 19-APR-2002; 2002US-0373805P.

XX 23-APR-2002; 2002US-0374738P.

XX 16-MAY-2002; 2002US-0381101P.

XX 17-MAY-2002; 2002US-0381635P.

XX 29-MAY-2002; 2002US-0383830P.

XX 01-OCT-2002; 2002US-00262839.

XX (CURA-) CURAGEN CORP.

XX PA

XX Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;

PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;

PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;

PI Rothenberg ME, Shimkets RA, Smithson G, Szytek KA, Taupier RJ;

PI Vernet CAM, Voss EZ, Zernhusen BD, Zhong M;

XX WPI; 2003-381625/36.
 DR N-PSDB; ACC72174.

XX NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
 PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
 PT dyslipidemia, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.

XX Claim 1; Page 267; 487pp; English.

XX The present invention relates to novel human NOV proteins and their
 CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
 CC proteins are useful in manufacturing a medicament for treating a syndrome
 CC associated with a human disease. The NOV proteins and coding sequences
 CC may be used to diagnose, treat or prevent metabolic disorders such as
 CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
 CC disorders such as Alzheimer's disease or Parkinson's disease, immune
 CC disorders, haematopoietic disorders and various dyslipidaemias
 XX
 SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 6; Length 1588;
 Best Local Similarity 100.0%; Pred. No. 6e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 6; Conservative 0;

Qy 13 QMLETK 18

Db 1393 QMLETK 1398

|||||

RESULT 29

ADG38871

ID ADG38871 standard; protein; 1588 AA.

XX ADG38871;

XX 26-FEB-2004 (first entry)

XX Human SECP10.

XX SECP; SECP-associated disorder; cancer; wound; AIDS; hepatitis;

KW arteriosclerosis; psoriasis; autoimmune disease; Crohn's disease;

KW inflammatory disorder; anaemia; allergy; asthma; Grave's disease;

KW multiple sclerosis; scleroderma; infection; diabetes; metabolic disorder;

KW Addison's disease; cystic fibrosis; glycogen storage disease;

KW Alzheimer's disease; Parkinson's disease; addiction; cardiomyopathy;

KW obesity; tissue typing; vaccine; human.

XX Homo sapiens.

XX US2003207348-A1.

XX 06-NOV-2003.

XX 13-FEB-2002; 2002US-00074566.

XX 20-JUL-1999; 99US-0144722P.

XX 29-NOV-1999; 99US-0167785P.

XX 19-JUL-2000; 2000US-00619252.

XX 19-MAR-2001; 2001US-0276994P.

XX 02-APR-2001; 2001US-0280898P.

XX 02-MAY-2001; 2001US-0288062P.

XX 17-MAY-2001; 2001US-0291766P.

XX 21-AUG-2001; 2001US-0314007P.

XX 14-NOV-2001; 2001US-0332241P.

XX (SHIM/) SHIMKETS R A.

PA (FERN/) FERNANDES E R.

PA (LILL/) LI L.

PA (GORM/) GORMAN L.

PA (GUSE/) GUSEV V Y.

PA (PADI/) PADIGARU M.

PA (PATT/) PATTURAJAN M.
 PA (SHEN/) SHENOY S G.
 PA (SPYT/) SPYTEK K A.
 XX
 PI Shimkets RA, Fernandes ER, Li L, Gorman L, Gusev VY, Padigaru M;
 PI Fatturajan M, Shenoy SG, Spytek KA;
 XX
 DR WPI; 2003-901057/82.
 DR N-PSDB; ADG38870.
 XX
 XX New SECP polypeptides and nucleic acids, useful for preventing or
 PT treating SECP-associated disorders, e.g. cancer, diabetes, asthma, AIDS
 PT or autoimmune diseases, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 PS Claim 1; SEQ ID NO 41; 278pp; English.
 XX
 CC The invention relates to a new isolated SECP polypeptide. The SECP
 CC polypeptide, nucleic acid molecule or antibody is useful in the
 CC manufacture of a medicament for treating a syndrome associated with a
 CC human disease, the disease being selected from SECP-associated disorders.
 CC These are used in diagnosing, treating or preventing the SECP-associated
 CC disorders such as cancer, wounds, AIDS, hepatitis, arteriosclerosis,
 CC psoriasis, autoimmune diseases, Crohn's disease, inflammatory disorder,
 CC anaemia, allergy, asthma, Grave's disease, multiple sclerosis,
 CC scleroderma, infection, diabetes, metabolic disorder, Addison's disease,
 CC cystic fibrosis, glycogen storage disease, Alzheimer's disease,
 CC Parkinson's disease, addiction, cardiomyopathy or obesity. The nucleic
 CC acids are further used as hybridisation probes, in chromosome mapping,
 CC tissue typing, preventive medicine, and pharmacogenomics. The
 CC polypeptides are also useful as vaccines. The present sequence is used in
 CC the exemplification of the present invention.
 XX
 SQ Sequence 1588 AA;
 Query Match 30.0%; Score 6; DB 7; Length 1588;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 QMLETK 18
 DB 1393 QMLETK 1398
 RESULT 30
 ADG38832
 ID ADG38832 standard; protein; 1588 AA.
 XX
 AC ADG38832;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human SECP1.
 XX
 KW SECP; SECP-associated disorder; cancer; wound; AIDS; hepatitis;
 KW arteriosclerosis; psoriasis; autoimmune disease; Crohn's disease;
 KW inflammatory disorder; anaemia; allergy; asthma; Grave's disease;
 KW multiple sclerosis; scleroderma; infection; diabetes; metabolic disorder;
 KW Addison's disease; cystic fibrosis; glycogen storage disease;
 KW Alzheimer's disease; Parkinson's disease; addiction; cardiomyopathy;
 KW obesity; tissue typing; vaccine; human.
 XX
 OS Homo sapiens.
 XX
 PN US2003207348-A1.
 XX
 PD 06-NOV-2003.
 XX
 XX 13-FEB-2002; 2002US-00074566.
 XX
 PF 20-JUL-1999; 99US-0144722P.
 XX
 PR 29-NOV-1999; 99US-0167785P.
 PR
 PR 19-JUL-2000; 2000US-00619252.

PR 19-MAR-2001; 2001US-0276994P.
 PR 02-APR-2001; 2001US-0280898P.
 PR 02-MAY-2001; 2001US-0289062P.
 PR 17-MAY-2001; 2001US-0291766P.
 PR 21-AUG-2001; 2001US-0314007P.
 PR 14-NOV-2001; 2001US-0332241P.
 XX
 XX (SHIM/) SHIMKETS R A.
 PA (FERN/) FERNANDES E R.
 PA (LILL/) LI L.
 PA (GORM/) GORMAN L.
 PA (GUSE/) GUSEV V Y.
 PA (PADI/) PADIGARU M.
 PA (PATT/) PATTURAJAN M.
 PA (SHEN/) SHENOY S G.
 PA (SPYT/) SPYTEK K A.
 XX
 XX Shimkets RA, Fernandes ER, Li L, Gorman L, Gusev VY, Padigaru M;
 PI Fatturajan M, Shenoy SG, Spytek KA;
 XX
 DR WPI; 2003-901057/82.
 DR N-PSDB; ADG38831.
 XX
 PT New SECP polypeptides and nucleic acids, useful for preventing or
 PT treating SECP-associated disorders, e.g. cancer, diabetes, asthma, AIDS
 PT or autoimmune diseases, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 PS Claim 1; SEQ ID NO 2; 278pp; English.
 XX
 CC The invention relates to a new isolated SECP polypeptide. The SECP
 CC polypeptide, nucleic acid molecule or antibody is useful in the
 CC manufacture of a medicament for treating a syndrome associated with a
 CC human disease, the disease being selected from SECP-associated disorders.
 CC These are used in diagnosing, treating or preventing the SECP-associated
 CC disorders such as cancer, wounds, AIDS, hepatitis, arteriosclerosis,
 CC psoriasis, autoimmune diseases, Crohn's disease, inflammatory disorder,
 CC anaemia, allergy, asthma, Grave's disease, multiple sclerosis,
 CC scleroderma, infection, diabetes, metabolic disorder, Addison's disease,
 CC cystic fibrosis, glycogen storage disease, Alzheimer's disease,
 CC Parkinson's disease, addiction, cardiomyopathy or obesity. The nucleic
 CC acids are further used as hybridisation probes, in chromosome mapping,
 CC tissue typing, preventive medicine, and pharmacogenomics. The
 CC polypeptides are also useful as vaccines. The present sequence is used in
 CC the exemplification of the present invention.
 XX
 SQ Sequence 1588 AA;
 Query Match 30.0%; Score 6; DB 7; Length 1588;
 Best Local Similarity 100.0%; Pred. No. 6e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 13 QMLETK 18
 DB 1393 QMLETK 1398
 RESULT 31
 AAE23979
 ID AAE23979 standard; protein; 1624 AA.
 XX
 AC AAE23979;
 XX
 DT 23-SEP-2002 (first entry)
 XX
 DE Human LP217 secreted protein.
 XX
 KW Human; secreted protein; atherosclerosis; Alzheimer's disease; LP217;
 KW diabetic retinopathy; severe combined immunodeficiency; pancreatitis;
 KW rheumatoid arthritis; colorectal adenoma; haemolytic anaemia; cancer;
 KW reperfusion injury; arteriosclerosis; wound healing; transgenic animal;
 KW gene therapy; neoplasm; psoriasis; psoriasis; ischaemia; carcinoma;
 KW chromosome 7p21-p22.

```
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX FT Peptide 1..15
XX FT /label= Signal_peptide
XX FT Protein 16..1624
XX FT /note= "Mature human LP217 secreted protein"
XX
XX PN W0200226801-A2.
XX
XX PD 04-APR-2002.
XX
XX PF 14-SEP-2001; 2001WO-US026026.
XX
XX PR 28-SEP-2000; 2000US-0236088P.
XX
XX PA (ELIL ) LILLY & CO ELI.
XX
XX PI Su EW, Wang H;
XX
XX DR WPI; 2002-471259/50.
XX DR N-PSDB; AAD38694.
XX
XX PT Novel proteins and polynucleotides of secreted proteins useful for
XX PT treating various diseases e.g. rheumatoid arthritis, cancer, psoriasis,
XX PT diabetic retinopathy, arteriosclerosis, ischemia or reperfusion injury.
XX
XX PS Claim 8; Page 117-123; 145pp; English.
XX
XX CC The invention relates to human secreted polypeptides designated LP095,
XX CC LP191, LP217, LP220, LP221, LP222, LP229, LP237 or LP238 and nucleic acid
XX CC molecules encoding such polypeptides. Novel secreted proteins of the
XX CC invention are used for treating diseases such as atherosclerosis,
XX CC Alzheimer's disease, diabetic retinopathy, psoriasis, pancreatitis,
XX CC arteriosclerosis, rheumatoid arthritis, colorectal adenomas, severe
XX CC combined immunodeficiency, ischaemia, carcinomas, haemolytic anaemia,
XX CC reperfusion injury, neoplasms and cancer especially liver cancer. They
XX CC are also used for wound healing. Polynucleotides of the invention can be
XX CC used to generate transgenic animals or knock out animals, which in turn,
XX CC are useful in the development and screening of therapeutically useful
XX CC reagents for use in the treatment of diseases associated with LP
XX CC polypeptide associated activity. They are also used in gene therapy. The
XX CC present sequence is human LP217 secreted protein. LP217 gene is located
XX CC on chromosome 7p21-p22
XX
XX SQ Sequence 1624 AA;

Query Match 30.0%; Score 6; DB 5; Length 1624;
Best Local Similarity 100.0%; Pred. No. 6.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
Db 1429 QMLETK 1434

RESULT 32
AAR37732
ID AAR37732 standard; peptide; 9 AA.
XX
XX AC AAR37732;
XX
XX DT 25-MAR-2003 (revised)
XX DT 07-SEP-1993 (first entry)
XX
XX DE Collagen-like polymer #15.
XX
XX KW Recombinant; collagen-like polymer; CLP; tripeptide; helix; membrane;
XX KW fibre; film; coating; triad sequence; collagen; mammalian; moulding;
XX KW hydrogel; interchain linkage; colloid suspension.
XX
XX OS Synthetic.
```

```
XX WO9310154-A1.
XX
XX PD 27-MAY-1993.
XX
XX PF 04-NOV-1992; 92WO-US009485.
XX
XX PR 12-NOV-1991; 91US-00791960.
XX
XX (PROT-) PROTEIN POLYMER TECHNOLOGIES INC.
XX
XX PI Cappello J, Ferrari FA;
XX PI WPI; 1993-182496/22.
XX
XX PT High mol. wt. collagen-like protein polymers - capable of being produced
XX PT in unicellular microorganisms.
XX
XX PS Disclosure; Page 12; 82pp; English.
XX
XX CC The sequences given in AAR37718-32 are examples of recombinantly produced
XX CC collagen-like polymers (CLPs) which consist of repeated tripeptide
XX CC sequences selected from a wide range of GXY sequences, where X and Y can
XX CC be any amino acid. These polymers have molecular weights of >30 kD and
XX CC are able to form helices due to interchain linkages. These polymers pref.
XX CC contain a proportion of tripeptide triad linkages. The CLPs impart unique
XX CC collagens, pref. mammalian collagens. The CLPs impart unique
XX CC characteristics to materials such as fibres, membranes, films, coatings,
XX CC hydrogels, colloid suspensions and moulded articles. (Updated on 25-MAR-
XX CC 2003 to correct PN field.)
XX
XX SQ Sequence 9 AA;

Query Match 25.0%; Score 5; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.1e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 5 PRGAP 9

RESULT 33
AAR93239
ID AAR93239 standard; peptide; 9 AA.
XX
XX AC AAR93239;
XX
XX DT 25-MAR-2003 (revised)
XX DT 24-FEB-1996 (first entry)
XX
XX DE Collagen-like GUB sequence motif 5.
XX
XX KW collagen; repetitive triad motif; recombinant production; photographic;
XX KW medical; structural; fibre.
XX
XX OS Synthetic.
XX
XX PN US5496712-A.
XX
XX PD 05-MAR-1996.
XX
XX PF 05-NOV-1992; 92US-00972032.
XX
XX PR 06-NOV-1990; 90US-00609716.
XX PR 12-NOV-1991; 91US-00791960.
XX
XX (PROT-) PROTEIN POLYMER TECHNOLOGIES INC.
XX
XX PI Cappello J, Ferrari FA;
XX
XX DR WPI; 1996-150728/15.
XX
```

PT Collagen-like polymers comprising repetitive triads - produced in
 PT unicellular organisms with improved characteristics, useful in, e.g.
 PT photographic and medical fibres.

XX Disclosure; Col 6; 43pp; English.

XX The invention concerns collagen-like polymers having repetitive triads
 CC with reduced proline content, and where glycine is the initial amino acid
 CC and the subsequent amino acids are varied. The choice of triads utilised
 CC in a recombinant collagen-like polymer are chosen in order to affect
 CC properties such as helix stability, hydration, solubility, gel point,
 CC biodegradation and immunogenicity. Also considered is the level of
 CC guanidine and cytosine nucleotides (due to levels of glycine and proline)
 CC present in the genes encoding the polymers. As the gene is synthesised
 CC there is opportunity for strands to loop out, single-stranded DNA to be
 CC excised, recombination events to occur which can result in loss of
 CC segments of the gene, and inefficient transcription and/or translation
 CC (due to the presence of self-complementary sequences), hence genes of the
 CC invention are designed to provide the advantageous properties of
 CC collagen, while at the same time allowing for stable expression of high
 CC mol. wt. collagen-like proteins. Triads of particular interest include
 CC GAP, GPA, GPP, GAS, GPG, GPS, GAQ, GSP, GIQ, GPR, GPK, GAK, GAR, GER,
 CC GPR, GEP, GPA, GAH and GEA. The collagen-like polymers may impart new
 CC characteristics, finding wide use in photographic, medical, structural
 CC and fibre applications, and are capable of being produced in unicellular
 CC microorganisms at high mol. wts. and in high efficiency. AAR9235-39 are
 CC peptides defining GUB (sic) sequences. The peptides are useful as
 CC haptens, to produce antisera or monoclonal antibodies specific to the
 CC sequences which are then used for affinity purification, identification
 CC of the polymers, etc. (Updated on 25-MAR-2003 to correct PF field.)
 CC (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 9 AA;

Query Match 25.0%; Score 5; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
 Db |||||
 5 PRGAP 9

RESULT 34

AAW57686
 ID AAW57686 standard; peptide; 9 AA.

XX AAW57686;

XX 27-AUG-1998 (first entry)

XX Collagen-like polymer fragment.

XX Collagen-like polymer; synthetic polymer; fibre coating;
 KW prosthetic device; catalytic substance.

XX Synthetic.

XX US5773249-A.

XX 30-JUN-1998.

XX 02-MAY-1996; 96US-00642255.

XX 04-NOV-1986; 86US-00927258.

XX 29-OCT-1987; 87US-00114618.

XX 09-NOV-1988; 88US-00269429.

XX 06-NOV-1990; 90US-00603716.

XX 12-NOV-1991; 91US-00791960.

XX 05-NOV-1992; 92US-00972032.

XX 22-DEC-1995; 95US-00577046.

(PROT-) PROTEIN POLYMER TECHNOLOGIES INC.

XX Ferrari PA, Cappello J;
 PI
 XX WPI; 1998-387004/33.

XX Recombinant collagen-like polymers - useful for making gels, films,
 PT fibres, etc.

XX Disclosure; Col 6; 93pp; English.

XX This sequence represents a fragment of a unnatural collagen-like polymer
 CC of the invention. The products may be used as films, fibres, moulded
 CC objects and admixed with other natural or synthetic polymers or coatings
 CC on fibres, films, labware or other surfaces, e.g. prosthetic devices. The
 CC polymers may be used for binding a wide variety of specific binding
 CC materials, as catalytic substances (where the amino acid sequence may
 CC specifically chelate a wide variety of elements), as purification media,
 CC composites, laminates or adhesives. They may also be combined with
 CC inorganic or organic materials such as carbon fibres, nylon fibres,
 CC nitrocellulose, etc., as flask coatings or in synthetic matrices for the
 CC growth and study of cells, as affinity columns or as supports for
 CC biological materials. The polymers have collagen-like properties, but may
 CC be easily expressed in micro-organisms in high efficiency. The new
 CC sequences can be tailored to give the desired properties

XX Sequence 9 AA;

Query Match 25.0%; Score 5; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
 Db |||||
 5 PRGAP 9

RESULT 35

AAU71713
 ID AAU71713 standard; peptide; 9 AA.

XX AAU71713;

XX 26-FEB-2002 (first entry)

XX Human MHC molecule HLA-B35 binding 103P3E8 peptide #20.

XX 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach;
 KW tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme;
 KW single chain monoclonal antibody; serum; blood; urine; tissue; human;
 KW chromosome 9q13-q21.

XX Homo sapiens.

XX WO200179557-A2.

XX 25-OCT-2001.

XX 12-APR-2001; 2001WO-US012181.

XX 12-APR-2000; 2000US-0196647P.

XX (UROG-) UROGENESYS INC.

XX Paris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH;
 PI Jakobovits A;

XX WPI; 2002-061976/08.

XX Monitoring 103P3E8 gene products in sample from patient (suspected of)
 PT having cancer, useful for diagnosing, managing or treating cancers, e.g.
 PT prostate cancer, comprises determining presence of aberrant 103P3E8 gene
 PT products.

PS Disclosure; Page 98; 128pp; English.

XX Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and peptide fragments of the protein. 103P3E8 exhibits tissue specific expression in normal adult tissue, but it is also aberrantly expressed in many cancers including tumours of the prostate, bladder, kidney, colon, lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related protein and peptide fragments and specific PCR primers are therefore useful for diagnosing and treating cancer. A vector comprising a polynucleotide which encodes a single chain monoclonal antibody, that immunospecifically binds to an 103P3E8-related protein, and a ribozyme capable of cleaving a polynucleotide having the 103P3E8 coding sequence, are both useful in the preparation of a composition for treating a patient with a cancer that expresses 103P3E8. The sequences can be used in diagnostic methods to monitor the level of 103P3E8 gene products in serum, blood, urine and tissue and to thereby detect the presence of cancerous cells

XX Sequence 9 AA;

Query Match 25.0%; Score 5; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06; Mismatches 0; Indels 0; Gaps 0;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||

Db 2 PRGAP 6

RESULT 36

AAU71607

ID AAU71607 standard; peptide; 9 AA.

XX AAU71607;

AC AAU71607;

XX 26-FEB-2002 (first entry)

DT Human MHC class I molecule HLA-B7 binding 103P3E8 peptide #14.

DE 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach; tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme; single chain monoclonal antibody; serum; blood; urine; tissue; human; chromosome 9q13-q21.

XX Homo sapiens.

OS WO200179557-A2.

PN 25-OCT-2001.

XX 12-APR-2001; 2001WO-US012181.

PF 12-APR-2000; 2000US-0196647P.

PR (UROC-) UROGENESYS INC.

XX Faris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH; Jakobovits A;

PI WPI; 2002-061976/08.

XX Monitoring 103P3E8 gene products in sample from patient (suspected of) having cancer, useful for diagnosing, managing or treating cancers, e.g. prostate cancer, comprises determining presence of aberrant 103P3E8 gene products.

PS Disclosure; Page 95; 128pp; English.

XX Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and peptide fragments of the protein. 103P3E8 exhibits tissue specific expression in normal adult tissue, but it is also aberrantly expressed in many cancers including tumours of the prostate, bladder, kidney, colon, lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related

CC protein and peptide fragments and specific PCR primers are therefore useful for diagnosing and treating cancer. A vector comprising a polynucleotide which encodes a single chain monoclonal antibody, that immunospecifically binds to an 103P3E8-related protein, and a ribozyme capable of cleaving a polynucleotide having the 103P3E8 coding sequence, are both useful in the preparation of a composition for treating a patient with a cancer that expresses 103P3E8. The sequences can be used in diagnostic methods to monitor the level of 103P3E8 gene products in serum, blood, urine and tissue and to thereby detect the presence of cancerous cells

XX Sequence 9 AA;

Query Match 25.0%; Score 5; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06; Mismatches 0; Indels 0; Gaps 0;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||

Db 2 PRGAP 6

RESULT 37

AAU71662

ID AAU71662 standard; peptide; 10 AA.

XX AAU71662;

AC AAU71662;

XX 26-FEB-2002 (first entry)

DT Human MHC class I molecule HLA-B7 binding 103P3E8 peptide #69.

DE 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach; tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme; single chain monoclonal antibody; serum; blood; urine; tissue; human; chromosome 9q13-q21.

XX Homo sapiens.

OS WO200179557-A2.

PN 25-OCT-2001.

XX 12-APR-2001; 2001WO-US012181.

PF 12-APR-2000; 2000US-0196647P.

PR (UROC-) UROGENESYS INC.

XX Faris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH; Jakobovits A;

PI WPI; 2002-061976/08.

XX Monitoring 103P3E8 gene products in sample from patient (suspected of) having cancer, useful for diagnosing, managing or treating cancers, e.g. prostate cancer, comprises determining presence of aberrant 103P3E8 gene products.

PS Disclosure; Page 96; 128pp; English.

XX Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and peptide fragments of the protein. 103P3E8 exhibits tissue specific expression in normal adult tissue, but it is also aberrantly expressed in many cancers including tumours of the prostate, bladder, kidney, colon, lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related protein and peptide fragments and specific PCR primers are therefore useful for diagnosing and treating cancer. A vector comprising a polynucleotide which encodes a single chain monoclonal antibody, that immunospecifically binds to an 103P3E8-related protein, and a ribozyme capable of cleaving a polynucleotide having the 103P3E8 coding sequence, are both useful in the preparation of a composition for treating a patient with a cancer that expresses 103P3E8. The sequences can be used

CC in diagnostic methods to monitor the level of 103P3E8 gene products in
 CC serum, blood, urine and tissue and to thereby detect the presence of
 CC cancerous cells
 XX
 SQ Sequence 10 AA;
 Query Match 25.0%; Score 5; DB 5; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PRGAP 5
 Db 2 PRGAP 6
 RESULT 38
 ABP72812
 ID ABP72812 standard; peptide; 12 AA.
 XX
 AC ABP72812;
 XX
 DT 17-JUN-2003 (first entry)
 XX
 DE Human cancer antigen cytokeratin 8 peptide fragment.
 XX
 KW Human; cytokeratin 8; cancer; antigen; immunotherapy; therapy; diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2003024191-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 23-SEP-2002; 2002WO-US030262.
 XX
 PR 21-SEP-2001; 2001US-0323844P.
 PR 04-SEP-2002; 2002US-0408253P.
 XX
 PA (RAVE-) RAVEN BIOTECHNOLOGIES INC.
 XX
 PI Mather JP;
 XX
 DR WPI; 2003-354547/33.
 XX
 PT New antibodies that bind to cancer-associated antigen cytokeratin 8,
 PT useful for diagnosing or inhibiting proliferation of cancer cells, e.g.
 PT thyroid, ovarian, prostate, lung, colon, pancreas, breast or renal cancer
 PT cells.
 XX
 PS Claim 1; Page 65; 74pp; English.
 XX
 CC The present sequence is that of a peptide fragment of human cytokeratin 8
 CC (CK8), an antigen present on a variety of human cancers, including
 CC ovarian, breast, lung, prostate, colon, kidney, thyroid, bone, upper
 CC digestive tract and pancreatic cancers. The invention provides antibodies
 CC that bind to CK8, but not to cytokeratin 18. A preferred antibody is mAb
 CC -4, which is produced by a host cell deposited as ATCC PTA-3159. Antibody
 CC mAb-4 preferentially binds to CK8 and to the CK8 peptides given in
 CC ABP72812-18 including the present peptide. The antibody may be linked to
 CC a therapeutic agent, and a humanised mAb-4 antibody is also claimed. The
 CC antibody is used in claimed methods of detecting the presence or absence
 CC of thyroid cancer cells, and for detecting the presence or absence of
 CC ovarian, prostate, lung, colon, pancreas, breast and renal cancerous
 CC cells. A claimed method of inhibiting proliferation of cancerous cells
 CC comprises administering the antibody linked to a therapeutic agent, such
 CC as saponin, where the cancer cells are ovarian or prostate cancer cells
 XX
 SQ Sequence 12 AA;
 Query Match 25.0%; Score 5; DB 6; Length 12;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
 Db 8 MLETK 12
 RESULT 39
 AAR93209
 ID AAR93209 standard; peptide; 15 AA.
 XX
 AC AAR93209;
 XX
 DT 04-OCT-1996 (first entry)
 XX
 DE New contraceptive peptide #5 derived from Zona Pellucida ZP3 protein.
 XX
 KW Zona pellucida; ZP3; vaccine; humoral response; contraception; epitope;
 KW pathogenic T cell response; ovary; assay; autoimmune; antibody;
 KW passive immunisation.
 XX
 OS Synthetic.
 XX
 PN WO9606113-A1.
 XX
 PD 29-FEB-1996.
 XX
 PF 18-AUG-1995; 95WO-EP003311.
 XX
 PR 22-AUG-1994; 94EP-00202392.
 XX
 PA (ALKU) AKZO NOBEL NV.
 XX
 PI Van Duin M, Grootenhuis AJ, Bunschoten EJ;
 XX
 DR WPI; 1996-151331/15.
 XX
 PT Immunocontraceptive peptide(s) derived from Zona Pellucida protein Zp3 -
 PT used to prepare contraceptive vaccine and in assays to measure autoimmune
 PT antibodies.
 XX
 PS Claim 5; Page 31; 43pp; English.
 XX
 CC Peptides AAR93205-9 are examples of peptides derived from the sequence of
 CC the Zona Pellucida protein ZP3 which contain the amino acid sequences
 CC AAR93210 or AAR93214-5. The peptides are esp. based on amino acids 23-30
 CC of the ZP3 protein. The novel peptides can be used in vaccines to induce
 CC a humoral response against the ZP3 protein e.g. for contraception, esp.
 CC as they do not raise a pathogenic T cell response since they do not
 CC contain T cell epitopes. The novel peptides thus avoid potential ovarian
 CC damage caused by some peptides used as vaccines. The peptides are also
 CC useful in assays for detecting autoimmune antibodies or for generating
 CC antibodies for passive immunisation
 XX
 SQ Sequence 15 AA;
 Query Match 25.0%; Score 5; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3 GAPMW 7
 Db 3 GAPMW 7
 RESULT 40
 AAW96728
 ID AAW96728 standard; peptide; 15 AA.
 XX
 AC AAW96728;
 XX
 DT 15-APR-1999 (first entry)
 XX
 DE ENA-78 derived peptide used to stimulate angiogenesis.
 XX

KW Epithelial neutrophil activating protein-78; ENA-78; CXCL chemokine;
 KW angiogenesis inhibitor; angiostasis inducer; tumour growth inhibition;
 KW haemangiomas; rheumatoid arthritis; atherosclerosis; meningioma;
 KW idiopathic pulmonary fibrosis; benign prostatic hypertrophy; psoriasis;
 KW vascular restenosis; arteriovenous malformation; neovascular glaucoma;
 KW angiofibroma; haemophilic joint; hypertrophic scar; Osler-Weber syndrome;
 KW pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
 KW vascular adhesion; synovitis; dermatitis; endometriosis; pterygium;
 KW diabetic retinopathy; neovascularisation; chronic bronchitis;
 KW adult respiratory distress syndrome; ARDS; pseudogout; metastasis;
 KW cystic fibrosis.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US5871723-A.
 PN
 XX
 XX 16-FEB-1999.
 PD
 XX
 XX 06-JUN-1995; 95US-00468819.
 PF
 XX
 XX 06-JUN-1995; 95US-00468819.
 PR
 XX
 XX (UNMI) UNIV MICHIGAN.
 PA
 XX
 XX Kunkel SL, Strieter RM, Polverini PJ;
 PI
 XX
 XX WPI; 1999-166569/14.
 DR
 XX
 XX Use of chemokines with a conserved Cys Xaa Cys (CXC) sequence - which do
 PT not contain amino acid sequence ELR, for inhibiting angiogenesis in
 PT tumours, rheumatoid arthritis, restenosis or glaucoma.
 PT
 XX
 PS Disclosure; Col 16; 145pp; English.
 XX
 CC The present sequence represents a peptide derived from epithelial
 CC neutrophil activating protein-78 (ENA-78). The present peptide stimulates
 CC angiogenesis. The specification describes methods for inhibiting
 CC angiogenesis or for inducing angiostasis, using chemokines (with a
 CC conserved Cys Xaa Cys (CXC) sequence at the N-terminal) other than
 CC platelet factor-4, and which do not contain the amino acid sequence ELR.
 CC The methods are useful for inhibiting tumour growth and metastasis and
 CC for treating diseases such as haemangiomas, rheumatoid arthritis,
 CC atherosclerosis and idiopathic pulmonary fibrosis (IPF), benign prostatic
 CC hypertrophy (BPH), vascular restenosis, arteriovenous malformations
 CC (AVM), meningioma, neovascular glaucoma, psoriasis, angiofibroma,
 CC haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic
 CC granuloma retrolental fibroplasia, scleroderma, trachoma, vascular
 CC adhesions, synovitis, dermatitis, endometriosis, pterygium, diabetic
 CC retinopathy neovascularisation associated with corneal injury or grafts,
 CC adult respiratory distress syndrome (ARDS), chronic bronchitis,
 CC pseudogout and cystic fibrosis
 XX
 XX Sequence 15 AA;
 SQ
 Query Match 25.0%; Score 5; DB 2; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 8 LRCVC 12
 Db |||||
 11 LRCVC 15
 RESULT 41
 ABU67730
 ID ABU67730 standard; peptide; 15 AA.
 XX
 XX ABU67730;
 AC
 XX
 DT 30-MAY-2003 (first entry)
 XX
 XX Human angiogenesis stimulatory peptide from ENA-78.
 DE
 XX

KW CXCL chemokine; angiogenesis; tumour; platelet factor 4 (PF4);
 KW ELR CXC chemokine; IP-10; benign tumour; haemangioma; BPH; angiofibroma;
 KW rheumatoid arthritis; atherosclerosis; idiopathic pulmonary fibrosis;
 KW benign prostatic hyperplasia; vascular restenosis; meningioma;
 KW arteriovenous malformation; neovascular glaucoma; psoriasis;
 KW haemophilic joint; hypertrophic scar; Osler-Weber syndrome;
 KW pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
 KW vascular adhesion; synovitis; dermatitis; endometriosis; wound healing;
 KW sore healing; vascular graft; transplant; skin ulcer; gastric ulcer;
 KW duodenal ulcer; human.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US6491906-B1.
 PN
 XX
 XX 10-DEC-2002.
 PD
 XX
 XX 09-DEC-1998; 98US-00213383.
 PF
 XX
 XX 06-JUN-1995; 95US-00468819.
 PR
 XX
 XX (UNMI) UNIV MICHIGAN.
 PA
 XX
 XX Strieter RM, Polverini PJ, Kunkel SL;
 PI
 XX
 XX WPI; 2003-327304/31.
 DR
 XX
 XX Inhibition of angiogenesis in human having tumor, by administering to
 PT human, composition comprising recombinant adenovirus having nucleic acid
 PT segment that encodes chemokine other than platelet factor.
 PT
 XX
 PS Disclosure; Col 16; 148pp; English.
 XX
 CC The invention relates to an angiogenesis inhibited by administering to a
 CC human having a tumor, a composition comprising a recombinant adenovirus
 CC that comprises and expresses a nucleic acid segment that encodes a non-
 CC ELR-CXC (Glu-Leu-Arg, Cys-Xaa-Cys) chemokine other than platelet factor 4
 CC (PF4). The non-ELR CXC chemokine lacks the amino acid sequence ELR e.g.
 CC IP-10 or a CXC chemokine protein where the ELR sequence has been replaced
 CC with TVR or DIQ. The method is for inhibiting angiogenesis. It is also
 CC useful for treating benign tumors, haemangiomas, rheumatoid arthritis,
 CC atherosclerosis, idiopathic pulmonary fibrosis, BPH (benign prostatic
 CC hypertrophy or hyperplasia), vascular restenosis, arteriovenous
 CC malformations, meningioma, neovascular glaucoma, psoriasis, angiofibroma,
 CC haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic
 CC granuloma retrolental fibroplasia, scleroderma, trachoma, vascular
 CC adhesions, synovitis, dermatitis, or endometriosis. It is also useful in
 CC wound or sore healing, treatment of vascular grafts or transplants, and
 CC treatment of skin, gastric, or duodenal ulcers. The invention allows
 CC angiogenic or angiostatic chemokines to be identified or designed without
 CC laborious experimentation and avoiding the expense of trial and error
 CC screening. It inhibits or reduces angiogenesis in the animal or in a
 CC defined biological site within the animal. The present sequence
 CC represents an angiogenesis stimulatory peptide derived from a CXC
 CC chemokine
 XX
 XX Sequence 15 AA;
 SQ
 Query Match 25.0%; Score 5; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 8 LRCVC 12
 Db |||||
 11 LRCVC 15
 RESULT 42
 ABO07364
 ID ABO07364 standard; peptide; 15 AA.
 XX
 XX ABO07364;
 AC
 XX

DT 14-AUG-2003 (first entry)
 XX Angiogenesis stimulating peptide #5.
 XX Human; inhibiting angiogenesis; Cys-Xaa-Cys chemokine; CXK chemokine;
 KW platelet factor 4; PF4; interleukin-8; IL-8; IP-10; GROalpha;
 KW gamma interferon-inducible protein-10; growth related oncogene; GRObeta;
 KW GROgamma; monokine induced by gamma interferon; MIG;
 KW epithelial neutrophil activating protein-78; ENA-78; GCP-2;
 KW granulocyte chemotactic protein-2; platelet basic protein; PBP;
 KW connective tissue activating protein-III; CTAP-III; betaTG;
 KW beta-thromboglobulin; neutrophil activating peptide-2; NAP-2; tumour;
 KW sarcoma; lung; ovary; pancreas; stomach; prostate; haemangioma;
 KW rheumatoid arthritis; atherosclerosis; IPF; AVM;
 KW idiopathic pulmonary fibrosis; vascular restenosis; meningioma;
 KW arteriovenous malformation; neovascular glaucoma; psoriasis;
 KW angiofibroma; haemophilic joint; hypertrophic scar; scleroderma;
 KW osler-weber syndrome; pyogenic granuloma retrolental fibroplasia;
 KW trachoma; vascular adhesion; synovitis; dermatitis; endometriosis;
 KW inducing angiostasis; stimulating angiogenesis; wound healing; vulneryary;
 KW antitumor; vasotropic; antirheumatic; antiarthritic; antiatherosclerotic;
 KW ophthalmological; antipsoriatic; dermatological; antiinflammatory;
 KW antiallergic.
 XX Homo sapiens.
 XX US2003031645-A1.
 XX 13-FEB-2003.
 XX 21-MAR-2002; 2002US-00104755.
 XX 06-JUN-1995; 95US-00468819.
 PR 09-DEC-1998; 98US-00213383.
 XX (UNMI) UNIV MICHIGAN.
 PA Strieter RM, Kunkel SL;
 XX WPI; 2003-466212/44.
 DR Inhibiting angiogenesis, by administering a pharmaceutical chemokine
 PT composition that comprises a chemokine other than platelet factor 4.
 XX Disclosure; Page 9; 156pp; English.
 CC The present invention relates to a method of inhibiting angiogenesis. The
 CC method comprises administering to an animal, preferably human, a
 CC biological amount of a pharmaceutical CXK (Cys-Xaa-Cys) chemokine
 CC composition that comprises chemokines other than platelet factor 4 (PF4),
 CC e.g. interleukin-8 (IL-8), gamma interferon-inducible protein-10 (IP-10),
 CC the growth related oncogene (GRO) peptides GROalpha, GRObeta, and
 CC GROgamma, monokine induced by gamma interferon (MIG), epithelial
 CC neutrophil activating protein-78 (ENA-78), granulocyte chemotactic
 CC protein-2 (GCP-2), and the NH2-terminal truncated forms of platelet basic
 CC protein (PBP) such as connective tissue activating protein-III (CTAP-
 CC III), beta-thromboglobulin (betaTG) and neutrophil activating peptide-2
 CC (NAP-2). The method is useful for inhibiting angiogenesis in humans, and
 CC is useful for treating tumours and even sarcomas of the lung, ovary,
 CC pancreas, stomach, and prostate. The method is also useful for treating
 CC haemangiomas, rheumatoid arthritis, atherosclerosis, idiopathic pulmonary
 CC fibrosis (IPF), vascular restenosis, arteriovenous malformations (AVM),
 CC meningioma, neovascular glaucoma, psoriasis, angiofibroma, haemophilic
 CC joints, hypertrophic scars, osler-weber syndrome, pyogenic granuloma
 CC retrolental fibroplasia, scleroderma, trachoma, vascular adhesions,
 CC synovitis, dermatitis and endometriosis. Also disclosed are methods for
 CC inducing angiostasis, stimulating angiogenesis, and promoting wound
 CC healing. The present sequence represents a peptide for stimulating
 CC angiogenesis.
 XX Sequence 15 AA;
 SQ Query Match 25.0%; Score 5; DB 7; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 8 LRCVC 12
 DB 11 LRCVC 15
 RESULT 43
 AAR91628
 ID AAR91628 standard; peptide; 16 AA.
 XX AAR91628;
 XX 30-OCT-1996 (first entry)
 XX Alpha chemokine ENA-78 peptide analogue 11.
 XX Alpha chemokine; peptide analogue; agonist activity; treatment;
 KW infection; arthritis; leukaemia; solid tumour; protective agent;
 KW immune system; chemotherapy; radiation therapy; interleukin-8; IL-8;
 KW rapid; extensive; tissue distribution; ENA-78.
 XX Synthetic.
 OS WO9609062-A1.
 XX 28-MAR-1996.
 PD 22-SEP-1995; 95WO-US012099.
 PF 23-SEP-1994; 94US-00311307.
 PR 23-SEP-1994; 94US-00311380.
 XX (UYNE-) UNIV NEBRASKA.
 XX Talmadge JE;
 XX WPI; 1996-188211/19.
 DR New human interleukin-8 peptide analogues - useful as agonists or
 PT antagonists for alpha chemokines for treating e.g. neoplasms, infection
 PT and auto-immune disease.
 XX Claim 4; Page 52; 75pp; English.
 XX The present peptide is an alpha chemokine derived peptide analogue, with
 CC alpha chemokine agonist activity. It can be used for the treatment of,
 CC e.g. viral, bacterial, fungal, yeast or parasitic infections, arthritis,
 CC leukaemia or solid tumours including primary and metastatic disease. The
 CC peptide can also be used as a protective agent for the immune system
 CC during chemotherapy and radiation-therapy. In contrast to the claimed
 CC invention in WO931159, which describes a 77 residue amino acid
 CC interleukin-8 antagonist, the present peptide is more efficiently prepd.
 CC (solid phase synthesis) and has a more rapid and extensive tissue
 CC distribution
 XX Sequence 16 AA;
 SQ Query Match 25.0%; Score 5; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 8 LRCVC 12
 DB 2 LRCVC 6
 RESULT 44
 ADK01531
 ID ADK01531 standard; peptide; 20 AA.
 XX ADK01531;
 AC

```

XX 06-MAY-2004 (first entry)
XX Hepatitis C virus 1b peptide SeqID183.
XX pathogenic virus; alternative reading frame; antigenic determinant;
XX virucide; vaccine; therapeutic agent; infection.
XX Hepatitis C virus.
XX WO2004011650-A2.
XX 05-FEB-2004.
XX 24-JUL-2003; 2003WO-EP008112.
XX 24-JUL-2002; 2002AT-00001124.
XX 11-JUL-2003; 2003EP-00450171.
XX (INTE-) INTERCELL AG.
XX Mattner F, Schmidt W, Habel A;
XX WPI; 2004-169243/16.
XX New polypeptide encoded by an alternative reading frame of a pathogenic
XX virus comprising an antigenic determinant, useful for treating or
XX preventing an infection with the pathogenic virus.
XX Claim 7; SEQ ID NO 183; 220pp; English.
XX This invention relates to a novel polypeptide encoded by an alternative
XX reading frame of a pathogenic virus, where the polypeptide starts with a
XX methionine amino acid residue, which comprises an antigenic determinant
XX and more than 7 amino acid residues. The invention may be useful for the
XX production of compounds with a virucide activity or the development of a
XX vaccine. The polypeptide or its fragments may be useful as a therapeutic
XX agent. It is also useful for the manufacture of a medicament for treating
XX or preventing an infection with the pathogenic virus. The present
XX sequence is that of a hepatitis C virus peptide of the invention.
XX Sequence 20 AA;
XX
XX Query Match 25.0%; Score 5; DB 8; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 2.7e+02;
XX Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 PRGAP 5
XX | | | | |
XX 7 PRGAP 11
XX
XX RESULT 45
XX ABG69986
XX ID ABG69986 standard; peptide; 22 AA.
XX AC ABG69986;
XX 21-OCT-2002 (first entry)
XX Rabbit platelet microbicidal protein, PMP-2, based peptide #98.
XX Antimicrobial; platelet microbicidal protein; PMP-1; PMP-2;
XX bacterial infection; fungal infection; fungicide; disinfectant;
XX preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;
XX mutant; mutein.
XX Oryctolagus cuniculus.
XX Synthetic.
XX WO200255554-A2.
XX 18-JUL-2002.

```

```

XX 24-AUG-2001; 2001WO-US041877.
XX PF
XX 25-AUG-2000; 2000US-00648816.
XX PR
XX (HARB-) HARBOR-UCLA RES & EDUCATION INST.
XX PA
XX Yeaman MR, Shen AJ;
XX PI
XX WPI; 2002-590659/63.
XX DR
XX New antimicrobial peptide composition for the prevention and treatment of
XX infections caused by organisms, such as bacteria and fungi, exhibiting
XX multiple antibiotic resistance.
XX Example; Page 66; 221pp; English.
XX
XX The invention relates to an antimicrobial peptide composition for use
XX against organisms such as bacteria and fungi comprising a peptide of 5-
XX 150 amino acids containing a 7-13 amino acid core sequence (derived from
XX PMP-1 and PMP-2, platelet microbicidal protein), and retromers,
XX truncations, extensions, combinations, fusions and their derivatives. The
XX possible structures are fully described in the specification. Also
XX included are (1) an antimicrobial peptide composition for direct activity
XX or for potentiating antimicrobial agents active against organisms such as
XX bacteria and fungi comprising a peptide of 13-74 containing an amino acid
XX core sequence selected from truncations of the peptides described above,
XX and retromers, extensions, combinations and fusions; and (2)
XX antimicrobial peptides for potentiating antimicrobial activity of
XX leukocytes against organisms such as bacteria and fungi. The
XX antimicrobial peptides are useful as individual antimicrobial agents,
XX specifically against bacteria and fungi, agents in combination with other
XX antimicrobials, agents that enhance, potentiate or restore efficacy of
XX conventional antimicrobials, agents that enhance the antimicrobial
XX functions of leukocytes, as disinfectants or preservatives for use in
XX foods and cosmetics and as agents to improve efficiency of molecular
XX biology techniques. Antimicrobial peptides of prior art have generally
XX been considered to have undesirable toxicity, immunogenicity and short
XX half-lives due to biodegradation. The peptides of the present invention
XX are based upon natural antimicrobial peptides that have potent and broad
XX spectrum activity against pathogens exhibiting multiple antibiotic
XX resistance. They exhibit lower inherent mammalian cell toxicities and
XX overcome problems of toxicity, immunogenicity, and shortness of duration
XX of effectiveness due to biodegradation, retaining activity in plasma and
XX serum. The present sequence is a rabbit PMP based antimicrobial peptide
XX
XX Sequence 22 AA;
XX
XX Query Match 25.0%; Score 5; DB 5; Length 22;
XX Best Local Similarity 100.0%; Pred. No. 2.8e+02;
XX Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 8 LRCVC 12
XX | | | | |
XX 11 LRCVC 15
XX
XX Db
XX
XX RESULT 46
XX ABG69985
XX ID ABG69985 standard; peptide; 22 AA.
XX AC ABG69985;
XX 21-OCT-2002 (first entry)
XX Rabbit platelet microbicidal protein, PMP-2, based peptide #97.
XX Antimicrobial; platelet microbicidal protein; PMP-1; PMP-2;
XX bacterial infection; fungal infection; fungicide; disinfectant;
XX preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;
XX mutant; mutein.
XX Oryctolagus cuniculus.
XX

```

OS Synthetic.
 PN WO200255554-A2.
 XX
 PD 18-JUL-2002.
 XX
 PF 24-AUG-2001; 2001WO-US041877.
 XX
 PR 25-AUG-2000; 2000US-00648816.
 XX
 PA (HARB-) HARBOR-UCLA RES & EDUCATION INST.
 PI Yeaman MR, Shen AJ;
 XX WPI; 2002-590659/63.
 DR
 XX
 XX New antimicrobial peptide composition for the prevention and treatment of
 PT infections caused by organisms, such as bacteria and fungi, exhibiting
 PT multiple antibiotic resistance.
 XX
 PS Example; Page 65; 22lpp; English.
 XX
 CC The invention relates to an antimicrobial peptide composition for use
 CC against organisms such as bacteria and fungi comprising a peptide of 5-
 CC 150 amino acids containing a 7-13 amino acid core sequence (Derived from
 CC PMP-1 and PMP-2, platelet microbicidal protein), and retromers,
 CC truncations, extensions, combinations, fusions and their derivatives. The
 CC possible structures are fully described in the specification. Also
 CC included are (1) an antimicrobial peptide composition for direct activity
 CC or for potentiating antimicrobial agents active against organisms such as
 CC bacteria and fungi comprising a peptide of 13-74 containing an amino acid
 CC core sequence selected from truncations of the peptides described above,
 CC and retromers, extensions, combinations and fusions; and (2)
 CC antimicrobial peptides for potentiating antimicrobial activity of
 CC leukocytes against organisms such as bacteria and fungi. The
 CC antimicrobial peptides are useful as individual antimicrobial agents,
 CC specifically against bacteria and fungi, agents in combination with other
 CC antimicrobials, agents that enhance, potentiate or restore efficacy of
 CC conventional antimicrobials, agents that enhance the antimicrobial
 CC functions of leukocytes, as disinfectants or preservatives for use in
 CC foods and cosmetics and as agents to improve efficiency of molecular
 CC biology techniques. Antimicrobial peptides of prior art have generally
 CC been considered to have undesirable toxicity, immunogenicity and short
 CC half-lives due to biodegradation. The peptides of the present invention
 CC are based upon natural antimicrobial peptides that have potent and broad
 CC spectrum activity against pathogens exhibiting multiple antibiotic
 CC resistance. They exhibit lower inherent mammalian cell toxicities and
 CC overcome problems of toxicity, immunogenicity, and shortness of duration
 CC of effectiveness due to biodegradation, retaining activity in plasma and
 CC serum. The present sequence is a rabbit PMP based antimicrobial peptide
 XX
 XX Sequence 22 AA;
 Query Match 25.0%; Score 5; DB 5; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.8e-02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 8 LRCVC 12
 DB 11 LRCVC 15
 RESULT 47
 ADM32132
 ID ADM32132 standard; protein; 25 AA.
 XX
 AC ADM32132;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 XX EphB4 blocking peptide 6, seq id 7.
 DE
 DE Cytostatic; gene therapy; Inhibitor; cancerous growth; cancer; breast;
 XX

KW prostate; ephrin type-B receptor 4 precursor; EphB4; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2004024773-A1.
 XX
 PD 25-MAR-2004.
 XX
 PF 16-SEP-2003; 2003WO-AU001209.
 XX
 PR 16-SEP-2002; 2002AU-00951409.
 XX
 PA (QUEE-) QUEEN ELIZABETH HOSPITAL.
 XX
 PI Stephenson S;
 XX
 DR WPI; 2004-270012/25.
 XX
 PT Inhibiting cancerous growth of a cell by contacting the cell with an
 PT antibody, or its antigen-binding portion, that binds to an epitope of
 PT EphB4 polypeptide.
 XX
 PS Example 6; SEQ ID NO 7; 73pp; English.
 XX
 CC The invention relates to a method of inhibiting cancerous growth of a
 CC cell, comprising contacting the cell with at least one antibody, or its
 CC antigen-binding portion, where the antibody or antigen-binding portion
 CC binds to an epitope located within residues 200-400 of EphB4, which
 CC consists of the sequence of 984 amino acids (S1) fully defined in the
 CC specification, or to an epitope located in a sequence at least 85%
 CC identical to residues 200-400, 201-245, 220-244 or 220-230 of EphB4. The
 CC composition and methods are useful for treating or preventing cancer
 CC (e.g. breast or prostate cancer) or for identifying agents that inhibit
 CC cancerous growth of a cell. The current sequence represents an EphB4
 CC blocking peptide used in an example from the invention in EphB4 epitope
 XX mapping.
 XX Sequence 25 AA;
 Query Match 25.0%; Score 5; DB 8; Length 25;
 Best Local Similarity 100.0%; Pred. No. 3.1e-02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PRGAP 5
 DB 15 PRGAP 19
 RESULT 48
 AAY20230
 ID AAY20230 standard; protein; 26 AA.
 XX
 AC AAY20230;
 XX
 DT 22-JUL-1999 (first entry)
 XX
 DE Human beta-amyloid precursor protein mutant fragment 55.
 XX
 KW Human; beta-amyloid precursor protein; beta-APP; diagnosis; cancer;
 KW frameshift mutation; age-related disease; neurodegenerative disorder;
 KW Alzheimer's disease; Down's syndrome; myotonic dystrophy; neuronal;
 KW Huntington's disease; multiple sclerosis; alcoholic liver disease;
 KW diabetes mellitus type II; microtubule associated protein; tau; Big Tau;
 KW ubiquitin B; apolipoprotein E; MAP2; neurofilament-L; neurofilament-M;
 KW neurofilament-F; presenilin 1; presenilin 2; cellular tumour antigen;
 KW glial fibrillary acidic protein; GFAP; p53; semaphorin III; HUPF-1;
 KW bcl-2; B-cell leukemia/lymphoma 2 proto-oncogene; HMGP-C; NSP-A;
 XX high mobility group protein-C; neuroendocrine specific protein A.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9845322-A2.

XX 15-OCT-1998.
XX 02-APR-1998; 98WO-IB000705.
XX 10-APR-1997; 97US-0043163P.
XX (ROYA-) ROYAL NETHERLANDS ACAD ARTS & SCI.
XX (UTRO-) UNIV ROTTERDAM ERASMUS.
XX (UYUT-) RIJKSUNIV UTRECHT.
XX Van Leeuwen FW, Grosveld FG, Burbach JPH;
XX WPI; 1998-609901/51.
XX N-PSDB; AAX75753.
XX
XX Diagnosing disease by detecting frameshift mutations in RNA or
XX corresponding protein mutations - used to diagnose cancer and
XX neurological diseases, particularly Alzheimer's disease, and also for
XX treatment and prevention with specific ribozymes or wild-type RNA.
XX
XX Disclosure; Fig 2; 258pp; English.
XX
XX This invention describes a novel method for the diagnosis of a disease
XX caused by, or associated with, an RNA molecule that has a frameshift
XX mutation. The method is used to diagnose age-related diseases, especially
XX cancer and a wide range of neurodegenerative disorders (e.g. Alzheimer's
XX disease, Down's syndrome, myotonic dystrophy, Huntington's disease, II
XX multiple sclerosis, alcoholic liver disease, diabetes mellitus type II
XX and many others listed) or susceptibility to these disorders. The method
XX allows a definitive diagnosis of Alzheimer's disease in living patients,
XX at an early stage. It is based on the observation that disease may be
XX caused by mutations in RNA rather than DNA. The invention describes the
XX use of neuronal system RNA molecules, specifically proteins including
XX beta-amyloid precursor protein (beta-APP), the microtubule associated
XX proteins Tau and Big Tau, ubiquitin B, apolipoprotein E, microtubule
XX associated protein 2 (MAP2), neurofilament-L, neurofilament-M,
XX neurofilament-F, presenilin I, presenilin II, glial fibrillary acidic
XX protein (GFAP), the cellular tumour antigen p53, B-cell leukemia/lymphoma
XX 2 (bcl-2) proto-oncogene, semaphorin III, HUPF-1, high mobility group
XX protein-C (HMGP-C) and neuroendocrine specific protein A
XX
XX Sequence 26 AA;
XX
XX Query Match 25.0%; Score 5; DB 2; Length 26;
XX Best Local Similarity 100.0%; Pred. No. 3.2e+02;
XX Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 PRGAP 5
XX |||||
XX 5 PRGAP 9
XX
XX
XX RESULT 49
XX AAY19651
XX ID AAY19651 standard; protein; 28 AA.
XX
XX AC AAY19651;
XX
XX 14-JUL-1999 (first entry)
XX
XX SEQ ID NO 369 from WO9922243.
XX
XX Human secreted protein; cancer; tumour; neurodegenerative disorder;
XX developmental abnormality; fetal deficiency; blood disorder; leukemia;
XX immune system disease; autoimmune disease; hepatic disease;
XX renal disease; lymphoma; inflammation; allergy; ischemic shock;
XX Alzheimer's; cognitive disorder; schizophrenia; prostate disease;
XX obesity; osteoclast; osteoporosis; arthritis; malignancy; testes disease;
XX lung disease; thymus disease; digestive disorder; endocrine disorder;
XX infection; AIDS.
XX
XX Homo sapiens.

XX WO9922243-A1.
XX 06-MAY-1999.
XX 23-OCT-1998; 98WO-US022376.
XX 24-OCT-1997; 97US-0062784P.
XX 24-OCT-1997; 97US-0063088P.
XX 24-OCT-1997; 97US-0063089P.
XX 24-OCT-1997; 97US-0063090P.
XX 24-OCT-1997; 97US-0063091P.
XX 24-OCT-1997; 97US-0063092P.
XX 24-OCT-1997; 97US-0063097P.
XX 24-OCT-1997; 97US-0063098P.
XX 24-OCT-1997; 97US-0063099P.
XX 24-OCT-1997; 97US-0063100P.
XX 24-OCT-1997; 97US-0063101P.
XX 24-OCT-1997; 97US-0063109P.
XX 24-OCT-1997; 97US-0063110P.
XX 24-OCT-1997; 97US-0063111P.
XX 24-OCT-1997; 97US-0063148P.
XX 24-OCT-1997; 97US-0063386P.
XX 24-OCT-1997; 97US-0063387P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Feng P, Rosen CA, Ruben SM, Ni J, Wei Y, Soppet DR, Moore PA;
XX Kayw H, Laflaur DW, Olsen HS, Brewer LA, Shi Y, Ebner R, Young P;
XX Greene JM, Florence KA, Florence C, Duan DR, Janat F, Endress GA;
XX Carter KC;
XX
XX WPI; 1999-303069/25.
XX
XX New isolated human genes and the secreted polypeptides they encode.
XX
XX Disclosure; Page 485; 546pp; English.
XX
XX The specification describes human secreted proteins. The polynucleotides
XX and their corresponding secreted polypeptides are useful for preventing,
XX treating or ameliorating medical conditions, e.g. by protein or gene
XX therapy. Pathological conditions can also be diagnosed by determining the
XX amount of the polypeptides in a sample or by determining the presence of
XX mutations in the polynucleotides. Specific uses are described for each of
XX the polynucleotides, based on which tissues they are most highly
XX expressed in, and include developing products for the diagnosis or
XX treatment of cancer, tumours, neurodegenerative disorders, leukemias,
XX abnormalities and fetal deficiencies, blood disorders, developmental
XX diseases of the immune system, autoimmune diseases, hepatic and renal
XX disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's
XX and cognitive disorders, schizophrenia, prostate diseases, obesity,
XX disorders involving osteoclasts such as osteoporosis, arthritis or
XX malignancies, diseases of testes, lung or thymus, digestive/endocrine
XX disorders, infections and AIDS. The polypeptides are also useful for
XX identifying their binding partners
XX
XX Sequence 28 AA;
XX
XX Query Match 25.0%; Score 5; DB 2; Length 28;
XX Best Local Similarity 100.0%; Pred. No. 3.4e+02;
XX Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 12 CQMLE 16
XX |||||
XX 3 CQMLE 7
XX
XX
XX RESULT 50
XX AAG56952
XX ID AAG56952 standard; protein; 33 AA.
XX
XX AC AAG56952;
XX
XX


```
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155133P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156598P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157553P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0158293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 25.0%; Score 5; DB 3; Length 33;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLET 17
DB 26 QMLET 30

RESULT 51
ID ABG69992
XX ABG69992 standard; peptide; 40 AA.
AC ABG69992;
XX
XX 21-OCT-2002 (first entry)
DT
DE Rabbit platelet microbicidal protein, PMP-2, based peptide #104.
XX
XX Antimicrobial; platelet microbicidal protein; PMP-1; PMP-2;
KW bacterial infection; fungal infection; fungicide; disinfectant;
KW preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;

KW mutant; mutein.
XX Oryctolagus cuniculus.
OS Synthetic.
XX
XX WO200255554-A2.
XX
XX 18-JUL-2002.
XX
XX 24-AUG-2001; 2001WO-US041877.
XX
XX 25-AUG-2000; 2000US-00648816.
XX
XX (HARB-) HARBOR-UCLA RES & EDUCATION INST.
XX
XX Yeaman MR, Shen AJ;
XX
XX WPI; 2002-590659/63.
XX
XX New antimicrobial peptide composition for the prevention and treatment of
infections caused by organisms, such as bacteria and fungi, exhibiting
multiple antibiotic resistance.
XX
XX Example; Page 67; 221pp; English.
XX
XX The invention relates to an antimicrobial peptide composition for use
against organisms such as bacteria and fungi comprising a peptide of 5-
150 amino acids containing a 7-13 amino acid core sequence (derived from
PMP-1 and PMP-2, platelet microbicidal protein), and retromers,
truncations, extensions, combinations, fusions and their derivatives. The
possible structures are fully described in the specification. Also
included are (1) an antimicrobial peptide composition for direct activity
or for potentiating antimicrobial agents active against organisms such as
bacteria and fungi comprising a peptide of 13-74 containing an amino acid
core sequence selected from truncations of the peptides described above,
and retromers, extensions, combinations and fusions; and (2)
antimicrobial peptides for potentiating antimicrobial activity of
leukocytes against organisms such as bacteria and fungi. The
antimicrobial peptides are useful as individual antimicrobial agents,
specifically against bacteria and fungi, agents in combination with other
antimicrobials, agents that enhance, potentiate or restore efficacy of
conventional antimicrobials, agents that enhance the antimicrobial
functions of leukocytes, as disinfectants or preservatives for use in
foods and cosmetics and as agents to improve efficiency of molecular
biology techniques. Antimicrobial peptides of prior art have generally
been considered to have undesirable toxicity, immunogenicity and short
half-lives due to biodegradation. The peptides of the present invention
are based upon natural antimicrobial peptides that have potent and broad
spectrum activity against pathogens exhibiting multiple antibiotic
resistance. They exhibit lower inherent mammalian cell toxicities and
overcome problems of toxicity, immunogenicity, and shortness of duration
of effectiveness due to biodegradation, retaining activity in plasma and
serum. The present sequence is a rabbit PMP based antimicrobial peptide
Sequence 40 AA;

Query Match 25.0%; Score 5; DB 5; Length 40;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
DB 29 LRCVC 33

RESULT 52
ADF94734
ID ADF94734 standard; protein; 42 AA.
XX
XX ADF94734;
XX
XX 26-FEB-2004 (first entry)
DT
XX
```


DE Hepatitis D virus type III antigen protein fragment, SEQ ID 9.
 XX Virucide; hepatitis D virus antigen; HDV antigen; RNA polymerase II.
 KW Hepatitis D virus.
 OS
 XX WO200268655-A1.
 PN
 XX 06-SEP-2002.
 PD
 XX
 XX 27-FEB-2002; 2002WO-JP001817.
 PF
 XX
 XX 27-FEB-2001; 2001JP-00053163.
 PR
 XX
 PA (CIRC-) CIRCLE PROMOTION SCI & ENG.
 PA (KYOW) KYOWA HAKKO KOGYO KK.
 XX
 PI Handa H, Yamaguchi Y;
 XX WPI; 2002-698673/75.
 DR
 XX Non-infective cell-requiring method of searching for hepatitis D remedies
 PT in a system containing e.g. polypeptide binding to RNA polymerase II with
 PT measuring of binding level for indication.
 XX
 XX Claim 5; SEQ ID NO 9; 84pp; Japanese.
 PS
 CC The present invention relates to a method for searching hepatitis D
 CC remedies. The method comprises adding a test compound to a system
 CC containing e.g. a hepatitis D virus antigen (HDV antigen) and RNA
 CC polymerase II, measuring the binding level of HDV antigen binding to RNA
 CC polymerase II, and comparing with a control for selection of a compound
 CC inhibiting the binding. The method is for screening remedies for
 CC hepatitis D including for hepatitis virus D accompanying hepatitis B,
 CC such as gene expression promoters applicable in regeneration medicine for
 CC treating organs or tissues. The present sequence is a HDV antigen
 CC sequence.
 XX
 XX Sequence 42 AA;
 SQ

Query Match 25.0%; Score 5; DB 5; Length 42;
 Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
 DB 14 PRGAP 18

RESULT 53
 ADF94732
 ID ADF94732 standard; protein; 42 AA.
 XX
 XX ADF94732;
 AC
 XX 26-FEB-2004 (first entry)
 DT
 XX Hepatitis D virus type II antigen protein fragment, SEQ ID 7.
 DE
 XX Virucide; hepatitis D virus antigen; HDV antigen; RNA polymerase II.
 KW
 XX Hepatitis D virus.
 OS
 XX WO200268655-A1.
 PN
 XX 06-SEP-2002.
 PD
 XX
 XX 27-FEB-2002; 2002WO-JP001817.
 PF
 XX
 XX 27-FEB-2001; 2001JP-00053163.
 PR
 XX
 PA (CIRC-) CIRCLE PROMOTION SCI & ENG.
 PA (KYOW) KYOWA HAKKO KOGYO KK.
 XX

XX
 PI Handa H, Yamaguchi Y;
 XX WPI; 2002-698673/75.
 DR
 XX Non-infective cell-requiring method of searching for hepatitis D remedies
 PT in a system containing e.g. polypeptide binding to RNA polymerase II with
 PT measuring of binding level for indication.
 XX
 XX Claim 5; SEQ ID NO 7; 84pp; Japanese.
 PS
 CC The present invention relates to a method for searching hepatitis D
 CC remedies. The method comprises adding a test compound to a system
 CC containing e.g. a hepatitis D virus antigen (HDV antigen) and RNA
 CC polymerase II, measuring the binding level of HDV antigen binding to RNA
 CC polymerase II, and comparing with a control for selection of a compound
 CC inhibiting the binding. The method is for screening remedies for
 CC hepatitis D including for hepatitis virus D accompanying hepatitis B,
 CC such as gene expression promoters applicable in regeneration medicine for
 CC treating organs or tissues. The present sequence is a HDV antigen
 CC sequence.
 XX
 XX Sequence 42 AA;
 SQ

Query Match 25.0%; Score 5; DB 5; Length 42;
 Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
 DB 14 PRGAP 18

RESULT 54
 AAW57222
 ID AAW57222 standard; protein; 44 AA.
 XX
 XX AAW57222;
 AC
 XX 04-AUG-1998 (first entry)
 DT
 XX Targeting vector Tg-2/Not containing PGK-neomycin-resistant gene protein.
 DE
 XX Targeting vector; Tg-2/Not; nucleobindin; screening; nephritis;
 KW blood vessel; inflammation; PGK-neomycin-resistant gene.
 KW
 XX Synthetic.
 OS
 XX JP10117633-A.
 PN
 XX 12-MAY-1998.
 PD
 XX 21-OCT-1996; 96JP-00298219.
 PF
 XX 21-OCT-1996; 96JP-00298219.
 PR
 XX (MITS-) MITSUI SEIYAKU KOGYO KK.
 PA (KANA/) KANAI Y.
 PA (FUJI-) FUJITA GAKUEN.
 XX
 XX WPI; 1998-325762/29.
 DR N-PSDB; AAV28851.
 XX
 XX Gene-deleted animal e.g. mouse - useful for screening therapeutic agents
 PT for diseases such as blood vessel inflammation and nephritis.
 PT
 XX Example 2; Fig 3; 11pp; Japanese.
 PS
 XX The present sequence represents a protein from a targeting vector Tg-
 CC 2/Not containing a PGK-neomycin-resistant gene, from the present
 CC invention. The targeting vector is used in an example of the present
 CC invention for producing a gene-deleted animal e.g. a mouse comprising no
 CC gene to encode nucleobindin in which all or part of nucleobindin gene is

CC deleted or replaced by another gene. The mouse can be used for screening
 CC therapeutic agents against diseases such as blood vessel inflammation and
 CC nephritis

XX Sequence 44 AA;

Query Match 25.0%; Score 5; DB 2; Length 44;
 Best Local Similarity 100.0%; Pred. No. 4.8e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
 |||||
 Db 6 PRGAP 10

RESULT 55

AAE38084
 ID AAE38084 standard; protein; 44 AA.

XX AC AAE38084;

XX DT 06-NOV-2003 (first entry)

XX DE Human cytokerin K8 protein fragment #1.

XX KW Human; cancer-associated epitope; cytokerin K8; cytokerin K18;
 XX KW adenocarcinoma; therapy; cancer.

XX OS Homo sapiens.

XX PN WO2003057168-A2.

XX PD 17-JUL-2003.

XX PF 03-JAN-2003; 2003WO-US000297.

XX PR 03-JAN-2002; 2002US-0345208P.

XX PA (SCRI) SCRIPPS RES INST.

XX PI Ditzel H, Jensenius JC;

XX DR WPI; 2003-598315/56.

XX PT Novel isolated cancer-associated epitope comprising two separate
 PT polypeptides, a cytokerin 8 polypeptide and a cytokerin 18
 PT polypeptide, useful as component of vaccine for preventing or treating
 PT adenocarcinoma.

XX PS Claim 1; Page 20; 155pp; English.

XX CC The invention provides a cancer-associated epitope comprising two
 CC separate polypeptides, a cytokerin 8 polypeptide and a cytokerin 18
 CC polypeptide. Vaccine composition of the invention is useful for treating
 CC or preventing colon adenocarcinoma, ovarian adenocarcinoma, renal
 CC adenocarcinoma, mammary adenocarcinoma, lung adenocarcinoma, pancreatic
 CC adenocarcinoma or non-seminoma testis carcinoma. The invention is also
 CC useful for preparing a medicament for treating or preventing cancer in a
 CC mammal. The present sequence is human cytokerin K8 protein fragment

XX SQ Sequence 44 AA;

Query Match 25.0%; Score 5; DB 6; Length 44;
 Best Local Similarity 100.0%; Pred. No. 4.8e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 MLETK 18
 |||||
 Db 33 MLETK 37

RESULT 56

AAE39249

ID AAE39249 standard; protein; 46 AA.

XX AC AAE39249;

XX DT 02-FEB-2001 (first entry)

XX DE Gene 11 human secreted protein homologous amino acid sequence #129.

XX KW Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
 XX KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
 XX KW neurotropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
 XX KW ophthalmological; autoimmune disease; rheumatoid arthritis; angiogenesis;
 XX KW hyperproliferative disorder; cardiovascular disorder; infection;
 XX KW cerebrovascular disorder; nervous system disorder; ocular disorder;
 XX KW wound healing; chemotaxis.

XX OS Homo sapiens.

XX PN WO200056754-A1.

XX PD 28-SEP-2000.

XX PF 16-MAR-2000; 2000WO-US006792.

XX PR 19-MAR-1999; 99US-0125362P.

XX PR 10-DEC-1999; 99US-0169980P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PI Rosen GA, Ruben SM, Komatsoulis G;

XX DR WPI; 2000-579483/54.

XX PT Isolated nucleic acid molecule encoding a human secreted protein is used
 in preventing, treating or ameliorating a medical condition.

XX PS Disclosure; Page 27; 434pp; English.

XX CC The polynucleotide sequences given in AAC74223-C74279 encode the human
 CC secreted proteins represented in AAB39179-B39226. Sequences AAB39227-
 CC B39308 are alternative proteins encoded by the genes, and also protein
 CC sequences with which they share homology. The proteins have activities
 CC based on the tissues and cells in which they are expressed. Examples of
 CC activities include: immunosuppressive; antiarthritic; antirheumatic;
 CC antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
 CC neurotropic; neuroprotective; antibacterial; virucide; fungicide; and
 CC ophthalmological. The human secreted proteins, polynucleotides,
 CC antagonists and agonists of the invention may be useful in the treatment,
 CC prevention, and/or diagnosis of various disease disorders and conditions
 CC such as autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. Alzheimer's disease,
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
 CC infections caused by bacteria, viruses and fungi and ocular disorders
 CC e.g. corneal infection. The polypeptides can also be used to aid wound
 CC healing and epithelial cell proliferation, to regenerate tissues,
 CC maintain organs before transplantation, in chemotaxis and as a food
 CC additive or preservative e.g. to increase storage capabilities. Sequences
 CC AAC74214-C74222 and AAB39178 are used during the isolation and
 CC characterization of the genes of the invention

XX SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 3; Length 46;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
 |||||
 Db 41 LRCVC 45

RESULT 57

```

AM21142
ID  RAM21142 standard; protein; 46 AA.
XX
AC  RAM21142;
XX
DT  12-OCT-2001 (first entry)
XX
DE  Peptide #7576 encoded by probe for measuring cervical gene expression.
XX
KW  Probe; human; microarray; gene expression; cervical epithelial cell;
KW  cervical cancer.
XX
OS  Homo sapiens.
XX
PN  WO200157278-A2.
XX
PD  09-AUG-2001.
XX
PF  Peptide #7576 encoded by probe for measuring cervical gene expression.
XX
KW  Probe; human; microarray; gene expression; cervical epithelial cell;
KW  cervical cancer.
XX
OS  Homo sapiens.
XX
PN  WO200157278-A2.
XX
PD  09-AUG-2001.
XX
PF  30-JAN-2001; 2001WO-US000670.
XX
XX  04-FEB-2000; 2000US-0180312P.
XX  26-MAY-2000; 2000US-0207456P.
XX  30-JUN-2000; 2000US-00608408.
XX  03-AUG-2000; 2000US-00632366.
XX  21-SEP-2000; 2000US-0234687P.
XX  27-SEP-2000; 2000US-0236359P.
XX  04-OCT-2000; 2000GB-00024263.
XX
PA  (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI  Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX  WPI; 2001-488901/53.
XX
PT  Human genome-derived single exon nucleic acid probes useful for analyzing
PT  gene expression in human cervical epithelial cells.
XX
PS  Claim 27; SEQ ID NO 25968; 487pp; English.
XX
CC  The present invention relates to human single exon nucleic acid probes
CC  (SENP: see AA110068-AA128459). The present sequence is a peptide encoded
CC  by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC  can be used to produce a single exon microarray, which can be used for
CC  measuring human gene expression in a sample derived from human cervical
CC  epithelial cells. By measuring gene expression, the probes are therefore
CC  useful in grading and/or staging of diseases of the cervix, notably
CC  cervical cancer. Note: The sequence data for this patent did not form
CC  part of the printed specification, but was obtained in electronic format
CC  directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 46 AA;

Query Match      25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  13 QMLET 17
    |||||
DB  32 QMLET 36

RESULT 58
AAM15409
ID  AAM15409 standard; protein; 46 AA.
XX
AC  AAM15409;
XX
DT  12-OCT-2001 (first entry)
XX
DE  Peptide #1843 encoded by probe for measuring cervical gene expression.
XX
KW  Probe; human; microarray; gene expression; cervical epithelial cell;
KW  cervical cancer.

```

```

XX  Homo sapiens.
OS
PN  WO200157278-A2.
XX
XX  09-AUG-2001.
XX
XX  30-JAN-2001; 2001WO-US000670.
XX
XX  04-FEB-2000; 2000US-0180312P.
XX  26-MAY-2000; 2000US-0207456P.
XX  30-JUN-2000; 2000US-00608408.
XX  03-AUG-2000; 2000US-00632366.
XX  21-SEP-2000; 2000US-0234687P.
XX  27-SEP-2000; 2000US-0236359P.
XX  04-OCT-2000; 2000GB-00024263.
XX
PA  (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI  Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX  WPI; 2001-488901/53.
XX
PT  Human genome-derived single exon nucleic acid probes useful for analyzing
PT  gene expression in human cervical epithelial cells.
XX
PS  Claim 27; SEQ ID NO 20235; 487pp; English.
XX
CC  The present invention relates to human single exon nucleic acid probes
CC  (SENP: see AA110068-AA128459). The present sequence is a peptide encoded
CC  by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC  can be used to produce a single exon microarray, which can be used for
CC  measuring human gene expression in a sample derived from human cervical
CC  epithelial cells. By measuring gene expression, the probes are therefore
CC  useful in grading and/or staging of diseases of the cervix, notably
CC  cervical cancer. Note: The sequence data for this patent did not form
CC  part of the printed specification, but was obtained in electronic format
CC  directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 46 AA;

Query Match      25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  2 RCAPM 6
    |||||
DB  20 RGAPM 24

RESULT 59
ABB43459
ID  ABB43459 standard; peptide; 46 AA.
XX
AC  ABB43459;
XX
DT  04-FEB-2002 (first entry)
XX
DE  Peptide #10965 encoded by human foetal liver single exon probe.
XX
KW  Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS  Homo sapiens.
XX
PN  WO200157277-A2.
XX
PD  09-AUG-2001.
XX
XX  30-JAN-2001; 2001WO-US000669.
XX
XX  04-FEB-2000; 2000US-0180312P.
XX  26-MAY-2000; 2000US-0207456P.
XX  30-JUN-2000; 2000US-00608408.

```


Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
 Db 20 RGAPM 24

RESULT 62
 AAM37347
 ID AAM37347 standard; protein; 46 AA.
 XX
 AC AAM37347;
 XX
 DT 17-OCT-2001 (first entry)
 XX
 DE Peptide #11384 encoded by probe for measuring placental gene expression.
 XX
 KW Probe; microarray; human; placenta; antenatal diagnosis;
 KW genetic disorder.
 XX
 OS Homo sapiens.
 XX
 EN WO200157272-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US000663.
 XX
 PR 04-FEB-2000; 2000US-0180312P.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 DR WPI; 2001-488897/53.
 XX
 PT Human genome-derived single exon nucleic acid probes useful for analyzing
 PT gene expression in human placenta.
 XX
 PS Claim 27; SEQ ID NO 37616; 654pp; English.
 XX
 CC The present invention relates to single exon nucleic acid probes (SENPs;
 CC see AA131315-AA157546). The present sequence is a peptide encoded by one
 CC such probe. The probes are useful for producing a microarray for
 CC predicting, measuring and displaying gene expression in samples derived
 CC from human placenta. The probes are useful for antenatal diagnosis of
 CC human genetic disorders

QY 13 QMLET 17
 Db 32 QMLET 36

RESULT 63
 ABB29251
 ID ABB29251 standard; peptide; 46 AA.
 XX
 AC ABB29251;
 XX
 DT 01-FEB-2002 (first entry)
 XX

DE Peptide #1902 encoded by breast cell single exon nucleic acid probe.
 XX
 KW Human; microarray; single exon probe; gene expression; breast; disease;
 KW Cancer.
 XX
 OS Homo sapiens.
 XX
 PN WO200157271-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US000662.
 XX
 PR 04-FEB-2000; 2000US-0180312P.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 DR WPI; 2001-496933/54.
 XX
 PT New spatially-addressable set of single exon nucleic acid probes, useful
 PT for measuring gene expression in sample derived from human breast,
 PT comprises number of single exon nucleic acid probes.
 XX
 PS Claim 27; SEQ ID NO 12219; 327pp + Sequence Listing; English.
 XX
 CC The invention relates to a spatially-addressable set of single exon
 CC nucleic acid probes for measuring gene expression in a sample derived
 CC from human breast and BT 474 cells. The method involves contacting the
 CC probes with a collection of detectably labelled nucleic acids derived
 CC from mRNA of human breast, and then measuring the label bound to each
 CC probe of the microarray. The probes are useful for verifying the
 CC expression of regions of genomic DNA predicted to encode proteins. They
 CC are useful for gene discovery, and for determining predisposition and/or
 CC prognosing breast disease. Gene expression analysis is useful for
 CC assessing the toxicity of chemical agents on cells. The microarray of
 CC this invention presents a far greater diversity of probes for measuring
 CC gene expression, with far less bias than expressed sequence tag
 CC microarrays. The method is suitable for rapid production of functional
 CC information from genomic sequence. The present sequence is a peptide
 CC encoded by a single exon nucleic acid probe of the invention. Note: The
 CC sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

QY 2 RGAPM 6
 Db 20 RGAPM 24

RESULT 64
 AAU17884
 ID AAU17884 standard; protein; 46 AA.
 XX
 AC AAU17884;
 XX
 DT 07-NOV-2001 (first entry)
 XX
 DE Novel human respiratory antigen #200.
 XX

Query Match 25.0%; Score 5; DB 4; Length 46;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
 Db 20 RGAPM 24

RESULT 64
 AAU17884
 ID AAU17884 standard; protein; 46 AA.
 XX
 AC AAU17884;
 XX
 DT 07-NOV-2001 (first entry)
 XX
 DE Novel human respiratory antigen #200.
 XX

KW Human; respiratory antigen; respiratory disorder; throat disorder;
KW lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW respiratory active.
XX
XX OS Homo sapiens.
XX WO200155448-A1.
XX PD 02-AUG-2001.
XX PF 17-JAN-2001; 2001WO-US001333.
XX PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.

PR 08-DEC-2000; 2000US-0251990P.
 PR 11-DEC-2000; 2000US-0254097P.
 PR 05-JAN-2001; 2001US-0259678P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Barash SC, Ruben SM;
 PI WPI; 2001-476224/51.
 XX DR N-PSDS; AAS28068.
 XX
 XX Isolated polypeptide for treating, preventing and/or prognosing
 PT disorders related to the respiratory system including respiratory cancers
 PT and also for testing and detection e.g. diagnosis.
 XX
 XX Claim 11; SEQ ID NO 502; 546pp; English.
 XX
 XX The present invention relates to the isolation of novel human respiratory
 CC antigens, and cDNA (AAS27869-AAS28159) and genomic sequences encoding for
 CC these polypeptides. The sequences of the invention are useful for
 CC preventing, treating and/or prognosing disorders related to the
 CC respiratory system including throat disorders (e.g. vocal cord paralysis,
 CC tonsillitis, and laryngitis), lung disorders e.g. pneumonia, allergic
 CC disorders e.g. asthma, pleurisy, cystic fibrosis, emphysema, nose
 CC disorders and cancers of the respiratory tissues e.g. lung cancer. The
 CC polynucleotide sequences of the invention are useful in gene therapy and
 CC antisense therapy. AAU17685-AAU17975 represent novel human respiratory
 CC antigens. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 46 AA;
 SQ

Query Match 25.0%; Score 5; DB 4; Length 46;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
 DB 2 LETKF 6
 |||||

RESULT 65
 ABB19826
 ID ABB19826 standard; protein; 46 AA.
 XX
 XX ABB19826;
 AC
 DT 23-JAN-2002 (first entry)
 XX
 DE Protein #1825 encoded by probe for measuring heart cell gene expression.
 XX
 KW Human; gene expression; heart; microarray; vascular system;
 KW cardiovascular disease; hypertension; cardiac arrhythmia;
 KW congenital heart disease.
 XX
 OS Homo sapiens.
 XX
 XX WO200157274-A2.
 PN
 PD 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US000666.
 XX
 XX 04-FEB-2000; 2000US-0180312P.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 XX
 XX (MOLE-) MOLECULAR DYNAMICS INC.
 PA
 XX Penn SG, Hanzel DK, Chen W, Rank DR;
 PI WPI; 2001-488900/53.
 XX
 XX Human genome-derived single exon nucleic acid probes useful for analyzing
 PT gene expression in human bone marrow.
 XX
 XX Example 4; SEQ ID NO 27905; 658pp + Sequence Listing; English.

XX Penn SG, Hanzel DK, Chen W, Rank DR;
 XX WPI; 2001-48899/53.
 XX
 XX Single exon nucleic acid probes for analyzing gene expression in human
 PT hearts.
 XX
 XX Claim 15; SEQ ID NO 21596; 530pp; English.
 PS
 XX
 XX The present invention relates to single exon nucleic acid probes for
 CC measuring human gene expression in a sample derived from human heart (see
 CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
 CC probe. The probes may be used for predicting, measuring and displaying
 CC gene expression in samples derived from the human heart via microarrays.
 CC By measuring gene expression, the probes are useful for predicting,
 CC diagnosing, grading, staging, monitoring and prognosing diseases of the
 CC human heart and vascular system e.g. cardiovascular disease,
 CC hypertension, cardiac arrhythmias and congenital heart disease. Note: The
 CC sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 46 AA;
 SQ

Query Match 25.0%; Score 5; DB 4; Length 46;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
 DB 20 RGAPM 24
 |||||

RESULT 66
 AAM67599
 ID AAM67599 standard; protein; 46 AA.
 XX
 XX AAM67599;
 AC
 DT 06-NOV-2001 (first entry)
 XX
 XX Human bone marrow expressed probe encoded protein SEQ ID NO: 27905.
 DE
 DE Human; bone marrow expressed exon; gene expression analysis; probe;
 KW microarray; cancer; leukaemia; lymphoma; myeloma.
 KW
 XX Homo sapiens.
 OS
 XX WO200157276-A2.
 PN
 PD 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US000668.
 XX
 XX 04-FEB-2000; 2000US-0180312P.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 30-JUN-2000; 2000US-00608408.
 PR 03-AUG-2000; 2000US-00632366.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 XX
 XX (MOLE-) MOLECULAR DYNAMICS INC.
 PA
 XX Penn SG, Hanzel DK, Chen W, Rank DR;
 PI WPI; 2001-488900/53.
 XX
 XX Human genome-derived single exon nucleic acid probes useful for analyzing
 PT gene expression in human bone marrow.
 XX
 XX Example 4; SEQ ID NO 27905; 658pp + Sequence Listing; English.

XX The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
Db 20 RGAPM 24

RESULT 67
AAM64389
ID AAM64389 standard; protein; 46 AA.
XX
AC AAM64389;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 36494.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
PI 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
PI WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 36494; 650pp + Sequence Listing; English.
XX
SQ The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
Db 20 RGAPM 24

RESULT 68
ABG58835
ID ABG58835 standard; peptide; 46 AA.
XX
AC ABG58835;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID NO 37483.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
PI WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 37483; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SNP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLET 17
Db 32 QMLET 36

RESULT 69
ABG49246


```

ID ABG49246 standard; peptide; 46 AA.
XX
AC ABG49246;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 27894.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
(PMOLE-) MOLECULAR DYNAMICS INC.
PA
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 27; SEQ ID NO 11910; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes
CC (see AA100010-AA110067). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for measuring human gene expression in
CC a human breast sample, where the probe hybridises at high stringency to a
CC nucleic acid expressed in the human breast. The probes are useful for
CC predicting, diagnosing, grading, staging, monitoring and prognosing
CC diseases of the human breast, particularly those diseases with polygenic
CC aetiology. The diseases include: breast cancer, disorders of development,
CC inflammatory diseases of the breast, fibrocystic changes, proliferative
CC breast disease and non-carcinoma tumours. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;
XX
Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e-02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 RGAPM 6
DB 20 RGAPM 24
RESULT 71
ID ABG46222 standard; peptide; 46 AA.
XX
AC ABG46222;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 35887.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberosclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
XX
Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e-02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 RGAPM 6
DB 20 RGAPM 24
RESULT 70
ID AAM03170 standard; protein; 46 AA.
XX
AC AAM03170;
XX
DT 09-OCT-2001 (first entry)
XX
DE Peptide #1852 encoded by probe for measuring breast gene expression.
XX
```

KW	primary ciliary dyskinesia; pulmonary hypertension;	Matches	5; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
KW	hyaline membrane disease.						
OS							
XX	Homo sapiens.	Qy	13 QMLET 17				
XX		Db	32 QMLET 36				
XX							
XX	WO200186003-A2.						
XX	15-NOV-2001.						
XX	30-JAN-2001; 2001WO-US000665.						
XX	04-FEB-2000; 2000US-0180312P.						
XX	26-MAY-2000; 2000US-0207456P.						
XX	30-JUN-2000; 2000US-00608408.						
XX	03-AUG-2000; 2000US-00632366.						
XX	21-SEP-2000; 2000US-0234687P.						
XX	27-SEP-2000; 2000US-0236359P.						
XX	04-OCT-2000; 2000GB-00024263.						
XX	(MOLE-) MOLECULAR DYNAMICS INC.						
XX	Penn SG, Hanzel DK, Chen W, Rank DR;						
XX	WPI; 2002-114183/15.						
XX	Spatially-addressable set of single exon nucleic acid probes, used to						
XX	measure gene expression in human lung samples.						
XX	Claim 27; SEQ ID NO 35887; 634pp; English.						
XX	The invention relates to a spatially-addressable set of single exon						
XX	nucleic acid probes for measuring gene expression in a sample derived						
XX	from human lung comprising single exon nucleic acid probes having one of						
XX	12614 nucleic acid sequences mentioned in the specification, or their						
XX	complements or the 12387 open reading frames derived from the 12614						
XX	probes. Also included are a microarray comprising the novel set of probes						
XX	; the novel set of probes which hybridise at high stringency to a nucleic						
XX	acid expressed in the human lung; measuring gene expression in a sample						
XX	derived from human lung, comprising (a) contacting the array with a						
XX	collection of detectably labeled nucleic acids derived from human lung						
XX	RNA, and (b) measuring the label detectably bound to each probe of the						
XX	array; identifying exons in a eukaryotic genome, comprising (a)						
XX	algorithmically predicting at least one exon from genomic sequences of						
XX	the eukaryote; and (b) detecting specific hybridisation of detectably						
XX	labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,						
XX	having a fragment identical to the predicted exon, the probe is included						
XX	in the above mentioned microarray; assigning exons to a single gene,						
XX	comprising (a) identifying exons from genomic sequence by the method						
XX	above and (b) measuring the expression of each of the exons in several						
XX	tissues and/or cell types using hybridisation to a single exon						
XX	microarrays having a probe with the exon, where a common pattern of						
XX	expression of the exons in the tissues and/or cell types indicates that						
XX	the exons should be assigned to a single gene; a peptide comprising one						
XX	of 12011 sequences, mentioned in the specification, or encoded by the						
XX	probes/open reading frames (ORF). The probes are used for gene expression						
XX	analysis, and for identifying exons in a gene, particularly using human						
XX	lung derived mRNA and for the study of lung diseases such as asthma, lung						
XX	cancer, chronic obstructive pulmonary disease (COPD), interstitial lung						
XX	disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,						
XX	tuberos sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-						
XX	Pudlak syndrome, sarcoidosis, pulmonary haemorrhage, pulmonary						
XX	histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,						
XX	Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary						
XX	dyskinesia, pulmonary hypertension and hyaline membrane disease. The						
XX	present sequence is a peptide/protein encoded by a single exon probe of						
XX	the invention. Note: The sequence data for this patent did not form part						
XX	of the printed specification, but was obtained in electronic format						
XX	directly from WIPO at ftp.wipo.int/pub/published_pct_sequences						
XX	Sequence 46 AA;						
XX	Query Match 25.0%; Score 5; DB 5; Length 46;						
XX	Best Local Similarity 100.0%; Pred. No. 4.9e+02;						

CC tissues and/or cell types using hybridisation to a single exon
 CC microarrays having a probe with the exon, where a common pattern of
 CC expression of the exons in the tissues and/or cell types indicates that
 CC the exons should be assigned to a single gene; a peptide comprising one
 CC of 12011 sequences, mentioned in the specification, or encoded by the
 CC probes/open reading frames (ORF). The probes are used for gene expression
 CC analysis, and for identifying exons in a gene, particularly using human
 CC lung derived mRNA and for the study of lung diseases such as asthma, lung
 CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
 CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
 CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
 CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
 CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
 CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
 CC dyskinesia, pulmonary hypertension and bialine membrane disease. The
 CC present sequence is a peptide/protein encoded by a single exon probe of
 CC the invention. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIFO at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 5; Length 46;

Best Local Similarity 100.0%; Pred.No. 4.9e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6

Db 20 RGAPM 24

RESULT 73

ADG41264

ID ADG41264 standard; protein; 46 AA.

XX AC ADG41264;

XX DT 26-FEB-2004 (first entry)

XX DE Human respiratory system associated protein seq id 502.

XX KW antiinflammatory; antiallergic; antiasthmatic; cytostatic; gene therapy;
 KW respiratory system antigen;
 KW human respiratory system associated polynucleotide;
 KW respiratory system disorder; throat disorder; vocal cord paralysis;
 KW tonsillitis; laryngitis; lung disorder; pneumonia; allergic disorder;
 KW asthma; eosinophilic pneumonia; pleurisy; cystic fibrosis; emphysema;
 KW histiocytosis; sarcoidosis; nose disorder; rhinitis; sinusitis; neoplasm;
 KW cancer; respiratory tissue cancer; throat cancer; lung cancer;
 KW cancer of the nose; gene therapy; chromosome identification; forensic;
 KW human respiratory system associated protein; human.

XX OS Homo sapiens.

XX XX US2003215893-A1.

XX XX 20-NOV-2003.

XX PF 07-AUG-2002; 2002US-00212872.

XX XX 31-JAN-2000; 2000US-0179065P.

PR 04-FEB-2000; 2000US-0180628P.

PR 24-FEB-2000; 2000US-0184664P.

PR 02-MAR-2000; 2000US-0186350P.

PR 16-MAR-2000; 2000US-0198874P.

PR 17-MAR-2000; 2000US-0190076P.

PR 18-APR-2000; 2000US-0198123P.

PR 19-MAY-2000; 2000US-0205515P.

PR 07-JUN-2000; 2000US-0209467P.

PR 28-JUN-2000; 2000US-0214886P.

PR 30-JUN-2000; 2000US-0215135P.

PR 07-JUL-2000; 2000US-0216647P.

PR 07-JUL-2000; 2000US-0216880P.

PR 11-JUL-2000; 2000US-0217487P.
 PR 11-JUL-2000; 2000US-0217496P.
 PR 14-JUL-2000; 2000US-0218290P.
 PR 26-JUL-2000; 2000US-0220963P.
 PR 26-JUL-2000; 2000US-0220964P.
 PR 14-AUG-2000; 2000US-0224518P.
 PR 14-AUG-2000; 2000US-0224519P.
 PR 14-AUG-2000; 2000US-0225213P.
 PR 14-AUG-2000; 2000US-0225214P.
 PR 14-AUG-2000; 2000US-0225266P.
 PR 14-AUG-2000; 2000US-0225267P.
 PR 14-AUG-2000; 2000US-0225268P.
 PR 14-AUG-2000; 2000US-0225270P.
 PR 14-AUG-2000; 2000US-0225447P.
 PR 14-AUG-2000; 2000US-0225757P.
 PR 14-AUG-2000; 2000US-0225758P.
 PR 14-AUG-2000; 2000US-0225759P.
 PR 18-AUG-2000; 2000US-0226279P.
 PR 22-AUG-2000; 2000US-0226681P.
 PR 22-AUG-2000; 2000US-0226686P.
 PR 22-AUG-2000; 2000US-0227182P.
 PR 23-AUG-2000; 2000US-0227009P.
 PR 30-AUG-2000; 2000US-0228924P.
 PR 01-SEP-2000; 2000US-0229287P.
 PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 06-SEP-2000; 2000US-0230437P.
 PR 06-SEP-2000; 2000US-0230438P.
 PR 08-SEP-2000; 2000US-0231242P.
 PR 08-SEP-2000; 2000US-0231243P.
 PR 08-SEP-2000; 2000US-0231244P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 08-SEP-2000; 2000US-0231414P.
 PR 08-SEP-2000; 2000US-0232081P.
 PR 12-SEP-2000; 2000US-0231968P.
 PR 14-SEP-2000; 2000US-0232397P.
 PR 14-SEP-2000; 2000US-0232398P.
 PR 14-SEP-2000; 2000US-0232399P.
 PR 14-SEP-2000; 2000US-0232400P.
 PR 14-SEP-2000; 2000US-0232401P.
 PR 14-SEP-2000; 2000US-0233063P.
 PR 14-SEP-2000; 2000US-0233064P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 25-SEP-2000; 2000US-0234998P.
 PR 26-SEP-2000; 2000US-0235484P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 27-SEP-2000; 2000US-0235836P.
 PR 28-SEP-2000; 2000US-0235935P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236369P.
 PR 29-SEP-2000; 2000US-0236370P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.
 PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 02-OCT-2000; 2000US-0237040P.
 PR 13-OCT-2000; 2000US-0239937P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241221P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241786P.
 PR 20-OCT-2000; 2000US-0241787P.
 PR 20-OCT-2000; 2000US-0241808P.
 PR 20-OCT-2000; 2000US-0241809P.

Query Match 25.0%; Score 5; DB 4; Length 47;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 13 PRGAP 17

RESULT 75
AAM31580
ID AAM31580 standard; protein; 47 AA.
XX
AC AAM31580;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #5617 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN W0200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234587P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 31849; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENPs;
CC see AA131315-AA157546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 47 AA;

Query Match 25.0%; Score 5; DB 4; Length 47;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 13 PRGAP 17

Search completed: October 26, 2004, 07:16:23
Job time : 88 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2004, 07:22:37 ; Search time 65 Seconds
(without alignments)
99.618 Million cell updates/sec

Title: US-10-066-965A-4

Perfect score: 20

Sequence: 1 PRGAPWLRVCVQMLETKFL 20

Scoring table: OLIGO

Gapop 60.0 , Gapext 60.0

Searched: 1364641 seqs, 323758627 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1364641

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : Published Applications AA.*

1: /cgn2_6/prodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/prodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/prodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/prodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/prodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/prodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/prodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/prodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/prodata/2/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/prodata/2/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/prodata/2/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/prodata/2/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/prodata/2/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/prodata/2/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/prodata/2/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/prodata/2/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/prodata/2/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/prodata/2/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/prodata/2/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/prodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	100.0	20	14 US-10-066-965A-4	Sequence 4, Appli
2	20	100.0	20	14 US-10-066-965A-23	Sequence 23, Appl
3	7	35.0	20	14 US-10-066-965A-3	Sequence 3, Appl
4	7	35.0	20	14 US-10-066-965A-22	Sequence 22, Appl
5	6	30.0	81	16 US-10-437-963-181184	Sequence 181184,
6	6	30.0	278	14 US-10-369-493-17206	Sequence 17206, A
7	6	30.0	285	15 US-10-264-049-3133	Sequence 3133, Ap
8	6	30.0	395	14 US-10-094-749-3019	Sequence 3019, Ap
9	6	30.0	395	16 US-10-408-765A-2509	Sequence 2509, Ap
10	6	30.0	434	15 US-10-282-122A-76949	Sequence 76949, A
11	6	30.0	571	15 US-10-262-839-180	Sequence 180,
12	6	30.0	577	15 US-10-262-839-196	Sequence 196, App
13	6	30.0	731	16 US-10-408-765A-2869	Sequence 2869, Ap

1490	15	US-10-262-839-184	Sequence 184, App
1545	15	US-10-262-839-182	Sequence 182, App
1549	15	US-10-262-839-186	Sequence 186, App
1568	15	US-10-263-929-117	Sequence 117, App
1588	13	US-10-000-512-2	Sequence 2, Appli
1588	14	US-10-074-566-2	Sequence 2, Appli
1588	14	US-10-074-566-41	Sequence 41, Appl
1588	15	US-10-262-839-176	Sequence 176, App
1588	15	US-10-262-839-188	Sequence 188, App
1588	15	US-10-262-839-194	Sequence 194, App
1588	15	US-10-262-839-200	Sequence 200, App
9	9	US-09-834-765-528	Sequence 528, App
9	9	US-09-834-765-634	Sequence 634, App
10	9	US-09-834-765-583	Sequence 583, App
12	14	US-10-253-118-1	Sequence 1, Appli
15	14	US-10-104-755-20	Sequence 20, Appl
28	14	US-10-231-417-416	Sequence 416, App
44	15	US-10-424-599-167866	Sequence 167866,
44	16	US-10-437-963-120828	Sequence 120828,
45	15	US-10-424-599-186275	Sequence 186275,
46	9	US-09-864-761-35124	Sequence 35124, A
46	9	US-09-864-761-45993	Sequence 45993, A
46	9	US-09-764-860-502	Sequence 502, App
46	14	US-10-074-095-502	Sequence 502, App
46	14	US-10-212-872-502	Sequence 502, App
46	16	US-10-437-963-161908	Sequence 161908,
47	9	US-09-864-761-38656	Sequence 38656, A
47	16	US-10-437-963-202542	Sequence 202542,
50	16	US-10-387-346B-94	Sequence 94, Appl
50	16	US-10-437-963-204604	Sequence 204604,
51	15	US-10-686-947-94	Sequence 94, Appl
51	15	US-10-424-599-267231	Sequence 267231,
51	15	US-10-424-599-275966	Sequence 275966,
52	15	US-10-424-599-284525	Sequence 284525,
53	15	US-10-424-599-177624	Sequence 177624,
54	14	US-10-152-031-13	Sequence 13, Appl
56	15	US-10-424-599-262093	Sequence 262093,
57	9	US-09-867-550-1984	Sequence 1984, Ap
58	15	US-10-424-599-240745	Sequence 240745,
58	15	US-10-424-599-205956	Sequence 205956,
61	15	US-10-424-599-176161	Sequence 176161,
62	15	US-10-424-599-239535	Sequence 239535,
63	14	US-10-029-386-32143	Sequence 32143, A
64	15	US-10-424-599-282344	Sequence 282344,
66	15	US-10-424-599-210941	Sequence 210941,
67	9	US-09-867-550-1576	Sequence 1576, Ap
68	15	US-10-424-599-154428	Sequence 154428,
72	9	US-09-864-761-34034	Sequence 34034, A
72	13	US-10-001-879-175	Sequence 175, App
72	15	US-10-424-599-221140	Sequence 221140,
74	16	US-10-437-963-102863	Sequence 102863,
76	16	US-10-293-252C-102	Sequence 102, App
76	16	US-10-340-861B-102	Sequence 102, App
78	9	US-09-792-793A-90	Sequence 90, Appl
78	11	US-09-864-408A-5972	Sequence 5972, Ap
78	14	US-10-375-209A-90	Sequence 90, Appl
78	16	US-10-437-963-135152	Sequence 135152,
78	16	US-10-437-963-167155	Sequence 167155,
79	15	US-10-424-599-144203	Sequence 144203,
79	15	US-10-424-599-149863	Sequence 149863,
80	9	US-09-922-261-464	Sequence 464, App
81	16	US-10-437-963-105389	Sequence 105389,
81	16	US-10-437-963-173123	Sequence 173123,
82	15	US-10-424-599-151381	Sequence 151381,
83	15	US-10-424-599-240184	Sequence 240184,
84	14	US-10-106-698-7816	Sequence 7816, Ap
85	9	US-09-867-550-772	Sequence 772, App
85	16	US-10-437-963-183176	Sequence 183176,
86	9	US-09-864-761-47995	Sequence 47995, A
86	9	US-09-764-877-2023	Sequence 2023, Ap
86	15	US-10-242-515-2023	Sequence 2023, Ap
87	15	US-10-424-599-281783	Sequence 281783,
87	16	US-10-437-963-110760	Sequence 110760,

87 Sequence 102687, A
88 Sequence 50033, A
89 Sequence 215851,
90 Sequence 127248,
91 Sequence 236694,
92 Sequence 243343,
93 Sequence 115372,
94 Sequence 124347,
95 Sequence 7168, Ap
96 Sequence 153530,
97 Sequence 142846,
98 Sequence 157410,
99 Sequence 159333,
100 Sequence 134702,

ALIGNMENTS

RESULT 1
US-10-066-965A-4
; Sequence 4, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYPT 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-4

Query Match 100.0%; Score 20; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPMWLRVCVQMLETKFL 20
|||||
Db 1 PRGAPMWLRVCVQMLETKFL 20

RESULT 2
US-10-066-965A-23
; Sequence 23, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYPT 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-23

Query Match 35.0%; Score 7; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPMW 7
|||||
Db 1 PRGAPMW 7

Query Match 100.0%; Score 20; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPMWLRVCVQMLETKFL 20
|||||
Db 1 PRGAPMWLRVCVQMLETKFL 20

RESULT 3
US-10-066-965A-3
; Sequence 3, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYPT 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-3

Query Match 35.0%; Score 7; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPMW 7
|||||
Db 1 PRGAPMW 7

RESULT 4
US-10-066-965A-22
; Sequence 22, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYPT 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-22

Query Match 35.0%; Score 7; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPMW 7
|||||
Db 1 PRGAPMW 7

Db 365 QMLETK 370

RESULT 9

US-10-408-765A-2509
; Sequence 2509, Application US/10408765A
; Publication No. US20040101874A1

GENERAL INFORMATION:

; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Fahy, Eoin D.
; APPLICANT: Zhang, Bing
; APPLICANT: Gibson, Bradford W.
; APPLICANT: Taylor, Steven W.
; APPLICANT: Glenn, Gary M.
; APPLICANT: Waddock, Dale E.

; TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION

; FILE REFERENCE: 660088.465

; CURRENT APPLICATION NUMBER: US/10/408,765A

; CURRENT FILING DATE: 2003-04-04

; NUMBER OF SEQ ID NOS: 3077

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2509

; LENGTH: 395

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-408-765A-2509

Query Match

Best Local Similarity 30.0%; Score 6; DB 16; Length 395;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18

Db 365 QMLETK 370

RESULT 10

US-10-282-122A-76949

; Sequence 76949, Application US/10282122A

; Publication No. US20040029129A1

GENERAL INFORMATION:

; APPLICANT: Wang, Liangsu
; APPLICANT: Zamudio, Carlos
; APPLICANT: Malone, Cheryl
; APPLICANT: Haselbeck, Robert
; APPLICANT: Ohlsen, Kari
; APPLICANT: Zyskind, Judith
; APPLICANT: Wall, Daniel
; APPLICANT: Trawick, John
; APPLICANT: Carr, Grant
; APPLICANT: Yamamoto, Robert
; APPLICANT: Forsyth, R.

; APPLICANT: Xu, H.

; TITLE OF INVENTION: Identification of Essential Genes in Microorganisms

; FILE REFERENCE: ELITRA.034A

; CURRENT APPLICATION NUMBER: US/10/282,122A

; CURRENT FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: 60/191,078

; PRIOR FILING DATE: 2000-03-21

; PRIOR APPLICATION NUMBER: 60/206,848

; PRIOR FILING DATE: 2000-05-23

; PRIOR APPLICATION NUMBER: 60/207,727

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: 60/230,335

; PRIOR FILING DATE: 2000-09-06

; PRIOR APPLICATION NUMBER: 60/230,347

; PRIOR FILING DATE: 2000-09-09

; PRIOR APPLICATION NUMBER: 60/242,578

; PRIOR FILING DATE: 2000-10-23

; PRIOR APPLICATION NUMBER: 60/253,625

; PRIOR FILING DATE: 2000-11-27

; PRIOR APPLICATION NUMBER: 60/257,931

; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/267,636
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/269,308
; PRIOR FILING DATE: 2001-02-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 78614
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 76949
; LENGTH: 434
; TYPE: PRT
; ORGANISM: Vibrio cholerae
US-10-282-122A-76949

Query Match 30.0%; Score 6; DB 15; Length 434;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 APMWLR 9

Db 177 APMWLR 182

RESULT 11

US-10-262-839-180

; Sequence 180, Application US/10262839

; Publication No. US20040038877A1

GENERAL INFORMATION:

; APPLICANT: Alsobrook, John.
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shinkets, Richard,
; APPLICANT: Smithson, Glennda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei

; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD

; FILE REFERENCE: 21402-462A

; CURRENT APPLICATION NUMBER: US/10/262,839

; CURRENT FILING DATE: 2002-10-01

; PRIOR APPLICATION NUMBER: 60/326,483

; PRIOR FILING DATE: 2001-10-02

; PRIOR APPLICATION NUMBER: 60/327,917

; PRIOR FILING DATE: 2001-10-09

; PRIOR APPLICATION NUMBER: 60/328,029

; PRIOR FILING DATE: 2001-10-09

; PRIOR APPLICATION NUMBER: 60/328,056

; PRIOR FILING DATE: 2001-10-09

; PRIOR APPLICATION NUMBER: 60/381,101

; PRIOR FILING DATE: 2002-05-16

; PRIOR APPLICATION NUMBER: 60/371,972

; PRIOR FILING DATE: 2002-04-12

; PRIOR APPLICATION NUMBER: 60/327,342

; PRIOR FILING DATE: 2001-10-05

; PRIOR APPLICATION NUMBER: 60/328,044

; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 180
; LENGTH: 571
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-180

Query Match 30.0%; Score 6; DB 15; Length 571;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
|||||
Db 545 QMLETK 550

RESULT 12
US-10-262-839-196
; Sequence 196, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shinkets, Richard,
; APPLICANT: Smithson, Glennda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Vernhet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zernhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044

; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 196
; LENGTH: 577
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-196

Query Match 30.0%; Score 6; DB 15; Length 577;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLETK 18
|||||
Db 546 QMLETK 551

RESULT 13
US-10-408-765A-2869
; Sequence 2869, Application US/10408765A
; Publication No. US20040101874A1
; GENERAL INFORMATION:
; APPLICANT: Ghosh, Soumitra S.,
; APPLICANT: Fahy, Eoin D.,
; APPLICANT: Zhang, Bing
; APPLICANT: Gibson, Bradford W.,
; APPLICANT: Taylor, Steven W.,
; APPLICANT: Glenn, Gary M.,
; APPLICANT: Warnock, Dale E.,
; TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION
; FILE REFERENCE: 660088.465
; CURRENT APPLICATION NUMBER: US/10/408,765A
; CURRENT FILING DATE: 2003-04-04
; NUMBER OF SEQ ID NOS: 3077
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2869
; LENGTH: 731
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-765A-2869

Query Match 30.0%; Score 6; DB 16; Length 731;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAPM 6
|||||
Db 542 PRGAPM 547

RESULT 14
US-10-262-839-184
; Sequence 184, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,

```

; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glennnda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 184
; LENGTH: 1490
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-184

```

```

Query Match      30.0%; Score 6; DB 15; Length 1490;
Best Local Similarity 100.0%; Pred.No. 3.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      13 QMLETK 18
        |||||
Db      1393 QMLETK 1398

```

```

RESULT 15
US-10-262-839-182
; Sequence 182, Application US/10262839
; Publication No. US2004003877A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,

```

```

; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glennnda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 182
; LENGTH: 1545
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-182

```

```

Query Match      30.0%; Score 6; DB 15; Length 1545;
Best Local Similarity 100.0%; Pred.No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      13 QMLETK 18
        |||||
Db      1393 QMLETK 1398

```

```

RESULT 16
US-10-262-839-186
; Sequence 186, Application US/10262839
; Publication No. US2004003877A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,

```

```
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glenda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, Jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 186
; LENGTH: 1549
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-186

Query Match      30.0%; Score 6; DB 15; Length 1549;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      13 QMLETK 18
DB      1395 QMLETK 1400

RESULT 17
US-10-263-929-117
; Sequence 117, Application US/10263929
; Publication No. US2004006753A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jaeseob
; APPLICANT: Galant, Ron
; TITLE OF INVENTION: Alzheimer's Disease Linked Genes
; FILE REFERENCE: LSD-07417
; CURRENT APPLICATION NUMBER: US/10/263,929
; CURRENT FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 213
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 117
; LENGTH: 1568
; TYPE: PRT
```

```
; ORGANISM: Mus musculus
US-10-263-929-117

Query Match      30.0%; Score 6; DB 15; Length 1568;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVCQ 13
DB      394 LRCVCQ 399

RESULT 18
US-10-000-512-2
; Sequence 2, Application US/10000512
; Publication No. US20020164699A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A
; APPLICANT: Fernandes, Elma
; TITLE OF INVENTION: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
; FILE REFERENCE: 15966-556
; CURRENT APPLICATION NUMBER: US/10/000,512
; CURRENT FILING DATE: 2001-10-23
; PRIOR APPLICATION NUMBER: 09/619,252
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/167,785
; PRIOR FILING DATE: 1999-11-29
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-000-512-2

Query Match      30.0%; Score 6; DB 13; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      13 QMLETK 18
DB      1393 QMLETK 1398

RESULT 19
US-10-074-566-2
; Sequence 2, Application US/10074566
; Publication No. US20030207348A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Fernandes, Elma R.
; APPLICANT: Li, Li
; APPLICANT: Gorman, Linda
; APPLICANT: Gusev, Vladimir Y.
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Patturajan, Meera
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Polynucleotides Encoding Same
; FILE REFERENCE: 15966-556 CIP1
; CURRENT APPLICATION NUMBER: US/10/074,566
; CURRENT FILING DATE: 2002-02-13
; PRIOR APPLICATION NUMBER: 09/619,252
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/144,722
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/167,785
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 60/276,994
; PRIOR FILING DATE: 2001-03-19
; PRIOR APPLICATION NUMBER: 60/280,898
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: 60/332,241
```

; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/288,062
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/291,766
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/314,007
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 132
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: human
US-10-074-566-2

Query Match 30.0%; Score 6; DB 14; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
|||||
Db 1393 QMLETK 1398

RESULT 20
US-10-074-566-41
; Sequence 41, Application US/10074566
; Publication No. US20030207348A1
; GENERAL INFORMATION:
; APPLICANT: Shinkets, Richard A.
; APPLICANT: Fernandes, Elma R.
; APPLICANT: Li, Li
; APPLICANT: Gorman, Linda
; APPLICANT: Gusev, Vladimir Y.
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Patturajan, Meera
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Polynucleotides Encoding Same
; FILE REFERENCE: 15966-556 CIP1
; CURRENT APPLICATION NUMBER: US/10/074,566
; CURRENT FILING DATE: 2002-02-13
; PRIOR APPLICATION NUMBER: 09/619,252
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/144,722
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/167,785
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 60/276,994
; PRIOR FILING DATE: 2001-03-19
; PRIOR APPLICATION NUMBER: 60/280,898
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: 60/332,241
; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/288,062
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/291,766
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/314,007
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 132
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: human
US-10-074-566-41

Query Match 30.0%; Score 6; DB 14; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18

Db 1393 QMLETK 1398
|||||

RESULT 21
US-10-262-839-176
; Sequence 176, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shinkets, Richard,
; APPLICANT: Smithson, Glennda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, Jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 176
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-176

Query Match 30.0%; Score 6; DB 15; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18

Db 1393 QMLETK 1398
|||||

RESULT 22
US-10-262-839-188
; Sequence 188, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glenda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, Jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 188
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-188

Query Match 30.0%; Score 6; DB 15; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 QMLETK 18

Db 1393 QMLETK 1398
|||||

RESULT 23
US-10-262-839-194
; Sequence 194, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glenda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, Jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 194
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-194

Query Match 30.0%; Score 6; DB 15; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 QMLETK 18

Db 1393 QMLETK 1398
|||||

RESULT 24
US-10-262-839-200
; Sequence 200, Application US/10262839
; Publication No. US2004003897A1
; GENERAL INFORMATION:
; APPLICANT: Alsebrook, John,
; APPLICANT: Anderson, David W.,
; APPLICANT: Boldog, Ferenc,
; APPLICANT: Burgess, Catherine,
; APPLICANT: Catterton, Elina,
; APPLICANT: Edinger, Shlomit,
; APPLICANT: Ellerman, Karen,
; APPLICANT: Gerlach, Valerie,
; APPLICANT: Gorman, Linda,
; APPLICANT: Guo, Xiaojia,
; APPLICANT: Ji, Weizhen,
; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shinkets, Richard,
; APPLICANT: Smithson, Glennda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, Jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraSeqlist version 0.1
; SEQ ID NO 200
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-200

Query Match 30.0%; Score 6; DB 15; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 QMLETK 18

Db 1393 QMLETK 1398
|||||

RESULT 25
US-09-834-765-528
; Sequence 528, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
; APPLICANT: Mary Faris
; APPLICANT: Pia M. Challita-Bid
; APPLICANT: Arthur B. Raitano
; APPLICANT: Steve Chappell Mitchell
; APPLICANT: Daniel E.H. Afar
; APPLICANT: Aya Jakobovits
; TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
; TITLE OF INVENTION: AND DETECTION OF CANCER
; FILE REFERENCE: 129-6USU1
; CURRENT APPLICATION NUMBER: US/09/834,765
; CURRENT FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/197,647
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 770
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 528
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-834-765-528

Query Match 25.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 2 PRGAP 6

RESULT 26
US-09-834-765-634
; Sequence 634, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
; APPLICANT: Mary Faris
; APPLICANT: Pia M. Challita-Bid
; APPLICANT: Arthur B. Raitano
; APPLICANT: Steve Chappell Mitchell
; APPLICANT: Daniel E.H. Afar
; APPLICANT: Aya Jakobovits
; TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
; TITLE OF INVENTION: AND DETECTION OF CANCER
; FILE REFERENCE: 129-6USU1
; CURRENT APPLICATION NUMBER: US/09/834,765
; CURRENT FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/197,647
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 770
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 634
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-834-765-634

Query Match 25.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 2 PRGAP 6

RESULT 27
US-09-834-765-583
; Sequence 583, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
; APPLICANT: Mary Paris
; APPLICANT: Pia M. Challita-Eid
; APPLICANT: Arthur B. Raitano
; APPLICANT: Steve Chappell Mitchell
; APPLICANT: Daniel E.H. Afar
; APPLICANT: Aya Jakobovits
; TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
; TITLE OF INVENTION: AND DETECTION OF CANCER
; FILE REFERENCE: 129.6USU1
; CURRENT APPLICATION NUMBER: US/09/834,765
; CURRENT FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/197,647
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 770
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 583
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-834-765-583

Query Match 25.0%; Score 5; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||
DB 2 PRGAP 6

RESULT 28
US-10-253-118-1
; Sequence 1, Application US/10253118
; Publication No. US20030138425A1
; GENERAL INFORMATION:
; APPLICANT: Mather, Powell Jennie
; TITLE OF INVENTION: ANTIBODIES THAT BIND TO
; TITLE OF INVENTION: CANCER-ASSOCIATED ANTIGEN CYTOKERATIN 8 AND METHODS OF USE THERE
; FILE REFERENCE: 415072001000
; CURRENT APPLICATION NUMBER: US/10/253,118
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/323,844
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: US 60/408,253
; PRIOR FILING DATE: 2002-09-04
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-253-118-1

Query Match 25.0%; Score 5; DB 14; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
|||||
DB 8 MLETK 12

RESULT 29
US-10-104-755-20
; Sequence 20, Application US/10104755
; Publication No. US20030031645A1
; GENERAL INFORMATION:

; APPLICANT: Strieter, Robert M.
; Polverini, Peter J.
; Kunkel, Steven L.
; TITLE OF INVENTION: CXC Chemokines as Regulators of
; Angiogenesis
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: US
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/104,755
; FILING DATE: 21-Mar-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/213,383
; FILING DATE: 09-Dec-1998
; APPLICATION NUMBER: 08/468,819
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UMIC:003/HYL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7477
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-104-755-20

Query Match 25.0%; Score 5; DB 14; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
|||||
DB 11 LRCVC 15

RESULT 30
US-10-231-417-416
; Sequence 416, Application US/10231417
; Publication No. US20030176681A1
; GENERAL INFORMATION:
; APPLICANT: Feng et al.
; TITLE OF INVENTION: 148 Human Secreted Proteins
; FILE REFERENCE: P2019P1
; CURRENT APPLICATION NUMBER: US/10/231,417
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/296,622
; PRIOR FILING DATE: 1999-04-23
; NUMBER OF SEQ ID NOS: 619
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 416
; LENGTH: 28
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-231-417-416

Query Match 25.0%; Score 5; DB 14; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 12 CQMLE 16
| | | | |
Db 3 CQMLE 7

RESULT 31
US-10-424-599-167866
; Sequence 167866, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 167866
; LENGTH: 44
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_12259C.1.pap
US-10-424-599-167866

Query Match 25.0%; Score 5; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 WLRGV 11
| | | | |
Db 35 WLRGV 39

RESULT 32
US-10-437-963-120828
; Sequence 120828, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 120828
; LENGTH: 44
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_23912C.1.pap
US-10-437-963-120828

Query Match 25.0%; Score 5; DB 16; Length 44;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 VCQML 15
| | | | |
Db 10 VCQML 14

RESULT 33
US-10-424-599-186275
; Sequence 186275, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 186275
; LENGTH: 45
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_139219C.1.pap
US-10-424-599-186275

Query Match 25.0%; Score 5; DB 15; Length 45;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
| | | | |
Db 25 LRCVC 29

RESULT 34
US-09-864-761-35124
; Sequence 35124, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeonica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 35124
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC007688.15
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 1.5
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.8
; OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 1.1
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 0.99
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.1
; OTHER INFORMATION: EST_HUMAN HIT: R77154.1, EVALUATE 1.00e-08
US-09-864-761-35124

Query Match 25.0%; Score 5; DB 9; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
| | | | |
DB 20 RGAPM 24

RESULT 35
US-09-864-761-45993
; Sequence 45993, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 45993
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC005323.1
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.2
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.6
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.9
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.2e+02
; OTHER INFORMATION: EST_HUMAN HIT: BF339300.1, EVALUATE 4.00e+00
US-09-864-761-45993

Query Match 25.0%; Score 5; DB 9; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLET 17
| | | | |
DB 32 QMLET 36

RESULT 36
US-09-764-860-502
; Sequence 502, Application US/09764860
; Patent No. US20020094953A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC008
; CURRENT APPLICATION NUMBER: US/09/764,860
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1198
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 502
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-764-860-502

Query Match 25.0%; Score 5; DB 9; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
| | | | |
DB 2 LETKF 6

RESULT 37
US-10-074-095-502
; Sequence 502, Application US/10074095
; Publication No. US2003007704A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC008C1
; CURRENT APPLICATION NUMBER: US/10/074,095
; CURRENT FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: 09/764,860
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: 60/179,065
; PRIOR FILING DATE: 2000-01-31
; PRIOR APPLICATION NUMBER: 60/180,628
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: 60/214,886
; PRIOR FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/217,487
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,758
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,963
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/217,496
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,447
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/218,290
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/225,757
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/226,868
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/216,647
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,267
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/216,880
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,270
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/251,869
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/235,834
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/234,274
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/234,223
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/228,924
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/224,518
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,369
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/224,519
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,964
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/241,809
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/249,299
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/236,327
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/241,785
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/244,617
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 60/225,268
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,368
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/251,856
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/251,868
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/229,344
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/234,997
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: 60/229,343
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,345
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,287
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,513
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/231,413
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/229,509
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/236,367
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/237,039
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,038
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/236,370
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/236,802
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,037
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,040
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/240,960
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/239,935
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/239,937
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/241,787
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/246,474
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/246,532
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/249,216
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,210
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/226,681
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,759
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/225,213
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/227,182
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,214
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/235,836
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/230,438
; PRIOR FILING DATE: 2000-09-06
; PRIOR APPLICATION NUMBER: 60/215,135
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: 60/225,266
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/249,218
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,208

; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,213
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,212
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,207
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,245
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,244
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,217
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,211
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,215
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,264
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,214
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,297
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/232,400
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/231,242
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/232,081
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/232,080
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/231,414
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/231,244
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/233,064
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/233,063
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/232,397
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/232,399
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/232,401
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 60/241,808
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/241,826
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/241,786
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/241,221
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/246,475
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/231,243
; PRIOR FILING DATE: 2000-09-08

Query Match 25.0%; Score 5; DB 14; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
|||||
Db 2 LETKF 6

RESULT 38

US-10-212-872-502
; Sequence 502, Application US/10212872
; Publication No. US20030215893A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC008C2
; CURRENT APPLICATION NUMBER: US/10/212,872
; CURRENT FILING DATE: 2002-08-07
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 1198
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 502
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-212-872-502

Query Match 25.0%; Score 5; DB 14; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
|||||
Db 2 LETKF 6

RESULT 39

US-10-437-963-161908
; Sequence 161908, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping

; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 161908
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_6104C.1.pep
US-10-437-963-161908

Query Match 25.0%; Score 5; DB 16; Length 46;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 APWWL 8
|||||
Db 41 APWWL 45

RESULT 40

US-09-864-761-38656
; Sequence 38656, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aecmca-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312

```
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 38656
; LENGTH: 47
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC006024.1
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.6
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.5
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.4
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.4
; OTHER INFORMATION: EST_HUMAN HIT: BF241410.1, EVALUATE 6.00e-01
US-09-864-761-38656
```

```
Query Match 25.0%; Score 5; DB 9; Length 47;
Best Local Similarity 100.0%; Pred.No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 PRGAP 5
Db 13 PRGAP 17
```

RESULT 41

```
US-10-437-963-202542
; Sequence 202542, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
```

```
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated with
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 202542
; LENGTH: 47
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_97812C.1.pep
US-10-437-963-202542
```

```
Query Match 25.0%; Score 5; DB 16; Length 47;
Best Local Similarity 100.0%; Pred.No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 14 MLETK 18
Db 17 MLETK 21
```

RESULT 42

```
US-10-387-346B-94
; Sequence 94, Application US/10387346B
; Publication No. US20040117869A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Dongmei
; TITLE OF INVENTION: Cloning of Cytochrome P450 Genes from
; FILE REFERENCE: 78623
; CURRENT APPLICATION NUMBER: US/10/387,346B
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: 10/293,252
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: 10/340,861
; PRIOR FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 60/363,684
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/347,444
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/337,684
; PRIOR FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 94
; LENGTH: 50
; TYPE: PRT
; ORGANISM: Nicotiana
US-10-387-346B-94
```

```
Query Match 25.0%; Score 5; DB 16; Length 50;
Best Local Similarity 100.0%; Pred.No. 3.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 14 MLETK 18
Db 5 MLETK 9
```

RESULT 43

```
US-10-437-963-204604
; Sequence 204604, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
```

```
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 204604
; LENGTH: 50
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_99675C.1.pap
US-10-437-963-204604

Query Match      25.0%; Score 5; DB 16; Length 50;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
        |||||
DB      44 PRGAP 48

RESULT 44
US-10-686-947-94
; Sequence 94, Application US/10686947
; Publication No. US20040162420A1
; GENERAL INFORMATION:
; APPLICANT: Profigen Inc.
; TITLE OF INVENTION: Cloning of Cytochrome P450 Genes from Tobacco
; FILE REFERENCE: 79601
; CURRENT APPLICATION NUMBER: US/10/686,947
; CURRENT FILING DATE: 2003-10-16
; PRIOR APPLICATION NUMBER: US 10/387346
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 298
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
; LENGTH: 50
; TYPE: PRT
; ORGANISM: NICOTIANNATABACUM
US-10-686-947-94

Query Match      25.0%; Score 5; DB 16; Length 50;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      14 MLETK 18
        |||||
DB      5 MLETK 9

RESULT 45
US-10-424-599-267231
; Sequence 267231, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 267231
; LENGTH: 51
; TYPE: PRT
```

```
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_8332C.1.pap
US-10-424-599-267231

Query Match      25.0%; Score 5; DB 15; Length 51;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      11 VCQML 15
        |||||
DB      41 VCQML 45

RESULT 46
US-10-424-599-275966
; Sequence 275966, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 275966
; LENGTH: 51
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_91217C.1.pap
US-10-424-599-275966

Query Match      25.0%; Score 5; DB 15; Length 51;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      14 MLETK 18
        |||||
DB      1 MLETK 5

RESULT 47
US-10-424-599-284525
; Sequence 284525, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 284525
; LENGTH: 52
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_98951C.1.pap
US-10-424-599-284525

Query Match      25.0%; Score 5; DB 15; Length 52;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 8 LRCVC 12
|||||
Db 34 LRCVC 38

RESULT 48
US-10-424-599-177624
; Sequence 177624, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 177624
; LENGTH: 53
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_13140C.1.pap
US-10-424-599-177624

Query Match 25.0%; Score 5; DB 15; Length 53;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 ETKFL 20
|||||
Db 2 ETKFL 6

RESULT 49
US-10-152-031-13
; Sequence 13, Application US/10152031
; Publication No. US20030044825A1
; GENERAL INFORMATION:
; APPLICANT: IMAI, Yuji
; APPLICANT: AKAISUKA, Hiroyuki
; APPLICANT: KAWAI, Eri
; APPLICANT: OMORI, Kenji
; APPLICANT: YANAKA, No. US20030044825A1iyuki
; APPLICANT: SAKURAI, Naoki
; TITLE OF INVENTION: Bone Metabolism Related Protein and Gene Thereof
; FILE REFERENCE: 0283-0163F
; CURRENT APPLICATION NUMBER: US/10/152,031
; CURRENT FILING DATE: 2002-05-22
; PRIOR FILING DATE: 2002-05-22
; PRIOR FILING DATE: 2001-05-22
; PRIOR FILING DATE: 2001-05-22
; PRIOR FILING DATE: 2000-05-23
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 13
; LENGTH: 54
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-152-031-13

Query Match 25.0%; Score 5; DB 14; Length 54;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
|||||
Db 4 RGAPM 8

RESULT 50
US-10-424-599-262093
; Sequence 262093, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 262093
; LENGTH: 56
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_78692C.1.pap
US-10-424-599-262093

Query Match 25.0%; Score 5; DB 15; Length 56;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||
Db 13 PRGAP 17

RESULT 51
US-09-867-550-1954
; Sequence 1954, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Fuad,
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1954
; LENGTH: 57
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-867-550-1954

Query Match 25.0%; Score 5; DB 9; Length 57;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 VCQML 15
|||||
Db 22 VCQML 26

RESULT 52
US-10-424-599-240745
; Sequence 240745, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K


```
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 240745
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Glycine max
; NAME/KEY: unsure
; LOCATION: (1)...(58)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_5941C.1.pep
US-10-424-599-240745

Query Match      25.0%; Score 5; DB 15; Length 58;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      8 LRCVC 12
Db      16 LRCVC 20

RESULT 53
US-10-424-599-205956
; Sequence 205956, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 205956
; LENGTH: 60
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_28005C.1.pep
US-10-424-599-205956

Query Match      25.0%; Score 5; DB 15; Length 60;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      8 LRCVC 12
Db      26 LRCVC 30

RESULT 54
US-10-424-599-176161
; Sequence 176161, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; OTHER INFORMATION: MAP TO Z98883.3
```

```
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 176161
; LENGTH: 61
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_130090C.1.pep
US-10-424-599-176161

Query Match      25.0%; Score 5; DB 15; Length 61;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      9 RCVCQ 13
Db      48 RCVCQ 52

RESULT 55
US-10-424-599-239535
; Sequence 239535, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 239535
; LENGTH: 62
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_58325C.1.pep
US-10-424-599-239535

Query Match      25.0%; Score 5; DB 15; Length 62;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      15 LETKF 19
Db      46 LETKF 50

RESULT 56
US-10-029-386-32143
; Sequence 32143, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GI
; FILE REFERENCE: AECOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 32143
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO Z98883.3
```

; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.8
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.8
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 4.5
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.7
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.1
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.9
; OTHER INFORMATION: SWISSPROT HIT: O43451, EVALUE 2.00e-03
US-10-029-386-32143

Query Match 25.0%; Score 5; DB 14; Length 63;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 15 PRGAP 19
|||||

RESULT 57
US-10-424-599-282344
; Sequence 282344, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 282344
; LENGTH: 64
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_9697C.1.pap
US-10-424-599-282344

Query Match 25.0%; Score 5; DB 15; Length 64;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
Db 4 LETKF 8
|||||

RESULT 58
US-10-424-599-210941
; Sequence 210941, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 210941
; LENGTH: 66
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(66)
; OTHER INFORMATION: unsure at all Xaa locations

; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_32506C.1.pap
US-10-424-599-210941

Query Match 25.0%; Score 5; DB 15; Length 66;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKF 19
Db 46 LETKF 50
|||||

RESULT 59
US-09-867-550-1576
; Sequence 1576, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Fuad,
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1 Polynucleotides from Atherogenic Cells and
; TITLE OF INVENTION: Thereby
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: USSN 60/208,427
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1576
; LENGTH: 67
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-867-550-1576

Query Match 25.0%; Score 5; DB 9; Length 67;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 40 PRGAP 44
|||||

RESULT 60
US-10-424-599-154428
; Sequence 154428, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 154428
; LENGTH: 68
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_11046C.1.pap
US-10-424-599-154428

Query Match 25.0%; Score 5; DB 15; Length 68;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 WLRV 11
Db 4 WLRV 8

RESULT 64
US-10-437-963-102863
; Sequence 102863, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(S3221)B
; CURRENT FILING DATE: US/10/437,963
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 102863
; LENGTH: 74
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_100348C.1.pap
US-10-437-963-102863

Query Match 25.0%; Score 5; DB 16; Length 74;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 30 PRGAP 34

RESULT 65
US-10-293-252C-102
; Sequence 102, Application US/10293252C
; Publication No. US20040103449A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Dongmei
; TITLE OF INVENTION: Identification and Use of Cytochrome
; FILE REFERENCE: 78127
; CURRENT FILING DATE: US/10/293,252C
; PRIOR APPLICATION NUMBER: 60/363,684
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/347,444
; PRIOR FILING DATE: 2002-01-11
; PRIOR FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 152
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 102
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Nicotiana
US-10-293-252C-102

Query Match 25.0%; Score 5; DB 16; Length 76;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
Db 31 MLETK 35

RESULT 66
US-10-340-861B-102
; Sequence 102, Application US/10340861B
; Publication No. US20040111759A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Dongmei
; TITLE OF INVENTION: Identification and Use of Cytochrome
; FILE REFERENCE: 78406
; CURRENT FILING DATE: US/10/340,861B
; PRIOR APPLICATION NUMBER: 60/363,684
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/347,444
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/337,684
; PRIOR FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 102
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Nicotiana
US-10-340-861B-102

Query Match 25.0%; Score 5; DB 16; Length 76;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
Db 31 MLETK 35

RESULT 67
US-09-792-793A-90
; Sequence 90, Application US/09792793A
; Patent No. US20020168370A1
; GENERAL INFORMATION:
; APPLICANT: McDonald, John R.
; APPLICANT: Coggins, Philip
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND
; FILE REFERENCE: 25020-601D
; CURRENT FILING DATE: US/09/792,793A
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 90
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human Chemokine Polypeptide: ENA-78
; PUBLICATION INFORMATION:
; AUTHORS: Clark-Lewis et. al.,
; JOURNAL: J. Leukoc. Biol.
; VOLUME: 57
; PAGES: 703-711
; DATE: 1995
US-09-792-793A-90

Query Match 25.0%; Score 5; DB 9; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY      8 LRCVC 12
      |||||
Db      11 LRCVC 15

RESULT 68
US-09-864-408A-5972
; Sequence 5972, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Shimkets, Richard A.
; TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Enco
; FILE REFERENCE: 21402-012
; CURRENT APPLICATION NUMBER: US/09/864,408A
; CURRENT FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: 60/206,690
; PRIOR FILING DATE: 2000-05-24
; NUMBER OF SEQ ID NOS: 9068
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 5972
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (57)-(57)
; OTHER INFORMATION: Wherein Xaa may be any naturally occurring amino acid
US-09-864-408A-5972

Query Match      25.0%; Score 5; DB 11; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      5 PMWLR 9
      |||||
Db      74 PMWLR 78

RESULT 69
US-10-375-209A-90
; Sequence 90, Application US/10375209A
; Publication No. US20030215421A1
; GENERAL INFORMATION:
; APPLICANT: McDonald, John R.
; APPLICANT: Coggins, Philip
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND
; FILE REFERENCE: 25020-601E
; CURRENT APPLICATION NUMBER: US/10/375,209A
; CURRENT FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 90
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human Chemokine Polypeptide: ENA-78
; PUBLICATION INFORMATION:
; AUTHORS: Clark-Lewis et. al.,
; JOURNAL: J. Leukoc. Biol.
; VOLUME: 57
; PAGES: 703-711
; DATE: 1995
US-10-375-209A-90

Query Match      25.0%; Score 5; DB 14; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
      |||||
Db
```

```
Db      11 LRCVC 15

RESULT 70
US-10-437-963-135152
; Sequence 135152, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 135152
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_36855C.1.pep
US-10-437-963-135152

Query Match      25.0%; Score 5; DB 16; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
      |||||
Db      23 PRGAP 27

RESULT 71
US-10-437-963-167155
; Sequence 167155, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 167155
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_65794C.1.pep
US-10-437-963-167155

Query Match      25.0%; Score 5; DB 16; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      15 LETKF 19
      |||||
Db      72 LETKF 76
```

```
RESULT 72
US-10-424-599-144203
; Sequence 144203, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 144203
; LENGTH: 79
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_101228C.1.pap
US-10-424-599-144203

Query Match      25.0%; Score 5; DB 15; Length 79;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
Db      43 PRGAP 47

RESULT 73
US-10-424-599-149863
; Sequence 149863, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 149863
; LENGTH: 79
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_106348C.1.pap
US-10-424-599-149863

Query Match      25.0%; Score 5; DB 15; Length 79;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      13 QMLET 17
Db      20 QMLET 24

RESULT 74
US-09-922-261-464
; Sequence 464, Application US/09922261
; Patent No. US20020111471A1
; GENERAL INFORMATION:
; APPLICANT: COGENT NEUROSCIENCE, Inc.
; APPLICANT: Lo, Donald C.
```

```
; APPLICANT: Barney, Shawn
; APPLICANT: Thomas, Mary Beth
; APPLICANT: Portbury, Stuart D.
; APPLICANT: Puranam, Kasturi
; APPLICANT: Katz, Lawrence C.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
; TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
; FILE REFERENCE: 10001-005-999
; CURRENT APPLICATION NUMBER: US/09/922,261
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US/09/461,697
; PRIOR FILING DATE: 1999-12-14
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 464
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-922-261-464

Query Match      25.0%; Score 5; DB 9; Length 80;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
Db      54 PRGAP 58

RESULT 75
US-10-437-963-105389
; Sequence 105389, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 105389
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_102638C.1.pap
US-10-437-963-105389

Query Match      25.0%; Score 5; DB 16; Length 80;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
Db      24 PRGAP 28

Search completed: October 26, 2004, 07:47:57
Job time : 66 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 26, 2004, 07:06:01 ; Search time 22.25 Seconds
(without alignments)
59.612 Million cell updates/sec

Title: US-10-066-965A-4
Perfect score: 20
Sequence: 1 PRGAPWLRVCVCMLETKFL 20

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 478139 seqs, 66318000 residues

Word size : 0
Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : Issued Patents AA:*

1: /cgn2_6/ptodata/1/iaa/5A COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/5B COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/6A COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/6B COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	6	30.0	169	4	US-09-489-039A-8944
2	6	30.0	173	4	US-09-270-767-41955
3	6	30.0	394	4	US-09-248-796A-23067
4	5	25.0	9	1	US-07-972-032-15
5	5	25.0	9	1	US-08-642-255-15
6	5	25.0	15	2	US-08-468-819-20
7	5	25.0	15	4	US-09-213-383-20
8	5	25.0	16	1	US-08-311-307B-11
9	5	25.0	17	1	US-07-778-413B-3
10	5	25.0	17	1	US-08-340-102-3
11	5	25.0	34	1	US-07-778-413B-4
12	5	25.0	34	1	US-08-340-102-4
13	5	25.0	46	2	US-08-436-420-17
14	5	25.0	63	4	US-09-248-796A-24632
15	5	25.0	74	3	US-09-134-001C-3074
16	5	25.0	74	3	US-09-134-001C-4851
17	5	25.0	75	2	US-08-436-420-15
18	5	25.0	77	4	US-09-270-767-36912
19	5	25.0	77	4	US-09-270-767-52129
20	5	25.0	78	1	US-07-778-413B-12
21	5	25.0	78	1	US-08-340-102-12
22	5	25.0	78	1	US-08-330-163-8
23	5	25.0	78	1	US-08-482-111-8
24	5	25.0	78	1	US-08-436-420-32
25	5	25.0	80	3	US-09-461-697-464
26	5	25.0	85	4	US-09-270-767-41916
27	5	25.0	91	4	US-09-252-991A-24182
28	5	25.0	91	4	US-09-489-039A-8944
29	5	25.0	91	4	US-09-270-767-41955
30	5	25.0	95	4	US-09-248-796A-23067
31	5	25.0	9	1	US-07-972-032-15
32	5	25.0	9	1	US-08-642-255-15
33	5	25.0	15	2	US-08-468-819-20
34	5	25.0	15	4	US-09-213-383-20
35	5	25.0	16	1	US-08-311-307B-11
36	5	25.0	17	1	US-07-778-413B-3
37	5	25.0	17	1	US-08-340-102-3
38	5	25.0	34	1	US-07-778-413B-4
39	5	25.0	34	1	US-08-340-102-4
40	5	25.0	46	2	US-08-436-420-17
41	5	25.0	63	4	US-09-248-796A-24632
42	5	25.0	74	3	US-09-134-001C-3074
43	5	25.0	74	3	US-09-134-001C-4851
44	5	25.0	75	2	US-08-436-420-15
45	5	25.0	77	4	US-09-270-767-36912
46	5	25.0	77	4	US-09-270-767-52129
47	5	25.0	78	1	US-07-778-413B-12
48	5	25.0	78	1	US-08-340-102-12
49	5	25.0	78	1	US-08-330-163-8
50	5	25.0	78	1	US-08-482-111-8
51	5	25.0	78	1	US-08-436-420-32
52	5	25.0	80	3	US-09-461-697-464
53	5	25.0	85	4	US-09-270-767-41916
54	5	25.0	91	4	US-09-252-991A-24182
55	5	25.0	91	4	US-09-489-039A-8944
56	5	25.0	91	4	US-09-270-767-41955
57	5	25.0	95	4	US-09-248-796A-23067
58	5	25.0	9	1	US-07-972-032-15
59	5	25.0	9	1	US-08-642-255-15
60	5	25.0	15	2	US-08-468-819-20
61	5	25.0	15	4	US-09-213-383-20
62	5	25.0	16	1	US-08-311-307B-11
63	5	25.0	17	1	US-07-778-413B-3
64	5	25.0	17	1	US-08-340-102-3
65	5	25.0	34	1	US-07-778-413B-4
66	5	25.0	34	1	US-08-340-102-4
67	5	25.0	46	2	US-08-436-420-17
68	5	25.0	63	4	US-09-248-796A-24632
69	5	25.0	74	3	US-09-134-001C-3074
70	5	25.0	74	3	US-09-134-001C-4851
71	5	25.0	75	2	US-08-436-420-15
72	5	25.0	77	4	US-09-270-767-36912
73	5	25.0	77	4	US-09-270-767-52129
74	5	25.0	78	1	US-07-778-413B-12
75	5	25.0	78	1	US-08-340-102-12
76	5	25.0	78	1	US-08-330-163-8
77	5	25.0	78	1	US-08-482-111-8
78	5	25.0	78	1	US-08-436-420-32
79	5	25.0	80	3	US-09-461-697-464
80	5	25.0	85	4	US-09-270-767-41916
81	5	25.0	91	4	US-09-252-991A-24182
82	5	25.0	91	4	US-09-489-039A-8944
83	5	25.0	91	4	US-09-270-767-41955
84	5	25.0	95	4	US-09-248-796A-23067
85	5	25.0	9	1	US-07-972-032-15
86	5	25.0	9	1	US-08-642-255-15
87	5	25.0	15	2	US-08-468-819-20
88	5	25.0	15	4	US-09-213-383-20
89	5	25.0	16	1	US-08-311-307B-11
90	5	25.0	17	1	US-07-778-413B-3
91	5	25.0	17	1	US-08-340-102-3
92	5	25.0	34	1	US-07-778-413B-4
93	5	25.0	34	1	US-08-340-102-4
94	5	25.0	46	2	US-08-436-420-17
95	5	25.0	63	4	US-09-248-796A-24632
96	5	25.0	74	3	US-09-134-001C-3074
97	5	25.0	74	3	US-09-134-001C-4851
98	5	25.0	75	2	US-08-436-420-15
99	5	25.0	77	4	US-09-270-767-36912
100	5	25.0	77	4	US-09-270-767-52129

Sequence 38667, A
Sequence 53884, A
Sequence 27372, A
Sequence 13486, A
Sequence 9, Appli
Sequence 3, Appli
Sequence 4, Appli
Sequence 3, Appli
Sequence 149, App
Sequence 4, Appli
Sequence 3, Appli
Sequence 3, Appli
Sequence 11951, A
Sequence 34903, A
Sequence 50120, A
Sequence 36650, A
Sequence 51867, A
Sequence 4139, Ap
Sequence 30594, A
Sequence 425, App
Sequence 726, App
Sequence 39768, A
Sequence 54985, A
Sequence 6252, Ap
Sequence 18178, A
Sequence 23447, A
Sequence 23275, A
Sequence 3710, Ap
Sequence 36562, A
Sequence 51779, A
Sequence 21850, A
Sequence 32100, A
Sequence 61094, A
Sequence 47191, A
Sequence 385, App
Sequence 3778, Ap
Sequence 60336, A
Sequence 12, Appl
Sequence 818, App
Sequence 23304, A
Sequence 4165, Ap
Sequence 28343, A
Sequence 37, Appl
Sequence 27518, A
Sequence 21547, A
Sequence 6699, Ap
Sequence 39555, A
Sequence 54772, A
Sequence 1482, Ap
Sequence 106, App
Sequence 44940, A
Sequence 27676, A
Sequence 25496, A
Sequence 25370, A
Sequence 14594, A
Sequence 19219, A
Sequence 52, Appl
Sequence 16974, A
Sequence 19369, A
Sequence 19891, A
Sequence 45581, A
Sequence 27396, A
Sequence 20554, A
Sequence 2, Appli
Sequence 36276, A
Sequence 51493, A
Sequence 8, Appli
Sequence 17858, A
Sequence 31139, A
Sequence 23047, A
Sequence 19344, A

ALIGNMENTS

```
RESULT 1
US-09-489-039A-8944
; Sequence 8944, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; FILE OF INVENTION: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 8944
; LENGTH: 169
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-8944
Query Match          30.0%; Score 6; DB 4; Length 169;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GAPMWL 8
Db 90 GAPMWL 95

RESULT 2
US-09-270-767-41955
; Sequence 41955, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41955
; LENGTH: 173
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-41955
Query Match          30.0%; Score 6; DB 4; Length 173;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKFL 20
Db 17 LETKFL 22

RESULT 3
US-09-248-796A-23067
; Sequence 23067, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstein et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; FILE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
```

```
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 23067
; LENGTH: 394
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-23067
Query Match          30.0%; Score 6; DB 4; Length 394;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LETKFL 20
Db 87 LETKFL 92

RESULT 4
US-07-972-032-15
; Sequence 15, Application US/07972032
; Patent No. 5496712
; GENERAL INFORMATION:
; APPLICANT: Cappello, Joseph
; APPLICANT: Ferrari, Franco A.
; TITLE OF INVENTION: HIGH MOLECULAR WEIGHT COLLAGEN-LIKE
; TITLE OF INVENTION: PROTEIN POLYMERS
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Berttram I. Rowland
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: CA 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/972,032
; FILING DATE: 19921105
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/791,960
; FILING DATE: 12-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Rowland, Berttram I.
; REGISTRATION NUMBER: 20,015
; REFERENCE/DOCKET NUMBER: A-55556-1/BIR;PROP-08-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-07-972-032-15
Query Match          25.0%; Score 5; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.8e+05;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 5 PRGAP 9

RESULT 5
```


US-08-642-255-15
; Sequence 15, Application US/08642255
; Patent No. 5773249
; GENERAL INFORMATION:
; APPLICANT: CAPPELLO, Joseph
; APPLICANT: FERRARI, Franco A.
; TITLE OF INVENTION: High Molecular Weight Collagen-Like
; TITLE OF INVENTION: Protein Polymers
; NUMBER OF SEQUENCES: 135
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOBRACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/642,255
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: ROWLAND, Bertram I.
; REGISTRATION NUMBER: 20,015
; REFERENCE/DOCKET NUMBER: A55556-3/BIR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-8700
; TELEFAX: (415) 494-8771
; TELEX: 910 277299 PHT UR
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-642-255-15

Query Match 25.0%; Score 5; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.8e+05;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 5 PRGAP 9

RESULT 6
US-08-468-819-20
; Sequence 20, Application US/08468819
; Patent No. 5871723
; GENERAL INFORMATION:
; APPLICANT: Strieter, Robert M.
; APPLICANT: Polverini, Peter J.
; APPLICANT: Kunkel, Steven L.
; TITLE OF INVENTION: CXC Chemokines as Regulators of
; TITLE OF INVENTION: Angiogenesis
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: US
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/468,819
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UMIC:003/HYL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7477
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-468-819-20

Query Match 25.0%; Score 5; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 7
US-09-213-383-20
; Sequence 20, Application US/09213383
; Patent No. 6491906
; GENERAL INFORMATION:
; APPLICANT: Strieter, Robert M.
; APPLICANT: Polverini, Peter J.
; APPLICANT: Kunkel, Steven L.
; TITLE OF INVENTION: CXC Chemokines as Regulators of
; TITLE OF INVENTION: Angiogenesis
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: US
; ZIP: 77210

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/213,383
; FILING DATE: 09-Dec-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/468,819
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UMIC:003/HYL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7477
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 amino acids
; TYPE: amino acid

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-213-383-20

Query Match      25.0%; Score 5; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
Db      11 LRCVC 15

RESULT 8
US-08-311-307B-11
; Sequence 11, Application US/08311307B
; Patent No. 5627156
; GENERAL INFORMATION:
; APPLICANT: Talmadge, James E.
; TITLE OF INVENTION: Polypeptide Agonist Derived From Human
; TITLE OF INVENTION: Interleukin-8
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
; STREET: 1601 Market Street
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103-2307
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,307B
; FILING DATE: 23-SEP-1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hagan, Patrick J.
; REGISTRATION NUMBER: 27,643
; REFERENCE/DOCKET NUMBER: 63085
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215)563-4100
; TELEFAX: (215)563-4044
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 4..6
; OTHER INFORMATION: /note= "The cysteine residues may
; OTHER INFORMATION: be substituted with aminobutyric acid, homocysteine, or
; OTHER INFORMATION: diaminosuberic acid."
US-08-311-307B-11

Query Match      25.0%; Score 5; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
Db      2 LRCVC 6
```

```

RESULT 9
US-07-778-413E-3
; Sequence 3, Application US/07778413E
; Patent No. 5401651
; GENERAL INFORMATION:
; APPLICANT: Walz, Alfred
; TITLE OF INVENTION: No. 5401651el Neutrophil
; TITLE OF INVENTION: Activating Factors
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in., DS, 2.0 MB
; OPERATING SYSTEM: Apple Macintosh
; SOFTWARE: Microsoft Word Version 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/778,413E
; FILING DATE: 16-OCT-1991
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Cook, Robert R.
; REGISTRATION NUMBER: 31602
; REFERENCE/DOCKET NUMBER: A-204
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (805) 499-5725 EXTENSION 4955
; TELEFAX: (805) 499-8011
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-07-778-413E-3

Query Match      25.0%; Score 5; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
Db      11 LRCVC 15

RESULT 10
US-08-340-102-3
; Sequence 3, Application US/08340102
; Patent No. 5591718
; GENERAL INFORMATION:
; APPLICANT: Walz, Alfred
; TITLE OF INVENTION: No. 5591718el Neutrophil
; TITLE OF INVENTION: Activating Factors
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in., DS, 1.4 MB
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word Version 5.1a for
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/08/340,102
FILING DATE: 15-NOV-1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Cook, Robert R.
REGISTRATION NUMBER: 31602
REFERENCE/DOCKET NUMBER: A-204A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (805) 499-5725 EXTENSION 4955
TELEFAX: (805) 499-8011
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-340-102-3

Query Match 25.0%; Score 5; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 11
US-07-778-413E-4
Sequence 4, Application US/07778413E
Patent No. 5401651
GENERAL INFORMATION:
APPLICANT: Walz, Alfred
TITLE OF INVENTION: No. 5401651el Neutrophil
TITLE OF INVENTION: Activating Factors
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen Inc.
STREET: Amgen Center
STREET: 1840 Dehavilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in., DS, 2.0 MB
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh OS 7.0
SOFTWARE: Microsoft Word Version 5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/778,413E
FILING DATE: 16-OCT-1991
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Cook, Robert R.
REGISTRATION NUMBER: 31602
REFERENCE/DOCKET NUMBER: A-204
TELECOMMUNICATION INFORMATION:
TELEPHONE: (805) 499-5725 EXTENSION 4955
TELEFAX: (805) 499-8011
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 34
TYPE: Amino Acid
TOPOLOGY: Linear
US-07-778-413E-4

Query Match 25.0%; Score 5; DB 1; Length 34;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 12
US-08-340-102-4
Sequence 4, Application US/08340102
Patent No. 5591718
GENERAL INFORMATION:
APPLICANT: Walz, Alfred
TITLE OF INVENTION: No. 5591718el Neutrophil
TITLE OF INVENTION: Activating Factors
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Amgen Inc.
STREET: Amgen Center
STREET: 1840 Dehavilland Drive
CITY: Thousand Oaks
STATE: California
COUNTRY: USA
ZIP: 91320-1789
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in., DS, 1.4 MB
COMPUTER: MS-DOS
OPERATING SYSTEM: MS-DOS 6.22
SOFTWARE: Microsoft Word Version 5.1a for
SOFTWARE: Macintosh
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/340,102
FILING DATE: 15-NOV-1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Cook, Robert R.
REGISTRATION NUMBER: 31602
REFERENCE/DOCKET NUMBER: A-204A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (805) 499-5725 EXTENSION 4955
TELEFAX: (805) 499-8011
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 34
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-340-102-4

Query Match 25.0%; Score 5; DB 1; Length 34;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 13
US-08-436-420-17
Sequence 17, Application US/08436420
Patent No. 5840524
GENERAL INFORMATION:
APPLICANT: VAN DAMME, Jo; and
APPLICANT: PROOST, Paul
TITLE OF INVENTION: GRANULOCYTE CHEMOTACTIC PROTEIN
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: HALE and DORR LLP
STREET: 1455 PENNSYLVANIA AVENUE, N.W.
CITY: WASHINGTON
STATE: DISTRICT OF COLUMBIA
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/436,420
;/ FILING DATE: 24-MAY-1995
;/ CLASSIFICATION: 530
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: PCT/EP93/03330
;/ FILING DATE: 26-NOV-1993
;/ CLASSIFICATION: 530
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: US 07/982,539
;/ FILING DATE: 27-NOV-1992
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: BAKER, Hollie L.
;/ REGISTRATION NUMBER: 31,321
;/ REFERENCE/DOCKET NUMBER: 102378.215
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (202) 942-8400
;/ TELEFAX: (202) 942-8484
;/ INFORMATION FOR SEQ ID NO: 17:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 46 amino acids
;/ TYPE: amino acid
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ FRAGMENT TYPE: N-terminal
;/ FEATURE:
;/ NAME/KEY: Modified-site
;/ LOCATION: 44..46
;/ OTHER INFORMATION: /note= "Xaa was ambiguous at time
;/ of determination; later identified as "G..."
US-08-436-420-17

Query Match 25.0%; Score 5; DB 2; Length 46;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 3 LRCVC 7

RESULT 14
US-09-248-796A-24632
;/ Sequence 24632, Application US/09248796A
;/ Patent No. 6747137
;/ GENERAL INFORMATION:
;/ APPLICANT: Keith Weinstock et al
;/ TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
;/ FILE REFERENCE: 107196.132
;/ CURRENT APPLICATION NUMBER: US/03/248,796A
;/ PRIOR FILING DATE: 1999-02-12
;/ PRIOR APPLICATION NUMBER: US 60/074,725
;/ PRIOR FILING DATE: 1998-02-13
;/ PRIOR APPLICATION NUMBER: US 60/096,409
;/ PRIOR FILING DATE: 1998-08-13
;/ NUMBER OF SEQ ID NOS: 28208
;/ SEQ ID NO 24632
;/ LENGTH: 63
;/ TYPE: PRT
;/ ORGANISM: Candida albicans
US-09-248-796A-24632

Query Match 25.0%; Score 5; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 ETKFL 20
Db 49 ETKFL 53

RESULT 15

US-09-134-001C-3074
;/ Sequence 3074, Application US/09134001C
;/ Patent No. 6380370
;/ GENERAL INFORMATION:
;/ APPLICANT: Lynn Doucette-Stamm et al
;/ TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
;/ TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
;/ FILE REFERENCE: GTC-007
;/ CURRENT APPLICATION NUMBER: US/09/134,001C
;/ CURRENT FILING DATE: 1998-08-13
;/ PRIOR APPLICATION NUMBER: US 60/064,964
;/ PRIOR FILING DATE: 1997-11-08
;/ PRIOR APPLICATION NUMBER: US 60/055,779
;/ PRIOR FILING DATE: 1997-08-14
;/ NUMBER OF SEQ ID NOS: 5674
;/ SEQ ID NO 3074
;/ LENGTH: 74
;/ TYPE: PRT
;/ ORGANISM: Staphylococcus epidermidis
US-09-134-001C-3074

Query Match 25.0%; Score 5; DB 3; Length 74;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 58 PRGAP 62

RESULT 16
US-09-134-001C-4851
;/ Sequence 4851, Application US/09134001C
;/ Patent No. 6380370
;/ GENERAL INFORMATION:
;/ APPLICANT: Lynn Doucette-Stamm et al
;/ TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
;/ TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
;/ FILE REFERENCE: GTC-007
;/ CURRENT APPLICATION NUMBER: US/09/134,001C
;/ CURRENT FILING DATE: 1998-08-13
;/ PRIOR APPLICATION NUMBER: US 60/064,964
;/ PRIOR FILING DATE: 1997-11-08
;/ PRIOR APPLICATION NUMBER: US 60/055,779
;/ PRIOR FILING DATE: 1997-08-14
;/ NUMBER OF SEQ ID NOS: 5674
;/ SEQ ID NO 4851
;/ LENGTH: 74
;/ TYPE: PRT
;/ ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4851

Query Match 25.0%; Score 5; DB 3; Length 74;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 58 PRGAP 62

RESULT 17
US-08-436-420-15
;/ Sequence 15, Application US/08436420
;/ Patent No. 5840524
;/ GENERAL INFORMATION:
;/ APPLICANT: VAN DAMME, Jo; and
;/ APPLICANT: PROOST, Paul
;/ TITLE OF INVENTION: GRANULOCYTE CHEMOTACTIC PROTEIN
;/ NUMBER OF SEQUENCES: 45
;/ CORRESPONDENCE ADDRESS:
;/ ADDRESSEE: HALE and DORR LLP
;/ STREET: 1455 PENNSYLVANIA AVENUE, N.W.

```

; CITY: WASHINGTON
; STATE: DISTRICT OF COLUMBIA
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION NUMBER: US/08/436,420
; APPLICATION NUMBER: US/08/436,420
; FILING DATE: 24-MAY-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03330
; FILING DATE: 26-NOV-1993
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/982,539
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, Hollie L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 942-8400
; TELEFAX: (202) 942-8484
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 75 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-436-420-15

Query Match 25.0%; Score 5; DB 2; Length 75;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
DB 10 LRCVC 14

RESULT 18
US-09-270-767-36912
; Sequence 36912, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36912
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36912

Query Match 25.0%; Score 5; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
DB 70 PRGAP 74

RESULT 19
US-09-270-767-52129
; Sequence 52129, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 52129
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-52129

Query Match 25.0%; Score 5; DB 4; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
DB 70 PRGAP 74

RESULT 20
US-07-778-413E-12
; Sequence 12, Application US/07778413E
; Patent No. 5401651
; GENERAL INFORMATION:
; APPLICANT: Walz, Alfred
; TITLE OF INVENTION: No. 5401651el Neutrophil
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: Amgen Center
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in., DS, 2.0 MB
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh OS 7.0
; SOFTWARE: Microsoft Word Version 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/778,413E
; FILING DATE: 16-OCT-1991
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Cook, Robert R.
; REGISTRATION NUMBER: 31602
; REFERENCE/DOCKET NUMBER: A-204
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (805) 499-5725 EXTENSION 4955
; TELEFAX: (805) 499-8011
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 78
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-07-778-413E-12

Query Match 25.0%; Score 5; DB 1; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 8 LRCVC 12
| | | | |
Db 11 LRCVC 15

RESULT 21

US-08-340-102-12
; Sequence 12, Application US/08340102
; Patent No. 5591718
; GENERAL INFORMATION:
; APPLICANT: Walz, Alfred
; TITLE OF INVENTION: No. 5591718el Neutrophil
; TITLE OF INVENTION: Activating Factors
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: Amgen Center
; STREET: 1840 Behavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 in., DS, 1.4 MB
COMPUTER: MS-DOS
OPERATING SYSTEM: MS-DOS 6.22
SOFTWARE: Microsoft Word Version 5.1a for
SOFTWARE: Macintosh

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/340,102
FILING DATE: 15-NOV-1994
CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Cook, Robert R.
REGISTRATION NUMBER: 31602
REFERENCE/DOCKET NUMBER: A-204A

TELECOMMUNICATION INFORMATION:

TELEPHONE: (805) 499-5725 EXTENSION 4955
TELEFAX: (805) 499-8011

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 78
TYPE: Amino Acid
TOPOLOGY: Linear

US-08-340-102-12

Query Match 25.0%; Score 5; DB 1; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
| | | | |
Db 11 LRCVC 15

RESULT 22

US-08-330-163-8
; Sequence 8, Application US/08330163
; Patent No. 5656724
; GENERAL INFORMATION:

APPLICANT: Daly, Thomas J.
APPLICANT: LaRosa, Gregory J.
TITLE OF INVENTION: Chemokine-Like Proteins and Methods of
TITLE OF INVENTION: Use
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: U.S.A.
ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30B
APPLICATION NUMBER: US/08/482,111
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Fasse, J. Peter
REGISTRATION NUMBER: 32,983
REFERENCE/DOCKET NUMBER: 00231/083001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 78 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/330,163
FILING DATE: 05-AUG-1994
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Fasse, J. Peter
REGISTRATION NUMBER: 32,983
REFERENCE/DOCKET NUMBER: 00231/080001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 78 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide

US-08-330-163-8

Query Match 25.0%; Score 5; DB 1; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12

| | | | |

Db 11 LRCVC 15

RESULT 23

US-08-482-111-8

; Sequence 8, Application US/08482111
; Patent No. 5789539
; GENERAL INFORMATION:
; APPLICANT: Daly, Thomas J.
; APPLICANT: LaRosa, Gregory J.
; TITLE OF INVENTION: Chemokine-Like Proteins and Methods of
; TITLE OF INVENTION: Use
; NUMBER OF SEQUENCES: 70
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,111
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Fasse, J. Peter
REGISTRATION NUMBER: 32,983
REFERENCE/DOCKET NUMBER: 00231/083001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 78 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide

```
US-08-482-111-8
Query Match      25.0%; Score 5; DB 1; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 24
US-08-436-420-32
; Sequence 32, Application US/08436420
; Patent No. 5840524
; GENERAL INFORMATION:
; APPLICANT: VAN DAMME, Jo; and
; APPLICANT: PROOST, Paul
; TITLE OF INVENTION: GRANULOCYTE CHEMOTACTIC PROTEIN
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 1455 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: DISTRICT OF COLUMBIA
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,420
; FILING DATE: 24-MAY-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/982,539
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, Hollie L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 942-8400
; TELEFAX: (202) 942-8484
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 78 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-436-420-32

Query Match      25.0%; Score 5; DB 2; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 11 LRCVC 15

RESULT 25
US-09-461-697-464
; Sequence 464, Application US/09461697
; Patent No. 6277974
; GENERAL INFORMATION:
; APPLICANT: COGENT NEUROSCIENCE, Inc.
; APPLICANT: Lo, Donald C.
; APPLICANT: Barney, Shawn
; APPLICANT: Thomas, Mary Beth
; APPLICANT: Portbury, Stuart D.
; APPLICANT: Puranam, Kasturi
; APPLICANT: Katz, Lawrence C.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
; TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
; TITLE OF INVENTION: CELL DEATH
; FILE REFERENCE: 10001-005-999
; CURRENT APPLICATION NUMBER: US/09/461,697
; CURRENT FILING DATE: 1999-12-14
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 464
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-461-697-464

Query Match      25.0%; Score 5; DB 3; Length 80;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 54 PRGAP 58

RESULT 26
US-09-270-767-41916
; Sequence 41916, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41916
; LENGTH: 85
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-41916

Query Match      25.0%; Score 5; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 27 LRCVC 31

RESULT 27
US-09-252-991A-24182
; Sequence 24182, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
```

; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 24182
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-24182

Query Match 25.0%; Score 5; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
|||||
DB 37 RGAPM 41

RESULT 28
US-09-270-767-38667
; Sequence 38667, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 38667
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-38667

Query Match 25.0%; Score 5; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||
DB 65 PRGAP 69

RESULT 29
US-09-270-767-53884
; Sequence 53884, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 53884
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-53884

Query Match 25.0%; Score 5; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||
DB 65 PRGAP 69

RESULT 30
US-09-248-796A-27372

; Sequence 27372, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 27372
; LENGTH: 95
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-27372

Query Match 25.0%; Score 5; DB 4; Length 95;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 ETKFL 20
|||||
DB 53 ETKFL 57

RESULT 31
US-09-489-039A-13486
; Sequence 13486, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 13486
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-13486

Query Match 25.0%; Score 5; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 VCQML 15
|||||
DB 21 VCQML 25

RESULT 32
US-08-816-772-9
; Sequence 9, Application US/08816772
; Patent No. 6410268
; GENERAL INFORMATION:
; APPLICANT: NI, JIAN
; APPLICANT: LI, HAODONG
; APPLICANT: SU, JEFFREY
; TITLE OF INVENTION: CHEMOKINE ALPHA-3
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
; STREET: 1100 NEW YORK AVENUE, SUITE 600
; CITY: WASHINGTON
; STATE: DC


```

; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-352-324A-3

Query Match          25.0%; Score 5; DB 1; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e-02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
DB      47 LRCVC 51

RESULT 34
US-08-862-607-3
; Sequence 3, Application US/08862607
; Patent No. 5844084
; GENERAL INFORMATION:
; APPLICANT: Guegler, Karl J.
; APPLICANT: Hawkins, Phillip R.
; APPLICANT: Wilde, Craig G.
; APPLICANT: Seilhamer, Jeffrey J.
; TITLE OF INVENTION: A NOVEL CHEMOKINE EXPRESSED IN
; TITLE OF INVENTION: INFLAMED ADENOID, ITS PRODUCTION AND USES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/862,607
; FILING DATE: 23-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/352,324
; FILING DATE: 07-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Luther, Barbara J.
; REGISTRATION NUMBER: 33,954
; REFERENCE/DOCKET NUMBER: PF-0025 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-852-0195
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-862-607-3

Query Match          25.0%; Score 5; DB 2; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e-02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
DB      47 LRCVC 51

RESULT 35

```

US-08-468-819-4
; Sequence 4, Application US/08468819
; Patent No. 5871723
; GENERAL INFORMATION:
; APPLICANT: Strieter, Robert M.
; APPLICANT: Polverini, Peter J.
; APPLICANT: Kunkel, Steven L.
; TITLE OF INVENTION: CXK Chemokines as Regulators of
; TITLE OF INVENTION: Angiogenesis
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: US
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/468,819
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UMC:003/HYL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7477
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-468-819-4

Query Match 25.0%; Score 5; DB 2; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 47 LRCVC 51

RESULT 36
US-09-203-235-3
; Sequence 3, Application US/09203235
; Patent No. 6071701
; GENERAL INFORMATION:
; APPLICANT: Guegler, Karl J.
; APPLICANT: Hawkins, Phillip R.
; APPLICANT: Wilde, Craig G.
; APPLICANT: Seilhamer, Jeffrey J.
; TITLE OF INVENTION: A NOVEL CHEMOKINE EXPRESSED IN
; TITLE OF INVENTION: INFLAMED ADENOID, ITS PRODUCTION AND USES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/203,235
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/862,607
; FILING DATE: 23-MAY-1997
; APPLICATION NUMBER: 08/352,324
; FILING DATE: 07-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Luther, Barbara J.
; REGISTRATION NUMBER: 33,954
; REFERENCE/DOCKET NUMBER: PF-0025 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-858-0555
; TELEFAX: 415-852-0195
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
US-09-203-235-3

Query Match 25.0%; Score 5; DB 3; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 47 LRCVC 51

RESULT 37
US-08-679-493A-149
; Sequence 149, Application US/08679493A
; Patent No. 6303295
; GENERAL INFORMATION:
; APPLICANT: Taylor, Ethan W.
; TITLE OF INVENTION: SELENOPROTEINS, CODING SEQUENCES AND METHODS
; FILE REFERENCE: 55-95
; CURRENT APPLICATION NUMBER: US/08/679,493A
; CURRENT FILING DATE: 1996-07-12
; PRIOR APPLICATION NUMBER: 60/001203
; PRIOR FILING DATE: 1995-07-14
; PRIOR APPLICATION NUMBER: 60/003,112
; PRIOR FILING DATE: 1995-09-01
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 149
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-679-493A-149

Query Match 25.0%; Score 5; DB 3; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 47 LRCVC 51

RESULT 38
US-09-213-383-4
; Sequence 4, Application US/09213383
; Patent No. 6491906
; GENERAL INFORMATION:

```

; APPLICANT: Strieter, Robert M.
; Polverini, Peter J.
; Kunkel, Steven L.
; TITLE OF INVENTION: CXc Chemokines as Regulators of
; Angiogenesis
; NUMBER OF SEQUENCES: 93
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: US
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/213,383
; FILING DATE: 09-Dec-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/468,819
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UMC:003/HYL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7477
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-213-383-4
Query Match 25.0%; Score 5; DB 4; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 47 LRCVC 51

RESULT 39
US-09-588-044-3
; Sequence 3, Application US/09588044
; Patent No. 669290
; GENERAL INFORMATION:
; APPLICANT: Guesler, Karl J.
; Hawkins, Phillip R.
; Wilde, Craig G.
; Seilhamer, Jeffrey J.
; TITLE OF INVENTION: A NOVEL CHEMOKINE EXPRESSED IN
; INFLAMED ADENOID, ITS PRODUCTION AND USES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette

```

```

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/588,044
; FILING DATE: 05-Jun-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/352,324
; FILING DATE: 07-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Luther, Barbara J.
; REGISTRATION NUMBER: 33,954
; REFERENCE/DOCKET NUMBER: PF-0025 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-852-0195
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-588-044-3
Query Match 25.0%; Score 5; DB 4; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
Db 47 LRCVC 51

RESULT 40
PCT-US95-16144-3
; Sequence 3, Application PC/TUS9516144
; GENERAL INFORMATION:
; APPLICANT: INCYTE PHARMACEUTICALS, INC.
; TITLE OF INVENTION: A NOVEL CHEMOKINE EXPRESSED IN INFLAMED
; ADENOID, ITS PRODUCTION AND USES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1/MS-DOS 6.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/16144
; FILING DATE: 07-DEC-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/352,324
; FILING DATE: 07-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: LUTHER, BARBARA J.
; REGISTRATION NUMBER: 33954
; REFERENCE/DOCKET NUMBER: PF-0025 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-852-0195
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 114 amino acids

```

; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
PCT-US95-16144-3

Query Match 25.0%; Score 5; DB 5; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
|||
Db 47 LRCVC 51

RESULT 41

US-09-489-039A-11951
; Sequence 11951, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:

; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; FILE REFERENCE: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 11951
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae

US-09-489-039A-11951

Query Match 25.0%; Score 5; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||
Db 93 PRGAP 97

RESULT 42

US-09-270-767-34903
; Sequence 34903, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34903
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Drosophila melanogaster

; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-34903

Query Match 25.0%; Score 5; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||
Db 50 PRGAP 54

RESULT 43

US-09-270-767-50120
; Sequence 50120, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 50120
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Drosophila melanogaster

; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-50120

Query Match 25.0%; Score 5; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||
Db 50 PRGAP 54

RESULT 44

US-09-270-767-36650
; Sequence 36650, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36650
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Drosophila melanogaster

; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36650

Query Match 25.0%; Score 5; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 WLRVC 11
|||
Db 69 WLRVC 73

RESULT 45

US-09-270-767-51867
; Sequence 51867, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 51867
; LENGTH: 127
; TYPE: PRT

```
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-51867

Query Match          25.0%; Score 5; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      7 WLRVCV 11
      |||||
Db      69 WLRVCV 73

RESULT 46
US-09-583-110-4139
; Sequence 4139, Application US/09583110
; Patent No. 6699703
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al.
; TITLE OF INVENTION: Nucleic Acid and Amino Acid Sequences Relating to Streptococcus
; TITLE OF INVENTION: Pneumoniae for Diagnostics and Therapeutics
; FILE REFERENCE: PATH00-07A
; CURRENT APPLICATION NUMBER: US/09/583,110
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/107,433
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/085,131
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: US 60/051,553
; PRIOR FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 5322
; SEQ ID NO 4139
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Streptococcus pneumoniae
US-09-583-110-4139

Query Match          25.0%; Score 5; DB 4; Length 132;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      15 LETKVF 19
      |||||
Db      27 LETKVF 31

RESULT 47
US-09-252-991A-30594
; Sequence 30594, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30594
; LENGTH: 133
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-30594

Query Match          25.0%; Score 5; DB 4; Length 133;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4 APMWL 8
      |||||
```

```
QY      1 PRGAP 5
      |||||
Db      47 PRGAP 51

RESULT 48
US-09-312-283C-425
; Sequence 425, Application US/09312283C
; Patent No. 6573095
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James G.
; APPLICANT: Kumble, Krishanand D.
; TITLE OF INVENTION: Compositions Isolated from Skin Cells
; TITLE OF INVENTION: and Methods for Their Use
; FILE REFERENCE: 11000.1011c2
; CURRENT APPLICATION NUMBER: US/09/312,283C
; CURRENT FILING DATE: 1999-05-14
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 425
; LENGTH: 133
; TYPE: PRT
; ORGANISM: Mouse
US-09-312-283C-425

Query Match          25.0%; Score 5; DB 4; Length 133;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      8 LRCVC 12
      |||||
Db      52 LRCVC 56

RESULT 49
US-10-101-464A-726
; Sequence 726, Application US/10101464A
; Patent No. 6768041
; GENERAL INFORMATION:
; APPLICANT: Strabala, Timothy
; APPLICANT: Nieuwenhuizen, Nicolaas
; APPLICANT: Higgins, Colleen M.
; TITLE OF INVENTION: Compositions Isolated from Plant Cells
; TITLE OF INVENTION: and Their Use in the Modification of Plant Cell Signaling
; FILE REFERENCE: 11000.1020c2
; CURRENT APPLICATION NUMBER: US/10/101,464A
; CURRENT FILING DATE: 2002-03-18
; PRIOR APPLICATION NUMBER: 09/704,302
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 09/228,986
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/162,866
; PRIOR FILING DATE: 1999-11-01
; PRIOR APPLICATION NUMBER: PCT/US00/00724
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 989
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 726
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Pinus radiata
US-10-101-464A-726

Query Match          25.0%; Score 5; DB 4; Length 135;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4 APMWL 8
      |||||
```

Db 76 APMWL 80

RESULT 50

US-09-270-767-39768
; Sequence 39768, Application US/09270767
; Patent No. 6703491

GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39768

; LENGTH: 139

; TYPE: PRT

; ORGANISM: Drosophila melanogaster

; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid

US-09-270-767-39768

Query Match

Best Local Similarity 25.0%; Score 5; DB 4; Length 139;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5

Db 57 PRGAP 61

RESULT 51

US-09-270-767-54985
; Sequence 54985, Application US/09270767
; Patent No. 6703491

GENERAL INFORMATION:

; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 54985

; LENGTH: 139

; TYPE: PRT

; ORGANISM: Drosophila melanogaster

; FEATURE:

; OTHER INFORMATION: Xaa means any amino acid

US-09-270-767-54985

Query Match

Best Local Similarity 25.0%; Score 5; DB 4; Length 139;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5

Db 57 PRGAP 61

RESULT 52

US-09-513-999C-6252
; Sequence 6252, Application US/09513999C
; Patent No. 6783961

GENERAL INFORMATION:

; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961

; FILE REFERENCE: 59 US2 REG

; CURRENT APPLICATION NUMBER: US/09/513,999C

; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487

; NUMBER OF SEQ ID NOS: 36681

; SOFTWARE: Patent.pm

; SEQ ID NO 6252

; LENGTH: 141

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: UNSURE

; LOCATION: 109

; OTHER INFORMATION: Xaa=Ala or Val

US-09-513-999C-6252

Query Match

Best Local Similarity 25.0%; Score 5; DB 4; Length 141;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18

Db 118 MLETK 122

RESULT 53

US-09-248-796A-18178

; Sequence 18178, Application US/09248796A

; Patent No. 6747137

; GENERAL INFORMATION:

; APPLICANT: Keith Weinstock et al

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN

; FILE REFERENCE: 107196.132

; CURRENT APPLICATION NUMBER: US/09/248,796A

; CURRENT FILING DATE: 1999-02-12

; PRIOR APPLICATION NUMBER: US 60/074,725

; PRIOR FILING DATE: 1998-02-13

; PRIOR APPLICATION NUMBER: US 60/096,409

; PRIOR FILING DATE: 1998-08-13

; NUMBER OF SEQ ID NOS: 28208

; SEQ ID NO 18178

; LENGTH: 158

; TYPE: PRT

; ORGANISM: Candida albicans

US-09-248-796A-18178

Query Match

Best Local Similarity 25.0%; Score 5; DB 4; Length 158;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12

Db 126 LRCVC 130

RESULT 54

US-09-248-796A-23447

; Sequence 23447, Application US/09248796A

; Patent No. 6747137

; GENERAL INFORMATION:

; APPLICANT: Keith Weinstock et al

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN

; FILE REFERENCE: 107196.132

; CURRENT APPLICATION NUMBER: US/09/248,796A

; CURRENT FILING DATE: 1999-02-12

; PRIOR APPLICATION NUMBER: US 60/074,725

; PRIOR FILING DATE: 1998-02-13

; PRIOR APPLICATION NUMBER: US 60/096,409

; PRIOR FILING DATE: 1998-08-13

; NUMBER OF SEQ ID NOS: 28208

; SEQ ID NO 23447

; LENGTH: 158

; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-23447

Query Match 25.0%; Score 5; DB 4; Length 158;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
|||||
Db 36 MLETK 40

RESULT 55

US-09-252-991A-23275
; Sequence 23275, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 23275
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-23275

Query Match 25.0%; Score 5; DB 4; Length 160;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
|||||
Db 23 PRGAP 27

RESULT 56

US-09-134-000C-3710
; Sequence 3710, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
; FILE REFERENCE: 032796-032
; CURRENT APPLICATION NUMBER: US/09/134,000C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/055,778
; PRIOR FILING DATE: 1997-08-15
; NUMBER OF SEQ ID NOS: 6812
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3710
; LENGTH: 163
; TYPE: PRT
; ORGANISM: Enterococcus faecalis
US-09-134-000C-3710

Query Match 25.0%; Score 5; DB 4; Length 163;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 RGAPM 6
|||||
Db 12 RGAPM 16

RESULT 57

US-09-270-767-36562
; Sequence 36562, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36562
; LENGTH: 180
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36562

Query Match 25.0%; Score 5; DB 4; Length 180;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
|||||
Db 3 LRCVC 7

RESULT 58

US-09-270-767-51779
; Sequence 51779, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 51779
; LENGTH: 180
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-51779

Query Match 25.0%; Score 5; DB 4; Length 180;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 LRCVC 12
|||||
Db 3 LRCVC 7

RESULT 59

US-09-252-991A-21850
; Sequence 21850, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190

; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 21850
; LENGTH: 183
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-21850

Query Match 25.0%; Score 5; DB 4; Length 183;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 PRGAP 5
107 PRGAP 111
Db

RESULT 60
US-09-252-991A-32100
; Sequence 32100, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; PRIOR FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 32100
; LENGTH: 185
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-32100

Query Match 25.0%; Score 5; DB 4; Length 185;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 PRGAP 5
170 PRGAP 174
Db

RESULT 61
US-09-270-767-61094
; Sequence 61094, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61094
; LENGTH: 195
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-61094

Query Match 25.0%; Score 5; DB 4; Length 195;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 16 ETKFL 20

Db 138 ETKFL 142

RESULT 62
US-09-270-767-47191
; Sequence 47191, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 47191
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-47191

Query Match 25.0%; Score 5; DB 4; Length 199;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 13 QMLET 17
109 QMLET 113
Db

RESULT 63
US-09-615-192A-385
; Sequence 385, Application US/09615192A
; Patent No. 6410718
; GENERAL INFORMATION:
; APPLICANT: Bloksberg, Leonard N.
; TITLE OF INVENTION: Materials and Methods for the
; TITLE OF INVENTION: Modification of Plant Lignin Content
; FILE REFERENCE: 11000.1003C4U
; CURRENT APPLICATION NUMBER: US/09/615,192A
; CURRENT FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 08/975,316
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: US 08/713,000
; PRIOR FILING DATE: 1996-09-11
; PRIOR APPLICATION NUMBER: US 09/169,789
; PRIOR FILING DATE: 1998-10-09
; NUMBER OF SEQ ID NOS: 405
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 385
; LENGTH: 208
; TYPE: PRT
; ORGANISM: Pinus radiata
US-09-615-192A-385

Query Match 25.0%; Score 5; DB 4; Length 208;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 15 LETKF 19
182 LETKF 186
Db

RESULT 64
US-09-134-000C-3778
; Sequence 3778, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO


```
; TITLE OF INVENTION: ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 032796-032
; CURRENT APPLICATION NUMBER: US/09/134,000C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/055,778
; PRIOR FILING DATE: 1997-08-15
; NUMBER OF SEQ ID NOS: 6812
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3778
; LENGTH: 215
; TYPE: PRT
; ORGANISM: Enterococcus faecalis
US-09-134-000C-3778

Query Match          25.0%; Score 5; DB 4; Length 215;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      15 LETKF 19
        |||||
Db       40 LETKF 44

RESULT 65
US-09-270-767-60336
; Sequence 60336, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60336
; LENGTH: 220
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-60336

Query Match          25.0%; Score 5; DB 4; Length 220;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
        |||||
Db       90 PRGAP 94

RESULT 66
US-09-627-376-12
; Sequence 12, Application US/09627376
; Patent No. 6342385
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia          Caufield, Page          Chen, Ping
; TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: UAB-17402/22
; CURRENT APPLICATION NUMBER: US/09/627,376
; CURRENT FILING DATE: 2001-05-30
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 233
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-09-627-376-12

Query Match          25.0%; Score 5; DB 3; Length 233;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      14 MLETK 18
        |||||
Db       4 MLETK 8

RESULT 67
US-10-047-676B-12
; Sequence 12, Application US/10047676B
; Patent No. 6699970
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia
; APPLICANT: Caufield, Page W.
; APPLICANT: Chen, Ping
; TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: UAB-17403/22
; CURRENT APPLICATION NUMBER: US/10/047,676B
; CURRENT FILING DATE: 2002-01-14
; PRIOR APPLICATION NUMBER: US 09/627,376
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 233
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-10-047-676B-12

Query Match          25.0%; Score 5; DB 4; Length 233;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      14 MLETK 18
        |||||
Db       4 MLETK 8

RESULT 68
US-09-198-452A-818
; Sequence 818, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 818
; LENGTH: 235
; TYPE: PRT
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-818

Query Match          25.0%; Score 5; DB 4; Length 235;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      16 ETKFL 20
        |||||
Db       177 ETKFL 181

RESULT 69
US-09-252-991A-23304
; Sequence 23304, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
```

```
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 23304
; LENGTH: 237
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-23304

Query Match      25.0%; Score 5; DB 4; Length 237;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
DB      40 PRGAP 44

RESULT 70
US-09-134-001C-4165
; Sequence 4165, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC-007
; CURRENT APPLICATION NUMBER: US/09/134,001C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 4165
; LENGTH: 239
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4165

Query Match      25.0%; Score 5; DB 3; Length 239;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      11 VCQML 15
DB      52 VCQML 56

RESULT 71
US-09-252-991A-28343
; Sequence 28343, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 28343
; LENGTH: 242
; TYPE: PRT
```

```
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-28343

Query Match      25.0%; Score 5; DB 4; Length 242;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
DB      23 PRGAP 27

RESULT 72
US-08-426-819A-37
; Sequence 37, Application US/08426819A
; Patent No. 5723318
; GENERAL INFORMATION:
; APPLICANT: Yamaguchi, No. 5723318omi
; APPLICANT: Kojima, Tetsuo
; APPLICANT: Oh-Eda, Masayoshi
; APPLICANT: Hattori, Kunihiko
; TITLE OF INVENTION: Genes Coding for Megakaryocyte
; TITLE OF INVENTION: Potentiator
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/08/426,819A
; FILING DATE: 21-APR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M.
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 230-107P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-205-8000
; TELEFAX: 703-205-8050
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 248 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; FRAGMENT TYPE: internal
US-08-426-819A-37

Query Match      25.0%; Score 5; DB 1; Length 248;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 PRGAP 5
DB      115 PRGAP 119

RESULT 73
US-09-248-796A-27518
; Sequence 27518, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
```

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; FILE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 27518
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-27518

Query Match 25.0%; Score 5; DB 4; Length 257;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 QMLET 17
Db 180 QMLET 184

RESULT 74
US-09-252-991A-21547
; Sequence 21547, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 21547
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-21547

Query Match 25.0%; Score 5; DB 4; Length 259;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PRGAP 5
Db 56 PRGAP 60

RESULT 75
US-09-328-352-6699
; Sequence 6699, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; TITLE OF INVENTION: BAUMANNII FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 6699
; LENGTH: 264
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
US-09-328-352-6699

Query Match 25.0%; Score 5; DB 4; Length 264;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 MLETK 18
Db 133 MLETK 137

Search completed: October 26, 2004, 07:25:08
Job time : 24.25 secs

This Page Blank (uspto)